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ABSTRACT 
Two Stage Repair of Composite Craniofacial Defects with 
Antibiotic Releasing Porous Poly(methyl methacrylate) Space 
Maintainers and Bone Regeneration 
by 
Patrick Spicer 
Craniofacial defects resulting from trauma and resection present many challenges 
to reconstruction due to the complex structure, combinations of tissues, and environment, 
with exposure to the oral, skin and nasal mucosal pathogens.  Tissue engineering seeks to 
regenerate the tissues lost in these defects; however, the composite nature and proximity 
to colonizing bacteria remain difficult to overcome.  Additionally, many tissue 
engineering approaches have further hurdles to overcome in the regulatory process to 
clinical translation.  As such these studies investigated a two stage strategy employing an 
antibiotic-releasing porous polymethylmethacrylate space maintainer fabricated with 
materials currently part of products approved or cleared by the United States Food and 
Drug Administration, expediting the translation to the clinic.  This porous space 
maintainer holds the bone defect open allowing soft tissue to heal around the defect.  The 
space maintainer can then be removed and one regenerated in the defect.  These studies 
investigated the individual components of this strategy.  The porous space maintainer 
showed similar soft tissue healing and response to non-porous space maintainers in a 
rabbit composite tissue defect.  The antibiotic-releasing space maintainers showed release 
of antibiotics from 1-5 weeks, which could be controlled by loading and fabrication 
 
 
 
parameters.  In vivo, space maintainers releasing a high dose of antibiotics for an 
extended period of time increased soft tissue healing over burst release space maintainers 
in an infected composite tissue defect model in a rabbit mandible.  Finally, stabilization 
of bone defects and regeneration could be improved through scaffold structures and 
delivery of a bone forming growth factor.  These studies illustrate the possibility of the 
two stage strategy for repair of composite tissue defects of the craniofacial complex. 
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Chapter 1 
Introduction‡ 
The work described in this thesis covers biomaterial-based approaches for 
craniofacial reconstruction.  As such, the following chapter will outline the clinical 
problems in craniofacial reconstruction, the current treatment modalities, advances in 
area and finally, some of the hurdles and pitfalls many of these advances have faced 
preempting their translation into clinical practice.  This information will provide a basis 
for the work described and show relevance toward clinical translation. 
                                                
 
‡ This chapter will be published as a portion of Spicer PP, Young S, Kasper FK, 
Athanasiou KA, Mikos AG, Wong ME. Tissue Engineering in Oral and Maxillofacial 
Surgery. In Lanza R, Langer R, Vacanti J (Eds.), Principles of Tissue Engineering. 
Amsterdam: Elsevier (in press). 
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1.1. Craniofacial Reconstruction 
The desire to reconstruct portions of the craniofacial complex have existed for 
centuries, and with the technological developments of the late 19th century, craniofacial 
reconstruction began to form a significant library of operative and technological repairs 
to craniofacial defects.  This began in 1889, with C. Martin, who developed an artificial 
jaw to restore speech and mastication to a patient.  This technology was refined through 
the following decades with better materials and constructions [1].  
1.1.1. Craniofacial Anatomy 
Virtually all tissue types of ectodermal, mesodermal and endodermal origin are 
candidates for tissue engineering strategies and are present in the oral and maxillofacial 
region. However, certain structures are more commonly impacted by disease, trauma and 
developmental failures and constitute the focus of our discussion, though the 
reconstructive methods described can be applied to more rare conditions.  
A special concern in oral and maxillofacial reconstruction is the potential 
exposure of grafted tissue to the external environment. Constructs used to restore defects 
involving the jaws, orbits, nose and ears are potentially in direct contact with the mouth, 
sinuses (maxillary, ethmoidal and frontal), nasal passages and external environment. 
These areas are characterized by high moisture content, significant bacterial populations, 
and functional loads imposed by physiological activities such as chewing. If biological 
(i.e. tissue engineered) constructs are to survive under these conditions, modifications to 
account for the dilutional effects of moisture, presence of infective organisms, and 
mechanical loads, must be provided by the engineered tissue. For example, when in vivo 
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polymerization of materials is intended, the presence of fluid must be considered. 
Alternatively, pre-formed constructs can be used. Colonization of constructs with a 
mixed population of aerobic and anerobic bacteria is expected with reconstructions 
involving oral, nasal and sinus-related structures. Porous constructs, capable of harboring 
potentially pathological organisms might be modified to reduce either bacterial 
attachment or replication until lining tissue develops over the implant forming a barrier to 
the external environment. In addition to contaminated wound sites, tissue constructs may 
be exposed to complicated mechanical loads before anisotropy is restored with the 
regeneration of biological tissue. Both the mandible and temporomandibular joints are 
subject to a combination of compressive, shear and tensile loads depending on the type 
and degree of function [2, 3]. 
Another special feature of the maxillofacial region is the number of tissue types 
within a relatively small region. As a result of this proximity, traumatic, pathological and 
developmental events often lead to the creation of composite defects requiring 
reconstruction of multiple tissue types. This results in a special challenge not only to 
engineer composite tissues, but also to attach the various constructs to each other in their 
normal anatomical relationship. 
Facial symmetry is an important consideration in oral and maxillofacial 
reconstruction. Since most structures are paired or contiguous (e.g. the orbits, zygomas, 
left and right maxillae and mandible), accurate reproduction of the external form is an 
important aspect to preserve facial esthetics (Figure 1.1). The paucity of overlying soft 
tissue as camouflage contributes to the exacting nature of oral and maxillofacial 
reconstruction and these requirements impose upon tissue engineering methods the ability 
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to compose and maintain accurate morphology. The advent of new three-dimensional 
imaging techniques with the capacity to produce stereolithographic skeletal models 
(Figure 1.2) that mirror both the normal anatomy and defect is a valuable adjunctive tool.  
These models assist in the fabrication of scaffolds to support the reconstruction of 
missing tissue. 
1.1.2. Craniofacial Trauma and Resection 
Common pathological entities include both benign and malignant cystic and 
neoplastic processes affecting the upper (maxilla) and lower (mandible) jaws as well as 
degenerative conditions involving the mandibular articulation (temporomandibular 
joints). These diseases, or the subsequent removal of pathologically involved tissue, can 
produce continuity defects of the jaws requiring the replacement of bone, cartilage and 
lining epithelium (Figure 1.3 and Figure 1.4).  Since many of these conditions are 
frequently silent and the dimensions of the structures involved relatively small, their 
initial presentation is usually associated with significant tissue involvement. In addition 
to disease, non-physiological loading of bone can also produce loss of skeletal tissue 
affecting the jaws and joints. Edentulous bone loss as in Figure 1.5 involves the 
resorption of the alveolar processes of the jaws (i.e. that portion of the jaw bone 
surrounding the tooth roots) following tooth removal.  This phenomenon is believed to be 
the result of direct loading of bone during mastication and the loss of physiological 
maintenance forces transmitted by the teeth. Over time, the loss of bone produces 
severely atrophied alveolar ridges, posing significant challenges to prosthetic 
reconstruction of the dentition and a predisposition to pathological fracture of the 
mandible [4]. 
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Maxillofacial trauma constitutes another group of conditions providing 
opportunities for tissue engineering reconstruction. Whereas most forms of blunt trauma 
result in fractures where tissue loss is minimal, penetrating injuries produced by high 
velocity missiles and projectiles often create significant loss of bone and overlying soft 
tissue (Figure 1.6). Finally, consideration should be given to the various forms of 
congenital facial clefts that commonly affect the oral and maxillofacial region. In a 
limited form, failure of the maxillary processes to fuse unilaterally or bilaterally produces 
alveolar clefts (Figure 1.7 and Figure 1.8).  When the upper lip, maxilla and palate are 
involved, a constellation of deformities associated with unilateral or bilateral cleft lip and 
palate patients is present.  
In the reconstruction of anatomical defects, the causative events must be taken 
into account to ensure long-term success. Defects produced by traumatic, developmental 
and pathological conditions are associated with a defined end-point. Assuming that 
pathology has been completely eradicated or further traumatic insults do not occur, 
defects produced by these mechanisms can be fully characterized with respect to size and 
missing tissue types. In contrast, tissue loss as a result of parafunctional habits, non-
physiological loading patterns and immunologically mediated degeneration often 
continue following reconstruction. This set of circumstances will adversely affect any 
biological constructs produced by tissue engineering techniques and impose an important 
limitation on the clinical application of their usage. Before biological, rather than 
alloplastic materials can be employed, correction of the underlying etiology is of 
paramount importance. 
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1.1.3. Current Treatment Modalities 
There are several methods used for oral and maxillofacial reconstruction and the 
selection of a particular modality takes into account a number of important issues. Major 
factors that guide this process include the presence (or absence) of associated soft tissue, 
the vascularity and vascular pattern present, a multi-dimensional characterization of the 
defect size, the types of missing tissue, availability of tissue for transfer, and both patient 
and surgeon preference. Most reconstructive techniques can be categorized into four 
categories: 
• Soft tissue pedicled flaps 
• Non-vascularized soft and hard tissue grafts (the graft establishes in a 
delayed fashion, a vascular network following implantation, relying upon 
tissue diffusion to preserve the viability of the transplant) 
• Soft and hard tissue vascularized grafts (the graft is immediately perfused 
through an existing arterial-venous system) 
• Alloplastic reconstructions with prosthetic appliances  
On occasion, composite techniques can be used, such as the staged reconstruction 
of a defect where soft tissue is first added to a defect site followed by bone at a later time. 
 
1.2. Mandibular Defects 
 
Reconstruction of the lower jaw is indicated following removal of tissue during 
surgical excision of a pathological lesion or following loss of tissue from a traumatic 
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injury. When malignant disease is present, not only is more radical removal of tissue 
required, but post-operative radiation therapy produces lasting compromise to both the 
cellularity and vascularity of the remaining tissue. Blast effects from missile injuries can 
also produce significant composite injuries with loss of bone soft tissue, and diminished 
vascularity of the tissue bed. Two techniques are commonly employed for the 
reconstruction of mandibular defects. Vascularized grafts are indicated when the 
vascularity of the tissue bed is compromised by radiation or excessive scarring. They are 
also valuable when there is a requirement to replace both hard and soft tissue at the same 
time [5]. Hard and soft tissue defects can also be reconstructed using non-vascularized 
grafts, but their success relies upon an adequately vascularized tissue bed, which can be 
compromised in irradiated or traumatically injured tissue, to support the survival of 
transplanted cells before a new supply is established[6]. 
As composite structures, vascularized grafts contain either soft tissue alone 
(muscle, subcutaneous tissue with or without epithelium) or include hard and soft tissue 
components (bone and soft tissue). Since the vascular supply to bone is contained within 
a peri-osseous cuff of muscle and fibrous tissue, it is not possible to transplant only bone. 
The additional tissue transferred into the site of a bony defect often produces a bulky 
graft. While this can be easily excised once a new vascular network is established, a 
second procedure performed several months after the initial transplantation is required. 
Another potential limitation to the use of vascularized bone grafts for the reconstruction 
of mandibular defects is the amount of bone available, since the dimensions of the graft 
are determined by the morphology of the donor site and not the size of the defect. Special 
techniques such as osteotomizing the graft and folding it upon itself have been described, 
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but this can compromise the blood supply to the graft. Vascularized grafts are harvested 
from a limited number of anatomical sites characterized by a dominant arterial supply – 
venous drainage system. In addition, the en bloc harvesting of the graft must not 
compromise either the function of the donor site or the vascular and neural supply of 
structures distal to the harvest. Commonly used donor sites that meet these requirements 
include the fibula, ilium, scapula and distal radius. Vascularized grafts transplanted to 
mandibular defects are anastomosed to patent vessels adjacent to the mandible, such as 
the facial, lingual or superior thyroid arteries and veins. This reconstructive approach is 
highly technique-sensitive and while experienced microvascular surgeons achieve 
successful outcomes in over 90% of cases, less experienced surgeons or patients with 
underlying vascular disease (e.g. diabetes) enjoy less success. 
Mandibular defects can also be reconstructed using non-vascularized 
transplantations of autologous bone from various sites. Successful bone grafts rely upon 
adequate cellularity and a sufficiently cellular and vascular recipient bed. When the soft 
tissue bed is deficient or lacks a decent blood supply, addition of well-vascularized soft 
tissue is achieved by the rotation of a muscle flap (with or without skin) into the 
mandibular defect. The pectoralis major, latissimus dorsi and deltopectoral flaps have all 
been described for this purpose. The bony reconstruction is delayed for a period of three 
to six months until the soft tissue flap has healed. In patients whose soft tissue is 
adequate, but avascular as a result of radiation therapy, hyperbaric oxygen therapy can 
improve the quality of the vascular supply in a course of treatments lasting between four 
to six weeks where repeated exposures to pressurized room air promote tissue 
angiogenesis. This process adds both time and considerable expense to the reconstructive 
 9 
 
process, but has been shown to be effective in improving the quality of the recipient bed. 
Once the soft tissue in a mandibular defect has been optimized with respect to quantity, 
cellularity and vascularity, autologous bone is transferred from a donor site and molded 
to fit the dimensions of the defect. The bone graft can be retained with screws fixed to a 
rigid bone plate, or held in position with the aid of cribs fashioned either from processed 
allogeneic bone or alloplastic materials. Depending upon the size of the defect, bone can 
be harvested from the anterior ilium (suitable for defects up to 4 cm in length), the 
posterior ilium (defects up to 8 cm in length), and the tibia or mandibular symphysis and 
rami (defects of less than 2 cm in length). Non-vascularized grafts, especially those 
combined with allogeneic bone are susceptible to infectionespecially following exposure 
to the intra-oral environment, with a frequency of 43% in one case series [7]. When a 
non-vascularized graft is colonized by organisms, infection often ensues and the graft 
fails to survive or integrate with the host bone. Aside from the potential for infection, 
non-vascularized grafts are less technique sensitive, allow “complete” reconstruction of a 
defect by customizing the volume of bone harvested, and are associated with less donor 
site morbidity [8]. 
1.3. Maxillary Defects 
 
Defects of the upper jaw pose difficult reconstructive challenges from several 
perspectives, but must be undertaken to preserve speech, prevent the escape of food and 
fluids during eating, and maintain esthetics. Unlike the mandible which is related to the 
oral cavity alone, the maxilla is bounded both inferiorly by the mouth and superiorly by 
the nasal cavity and maxillary sinuses. Even when present, the thin lining epithelium does 
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not provide a sufficiently cellular or vascular bed to support the transplantation of 
sufficient quantities of non-vascularized bone and the potential for exposure of the graft 
to oral and nasal environments is high. Post-operative or post-traumatic scarring reduces 
the tissue envelope even more, further complicating reconstructive efforts. Staged 
reconstructions have been described involving the initial transfer of vascularized soft 
tissue with a pedicled flap, such as the temporalis muscle or temporo-parietal flap, 
followed by the addition of bone several months later [8]. As an alternative, vascularized 
flaps have been used because of their ability to transfer both hard and soft tissue at the 
same time [9]. However, the accompanying soft tissue and vascular pedicle may not be 
accommodated by the smaller dimensions of a maxillary defect and this has limited their 
use to hemi- or total maxillary reconstructions. The simultaneous transfer of a large bulk 
of overlying soft tissue also results in a post-operative recovery period of several months 
where the flap can prevent mouth closure and compromise eating. 
As a result of these challenges, prosthetic appliances have become the most 
commonly used method to reconstruct maxillary defects. These devices incorporate teeth 
and a fitted base to separate the mouth from the superior defect [10]. Excellent restoration 
of both esthetics and function can be achieved, but the fact that they are not permanently 
fixed in place and in fact, require daily removal and cleaning, reduces their acceptability 
by patients. In addition, adjustments are required periodically to account for remodeling 
of the underlying tissue bed. 
The reconstruction of maxillary alveolar clefts is one exception to the use of 
prosthetic appliances as a primary reconstruction technique, even though they can be 
used very effectively to restore missing teeth in the cleft site or obturate an oral-nasal 
 11 
 
communication. When teeth are present in a cleft site, provision of bone is essential for 
eruption and support [11]. Alveolar grafting is therefore timed according to the presence 
and stage of development of adjacent teeth and is usually performed between the ages of 
eight and eleven years. The procedure involves the development of soft tissue flaps to 
isolate the mouth from the nasal cavity and placing autogenous bone between the cleft 
segments to restore maxillary continuity. Loss of the graft from infection, insufficient 
vascularity or lack of functional stimulus is not an infrequent occurrence and 
opportunities for tissue engineering alternatives exist. This would be especially true if 
new interventions minimized the extent of surgery, since post-surgical scarring has been 
associated with restricted growth and development of the maxilla. 
1.4. Advances in Tissue Engineering and Regenerative Medicine in 
Craniofacial Reconstruction 
Driven by the limited supply and inherent shortcomings of various autogenous, 
allogeneic, and prosthetic materials currently used for the reconstruction of oral and 
maxillofacial tissues, the potential for tissue engineered biomaterials as alternatives is 
under serious investigation with the hope that significantly improved therapies will result. 
While a diverse number of strategies are presently under development, the 
fundamental tenets of tissue engineering (TE) remain the same. These include 
consideration of the biological and mechanical properties of the scaffold material and its 
interactions with relevant bioactive molecules and cell populations.  
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Although multiple tissue types exist in the oral and maxillofacial region, TE 
research in this field has focused primarily on the regeneration of single tissues: the bony 
craniofacial skeleton, lining epithelium, the cartilages of the temporomandibular joint, 
auricle, and nose, and the teeth and surrounding periodontal tissue.  
1.4.1. Bone Applications 
An ideal biodegradable TE bone construct should combine the biocompatibility 
and osteoinductive potential of autologous bone, with the availability and structural 
characteristics of allogeneic bone. Additional scaffold design considerations include 
porosity, pore interconnectivity, surface chemistry, and the ability to reproduce complex 
three-dimensional defects.  
Scaffolds are responsible for a construct’s initial mechanical integrity and provide 
surface area for cell attachment. Several biocompatible scaffold materials are currently 
used in oral and maxillofacial surgery, including naturally derived materials like 
collagen, gelatin, or hyaluronic acid, synthetic polymers like poly(lactic acid) and 
poly(glycolic acid) and ceramics like calcium phosphate granules, blocks and 
cements[12].  In addition to those materials clinically used, several materials have been 
tested using in vivo models for craniofacial bone, including alginate, chitosan, 
poly(propylene fumarate), oligo(poly(ethylene glycol)-co-fumarate), poly(caprolactone), 
and polyurethanes[12].  These materials are typically processed as porous structures or 
hydrogels that guide the morphology of regenerated tissue, allow for tissue in-growth, 
and control the release of bioactive molecules such as growth factors or nucleic acids. 
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Other approaches to tissue engineering use novel biomaterials capable of 
implantation through minimally invasive surgery.  This can be achieved via in situ 
crosslinking or polymerization via chemical reactions initiated by mixing chemicals 
immediately before injection, transcutaneous photopolymerization or thermogelation[13-
16]. Delivery of osteogenic factors or cells has been demonstrated with these techniques; 
however, parameters such as cell viability must be weighed against gel stiffness with 
such materials.   
Growth factors act as mediators of cellular growth and differentiation during 
tissue regeneration and play an important role in extracellular matrix synthesis. Utilized 
as recombinant proteins in TE strategies, growth factors require a local population of 
target cells capable of effecting the desired response [17]. This constituency of cells may 
be naturally present at the wound site or added to the scaffold at the time of fabrication 
[18] prior to implantation. 
Factors that have been used for the regeneration of in vivo TE craniofacial bone 
include the bone morphogenetic proteins (BMPs) [18, 19], transforming growth factor-
beta (TGF-β) [20], fibroblast growth factors (FGFs) [21], insulin-like growth factors 
(IGFs) [22], and platelet-derived growth factor (PDGF) [23]. The bulk of experience 
concerning the use of growth factors for bone repair has involved BMPs [24] and this 
popularity has been extended into clinical investigations using recombinant human BMP-
2 (rhBMP-2) for alveolar ridge augmentation [25], maxillary sinus floor augmentation 
[26], mandibular reconstruction following tumor resection [27], and distraction-assisted 
alveolar cleft repair [28].   A review by Herford et al., covers several cases of BMPs used 
in mandibular reconstruction secondary to tumor excision, trauma and infection, 
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highlighting the versatility of growth factor mediated bone regeneration [29].  However, 
the review notes a relatively small number, 37, of documented clinical cases in the 
literature with a significant failure rate of 13.5%. This highlights the need for further 
investigation of these growth factor based technologies in the craniofacial complex.  
BMP-2 has found some definitive success in other aspects of oral and 
maxillofacial surgery, such as dental implants and sinus floor augmentation  Jung et al 
[25]. examined the effect of combining recombinant human BMP-2 with a xenogeneic 
bone substitute in order to improve membrane-guided bone regeneration therapy of 
osseous defects in areas of dental implant placement. Although there was not a 
statistically significant difference in percentage of newly formed bone at the rhBMP-2 
treated site versus the control site at 6 months, a larger fraction of mature lamellar bone 
(76% vs. 56%) was present in the experimental sites, as well as increased graft to bone 
contact (57% vs. 29.5%). In addition, Boyne et al. [26] completed a phase II randomized 
controlled study investigating the safety and efficacy of rhBMP-2 combined with an 
absorbable collagen sponge (ACS) versus bone graft for staged maxillary sinus floor 
augmentation. It was concluded that rhBMP-2 had a similar safety profile to bone graft 
with the added benefit of lacking donor site morbidity. In addition, the rhBMP-2/ACS 
treatment induced similar amounts of bone to the bone graft group, allowing for the 
placement and long-term functional loading of dental implants in approximately 75-80% 
of the patients treated.  
The clinical use of rhBMP-2 to regenerate much larger bone defects has also been 
reported in the literature.  Carstens et al. [28] described the use of “distraction-assisted in 
situ osteogenesis” (DISO) to treat a severe facial cleft, in which rhBMP-2/ACS 
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implantation was combined with distraction osteogenesis to create the patient’s ramus 
and condyle as part of the surgical reconstruction.  A similarly spectacular application of 
rhBMP-7 has been described by Warnke et al. [30] for the reconstruction of a 7 cm 
mandibular continuity defect in a patient who had received ablative tumor surgery and 
subsequent radiation treatment. A bone-muscle-flap prefabrication technique was 
utilized, in which computed tomography and computer aided design techniques were 
used to fabricate a custom titanium mesh cage replicating the contours of the missing 
mandible. Within this cage, a combination of xenogeneic bone mineral blocks coated 
with rhBMP-7 and autologous bone marrow were placed, prior to implantation of the 
entire construct within the latissimus dorsi muscle of the patient. Following seven weeks 
of implantation within this “in vivo bioreactor”, the viable mandibular replacement was 
harvested from the patient along with part of the muscle containing a major artery and 
vein which were subsequently anastomosed with vessels at the recipient site using 
microsurgical techniques. Four weeks after this transplantation surgery, the patient was 
able to undertake a small amount of mastication and enjoy more solid foods. In a similar 
case of prevascularization, Mesimaki et al. implanted a titanium mesh containing β-TCP 
granules seeded with ASCs cultured in rhBMP-2 into the rectus abdominus muscle of a 
patient who had undergone hemimaxillectomy[31].  The mesh was harvested with a 
vascular pedicle 8 months later and anastomosed to vasculature in the face replacing the 
resected bone.  This patient went on to receive dental implants for complete dental 
rehabilitation.   
A significant drawback to growth factor strategies in tissue engineering is the 
shortage of naturally derived factors isolated from biological tissue. This deficiency has 
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been addressed with the development of techniques to produce biologically active 
proteins using recombinant engineering techniques. However, the use of recombinant 
proteins is not without concern [24]. Compared to animal models, bone regeneration in 
humans does not appear to be as robust. In order to overcome this species recalcitrance, 
administration of factors in excess of naturally occurring concentrations appears to be 
necessary. The augmented administration of exogenous factors may potentially stimulate 
harmful biological effects such as malignant transformation of cells and also prove to be 
too expensive when compared to alternative techniques for tissue regeneration.  In an 
effort to mitigate cost, potential for harmful stimulation or disease transmission, 
autologous supplies of growth factors have been investigated, primarily through the use 
of platelet rich plasma (PRP).  As a natural source of growth factors, PRP has been 
applied to craniofacial bone tissue engineering scaffolds, but with limited success, 
illustrating the inherent difference in the effect of therapies across species[32, 33]. 
Attempts to address the shortcomings of recombinant protein-based strategies 
have spurred investigation into the use of gene delivery for tissue engineering. By 
delivering the gene for the expression of a protein with specific effects on a target cell 
population, successfully transfected cells will elaborate the protein constitutively. This 
results in higher and more constant levels of protein production [34]. However, while 
both viral [35, 36] and non-viral [37] gene delivery vectors have been utilized for bone 
regeneration in cranial defect animal models, compromises must be made with each. 
Adenoviral constructs have commonly been used as viral vectors to transfect craniofacial 
tissues and have the advantage of efficiently transfecting both replicating and quiescent 
cells [38]. In addition, adenoviruses are easily manipulated, can be produced in high 
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titers, and large amounts of genetic information can be inserted into them. However, 
concerns related to viral vectors include in vivo homologous recombination and the 
possibility of an immune response from the expression of viral antigens on the surfaces of 
transfected cells. These concerns have led to the development of non-viral vector agents 
[34]. 
While numerous non-viral gene delivery systems exist, a common problem is 
their low in vivo transfer efficiency [38]. Nonetheless, such systems are able to deliver 
much larger genes with minimal immunogenicity. One promising modality of non-viral 
gene delivery for craniofacial applications is the use of cationic liposomes which have 
been used to regenerate cranial bone defects in rabbits by delivering BMP-2 plasmid 
cDNA [39]. The low transfection efficiency of uncondensed, naked plasmid DNA has 
also been addressed by the use of the cationic macromer poly(ethylene imine), which has 
been used to condense BMP-4 plasmid DNA and deliver it in a sustained and localized 
manner from poly(lactic-co-glycolic acid) scaffolds within critical size cranial defects 
[37]. 
Gene transfection can take place directly within the defect site by releasing the 
delivery vector in vivo from the TE scaffold [35, 36]. Indirect delivery methods have also 
been described utilizing a target cell population harvested from the patient, performing in 
vitro transfection of the cells, and then re-implanting the transfected cells into the defect 
along with the TE scaffold material [40]. While the direct technique may be simpler, it 
has a lower transfection efficiency and targets cells in a non-specific manner [24]. The 
indirect ex vivo approach on the other hand, requires additional harvesting and culturing 
procedures, but avoids the risks associated with placing viral vectors directly into the 
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patient and disturbing the host genome. Ex vivo transfected cells are not immunologically 
privileged and may still express viral antigens on their surface which can lead to a host 
response following implantation.  
As a corollary to gold standard approaches where bone grafts and flaps include 
the donor site cells, some TE approaches to craniofacial reconstruction employ cell-
seeded scaffolds as implants. These have potential benefits for regenerating tissues in 
large defects or those with compromised healing capacity, such as those affected by 
radiation therapy [6]. The majority of cell-seeded scaffolds have investigated 
mesenchymal stem cells (MSCs) or adipose derived stem cells (ASCs).  Reviews have 
covered some of the work in these areas looking at various stem cell sources, delivery 
and other parameters such as in vitro expansion and differentiation[6, 41]. To highlight a 
few studies, MSCs were applied to ceramic and polymer scaffolds with and without PRP 
in both cranial and alveolar defects of rats and minipigs, respectively[32, 33].  In both 
studies, the addition of MSCs enhanced bone regeneration over all other groups 
irrespective of PRP presence. In another study, autologous, culture expanded MSCs were 
utilized in combination with alginate hydrogels for the treatment of large cranial bone 
defects in sheep [42]. Finally, pre-differentiated ASCs were applied to rabbit cranial 
defects on gelatin scaffolds showing enhanced bone regeneration within the defect[43].  
However, in another rabbit cranial defect study, rhBMP-2 on collagen regenerated greater 
amounts of bone compared to ASCs or pre-differentiated ASCs, indicating that although 
cell delivery for bone regeneration in the craniofacial complex shows promise, issues of 
cell sourcing, purification and processing need to be investigated further[44]. 
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Aside from the biological components of tissue engineering constructs, scaffold 
properties are also extremely important to the overall success of any particular strategy. A 
common misconception is that bone TE scaffolds for craniofacial applications do not 
require substantial strength since the craniofacial skeleton is not subjected to heavy 
loading. However, in vivo studies demonstrate that many craniofacial bones undergo 
levels of strain similar to that experienced by the appendicular skeleton [45], 
substantiating the need for mechanical strength of potential bone TE scaffolds. Ideal 
scaffold design must therefore reconcile the need for high porosity and interconnectivity 
which promotes tissue in-growth and scaffold degradability, with a requirement for 
mechanical strength. Computational methods for designing and fabricating scaffold 
architectures to optimize both pore interconnectivity and load bearing characteristics have 
been performed [46], and a proof of concept study has illustrated the effectiveness of 
scaffold design in fabricating a mandibular condyle for a minipig[47]. 
The surface characteristics of bone tissue engineering scaffolds also determine 
their ability to regenerate tissue in the wound healing environment. Surface chemistry has 
a significant effect on the interactions between the cell populations present in the defect 
and the biomaterial. Hydrophilic synthetic polymers such as oligo(poly(ethylene glycol) 
fumarate) (OPF) have been shown to impede bone healing in extraction sockets as 
compared to the hydrophobic polymer poly(propylene fumarate), based on the OPF 
macromer’s prevention of protein adsorption and hence cell adhesion [48]. Interestingly, 
the resistance of OPF hydrogels to generalized cell adhesion has been used to advantage 
in the fabrication of biomimetic scaffolds, which are able to selectively encourage the 
migration of osteoblasts in vitro through the addition of specific binding peptides to their 
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surfaces such as osteopontin-derived peptide [49].   In addition to surface chemistry, 
surface topography can impact healing.  In a series of studies, porous materials in the 
mandibles of New Zealand White rabbits were shown to enhance the healing of the 
overlying mucosal surface in a composite tissue defect model [50-52].  However, 
contrary to traditional tissue engineering materials with high porosity led to an increased 
inflammatory response not seen with lower porosity materials [50].  Two of these studies, 
investigated porous poly(methyl methacrylate) (PMMA), a material currently part of 
many Food and Drug Administration (FDA) cleared products.  By creating porous 
PMMA and enhancing soft tissue interaction with the implant, these materials show 
promise for rapid translation to clinical use in a staged approach, whereby the implants 
serves to temporarily maintain the bone space during soft tissue regeneration and is 
removed for the definitive therapy.     
1.4.2. Oral Mucosa Applications 
Oral mucosa regeneration has followed many of the strategies of skin tissue 
engineering, in that cultured epithelial sheets showed inadequate results due to fragility, 
contractility and failure due to lack of underlying supporting tissue.  Thus many 
approaches have considered the use of thick cultured grafts containing single or multiple 
cell types.  An extensive review by Moharamzadeh et al. covers scaffold materials, cell 
sources and culture medium [53].  Many of the same materials have been investigated for 
oral mucosal engineering as in bone and cartilage such as collagen, fibrin, gelatin, PLGA, 
and PCL. Additionally, various cell sources have been used, primarily keratinocytes and 
fibroblasts either from oral or skin origins.  Finally, growth factors like epidermal growth 
factor have been employed to promote proliferation.  In one study, fibroblasts and 
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keratinocytes were cultured on a collagen composite scaffold [54].  The culture led not 
only to cell specific markers for a full thickness mucosa but structural components 
including a basement membrane and extracellular matrix.  A similar study used gingival 
fibroblasts and keratinocytes harvested from patients on a clinically available collagen 
matrix, resulting in cell markers and tissue structures similar to mucosal tissue [55].  In 
vivo, mucosal grafts of collagen precultured with gingival fibroblasts and keratinocttes 
have maintained their phenotype as mucosal tissue after 60 days of implantation[56].  
Finally, one group has shown translation of tissue engineered mucosal graft.  Creating a 
mucosal graft in vitro using canine cells cultured on AlloDerm, the group translated this 
technique by first using human cells in vitro [57, 58].  Subsequently, in a 30 patient study 
comparing AlloDerm alone to AlloDerm precultured with autologous cells, the 
precultured grafts show enhanced wound healing with earlier vascularization and 
maturation of the submucosal layer at 28 days after grafting [59]. 
In addition to oral mucosa, composite grafts for muco-cutaneous junctions such as 
the lips.  Peramo et al. presents a novel approach to creating these junctions, where oral 
mucosal cells and skin cells are cultured on AlloDerm in vitro with a separation barrier 
[60].  This barrier is lifted and the cells are allowed to migrate into the junction space and 
interact.  The cell construct was then lifted to air-liquid interface for maturation of the 
construct and characterized for morphology and immunohistochemical staining for 
keratin content.  Biochemical markers were consistent with spatial distribution in 
mucocutaneous tissues, illustrating the possibility of this strategy to be employed for 
tissue engineering lips. 
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1.4.3. Composite Tissue Applications 
Success with the regeneration of single tissue types such as bone and cartilage has 
encouraged investigators to attempt the reconstruction of structures composed of multiple 
tissue types. Such anatomic structures may exist as composites of hard and soft tissues, 
which differ in their cellular composition and mechanical properties, yet perform as a 
single functional unit [61].  
The temporomandibular joint condyle serves as an example of a maxillofacial 
composite structure consisting of articular cartilage and subchondral bone and provides 
an excellent opportunity for composite osteochondral tissue engineering. A study 
performed by Alhadlaq et al. [62], used adult bone marrow MSCs, expanded in culture 
and induced to differentiate into separate osteogenic and chondrogenic lineages in vitro. 
The resultant cells were then encapsulated in poly(ethylene glycol) based hydrogels and 
the cell-polymer solutions crosslinked in a mold which provided the correct stratified 
organization of the osteogenic and chondrogenic layers. Finally, the osteochondral 
constructs were implanted into the dorsum of immunodeficient mice for up to 8 weeks. 
Histological and immunohistological analysis revealed both structural and 
immunohistochemical differences between the osteogenic and chondrogenic layers, 
which served as a primitive proof of concept of the potential for composite tissue 
engineered constructs in the craniofacial region.  In a similar study trying to regenerate 
tissue within an osteochondral defect, a gradient scaffold releasing BMP-2 on the 
osteogenic side of the scaffold and TGF-β1 on the chondrogenic side was fabricated[63].  
This construct showed increased osteo- and chondrogenesis on the respective sides.   
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1.5. Tables and Figures 
 
Figure 1.1. The human skull is a complex region composed of many bones. Several 
key structures include the: (A) nasal bone; (B) maxilla; (C) mandible; (D) zygomatic 
bone; (E) temporomandibular joint; (F) temporal bone; (G) orbital cavity; and (H) 
frontal bone. 
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Figure 1.2. Stereolithographic model of a patient demonstrating the extent of a 
maxillary hard tissue defect. 
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Figure 1.3. Intra-oral photo of a patient with a giant cell tumor of the maxilla, which 
presents as a swelling of the palate and erosion of the supporting bone resulting in 
the loss of adjacent teeth. 
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Figure 1.4. Coronal CT scan of the same patient in Figure 1.3 with a giant cell lesion 
of the right maxilla which has produced marked bone destruction and displacement 
of developing teeth. Sinusitis of the left maxillary sinus is an incidental finding. 
 27 
 
 
Figure 1.5. Panoramic radiograph of a patient with a fractured atrophic mandible 
(courtesy of Kamal Busaidy, D.D.S.). 
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Figure 1.6. 3-D reconstructed radiograph of a patient with a self-inflicted gunshot 
wound demonstrating the significant disruption and loss of maxillofacial skeletal 
structures. 
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Figure 1.7. Intraoral view of a left maxillary alveolar cleft. An oro-nasal fistula is 
present at the superior-most aspect of the cleft (see arrow). 
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Figure 1.8. Radiograph of a cleft of the maxillary alveolar bone. 
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Chapter 2 
Objectives 
Tissue engineering in the craniofacial complex holds great promise for 
regenerating all tissue types present in the craniofacial complex.  These strategies 
typically employ complex approaches utilizing multiple arms of the tissue engineering 
paradigm: cells, bioactive factors, and scaffolds.  Considering the regulatory landscape 
and the time to clearance or approval of such strategies concomitantly with the pressing 
clinical needs of today, alternative strategies employing concepts from tissue engineering, 
conventional reconstruction and regulatory experience should be considered.  The work 
presented in this dissertation follows these principles by attempting to enhance the use of 
materials currently part of products approved or cleared by the United States Food and 
Drug Administration (FDA).  This strategy should accelerate the regulatory process and 
more rapidly impact clinical practice.   
The overarching strategy investigated in this thesis is the two-stage repair of 
craniofacial defects with an antibiotic-releasing porous polymethylmethacrylate (PMMA) 
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space maintainer and a stabilizing bone regenerating implant in the same patient.  To 
evaluate this strategy several aspects were investigated individually. 
2.1. Specific Aim 1: Porous Space Maintenance 
2.1.1. Study 1: Evaluation of Soft Tissue Coverage over Porous 
Polymethylmethacrylate Space Maintainers Within Nonhealing Alveolar 
Bone Defects 
Prefabricated porous PMMA scaffolds fabricated with carboxymethylcellulose 
gel (CMC) as the porogen were evaluated for soft tissue coverage and tissue response in a 
composite tissue defect model of the rabbit mandible. 
2.1.2. Study 2: In situ Formation of Porous Space Maintainers in a Composite 
Tissue Defect  
Porous PMMA scaffolds fabricated with CMC as the porogen were formed in situ 
and evaluated for soft tissue coverage and tissue response in a composite tissue defect 
model of the rabbit mandible to assess the effect of polymerization and curing on the 
tissue response. 
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2.2. Specific Aim 2: Antibiotic-releasing Porous Space Maintainers 
2.2.1. Study 1: Antibiotic--releasing Porous 
Polymethylmethacrylate/Gelatin/Antibiotic Constructs for Craniofacial 
Tissue Engineering 
Colistin-releasing porous PMMA scaffolds fabricated with gelatin microparticles 
as the porogen were evaluated for physical properties and release kinetics. 
2.2.2. Study 2: Evaluation of Antibiotic--‐releasing Porous 
Polymethylmethacrylate/Gelatin Scaffolds 
Colistin-releasing porous PMMA scaffolds fabricated with a clinical grade gelatin 
matrix as the porogen were evaluated for physical properties and release kinetics. 
2.2.3. Study 3: Evaluation of Antibiotic-releasing Porous 
Polymethylmethacrylate Space Maintainers in an Infected Composite Tissue 
Defect Model 
Colistin-releasing porous PMMA scaffolds fabricated with a clinical grade gelatin 
matrix as the porogen were evaluated for kidney function, soft tissue coverage, tissue 
response and infection clearance in a composite tissue defect model in a rabbit mandible 
that was inoculated with Acinetobacter baumannii.  
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2.3. Specific Aim 3: Bone Regeneration 
2.3.1. Study 1: Biodegradable Composite Scaffold Incorporating an 
Intramedullary Rod and Delivering Bone Morphogenetic Protein-2 for 
Stabilization and Bone Regeneration in Segmental Long Bone Defects 
Porous poly(propylene fumarate) (PPF) scaffolds with bone morphogenetic 
protein-2 (BMP-2) delivering poly(lactic-co-glycolic acid) (PLGA) microparticles with a 
solid PPF intramedullary rod were evaluated for bone regeneration, tissue response and 
mechanical stabilization in a rat femoral segmental defect model. 
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Chapter 3 
Evaluation of Soft Tissue Coverage 
over Porous Polymethylmethacrylate 
Space Maintainers Within Nonhealing 
Alveolar Bone Defects‡,* 
The incidence of traumatic facial injuries relative to injuries at other anatomic 
locations has risen sharply during combat operations in Iraq and Afghanistan compared to 
previous military conflicts [64].  The predominant cause of these wounds is improvised 
explosive devices, which often cause extensive damage to bone and soft tissues [65].  
                                                
 
‡ This chapter was published as Kretlow JD, Shi M, Young S, Spicer PP, Demian N, 
Jansen JA, Wong ME, Kasper FK, Mikos AG. “Evaluation of Soft Tissue Coverage over 
Porous Polymethylmethacrylate Space Maintainers Within Nonhealing Alveolar Bone 
Defects.”  Tissue Eng Pt C Methods. 16, 1427-1438 (2010). 
* The doctoral candidate performed portions of the presented work including animal 
tissue harvest, processing and analysis. 
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Similarly, combat related ballistic injuries often involve high velocity projectiles that 
cause significant and widespread damage to multiple types of tissue [66].   
Even in the civilian population, traumatic craniofacial bone injury is often 
accompanied by injury or loss of surrounding soft tissues [67].  One of the major 
difficulties reconstructive surgeons face when treating injuries involving significant bone 
loss is contracture and scarring of the overlying soft tissue envelope, which compromises 
facial projection and makes staged repair of bony structures difficult [68, 69].  
Previously, definitive bone reconstruction was delayed until soft tissue coverage and a 
sterile wound environment were achieved [70, 71].  More recently, despite reports of 
local complications and wound infection rates as high as 100% in civilians suffering 
gunshot wounds to the face [72, 73], early definitive repair of facial gunshot wounds via 
free tissue transfer has become common as the well vascularized tissues that are 
transferred survive well in hostile wound environments [71, 74].  
The field of regenerative medicine and the technologies borne from tissue 
engineering offer great hope towards providing an alternative and possibly better 
approach to regenerating injured or destroyed tissues.  Most proposed tissue engineering 
strategies, however, currently require planning in the form of material fabrication, 
autologous cell harvest and expansion, and/or ex vivo tissue generation.  Additionally, 
little to no evaluation of tissue engineering approaches is currently performed in wound 
environments involving infection, significant vascular injury, and large-scale tissue 
devitalization such as that encountered in a battlefield wound.  Therefore, the successful 
use of a tissue engineering approach to provide immediate, definitive regeneration of 
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tissues injured during craniofacial trauma such as those encountered during military 
service is unlikely using current approaches.   
In the absence of immediate reconstruction, clinical management of facial bone 
loss can involve the placement of an alloplastic space maintainer to provide a template 
for future definitive reconstruction and prevent wound contracture into the space 
normally occupied by bone [75].  Polymethylmethacrylate (PMMA), is commonly used 
in such space maintenance applications [75, 76] and others within the craniofacial 
complex [77].  Although PMMA has many desirable characteristics for such applications 
(moldable, FDA-regulated, familiar to surgeons), a number of problems exist with respect 
to wound healing around PMMA implants and other alloplastic craniofacial implants [78-
80]. 
For the purposes of facilitating a long-term tissue engineering approach to treating 
composite craniofacial defects, a temporary implant or space maintainer would allow 
time for a regenerative medicine approach to be used to definitively regenerate the 
injured or absent tissue.  In addition to providing space maintenance, such a temporary 
implant could be used to “prime” the defect site, enabling better long-term success of the 
definitive regenerated tissue construct.  Previous work has shown that recipient site 
characteristics such as vascularity are important for the regeneration of new bone tissue 
and support of grafted tissue [81-83].  For mandibular reconstruction, the defect site and 
surgical approach along with recipient site complications such as infection, intraoral 
exposure, and prolonged antibiotic use have been significantly linked to graft failure [84, 
85].  An ideal temporary space maintainer will therefore not only maintain the osseous 
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void and prevent soft tissue collapse or contracture into the space but also will allow or 
promote soft tissue coverage and healing without serving as a nidus for local infections.   
Despite the aforementioned shortcomings associated with solid PMMA implants, 
we hypothesized that an implant made of modified PMMA could fulfill many of these 
criteria.  Previously, a number of groups have explored different methods for making 
porous PMMA [86-91].  Based on this work, we hypothesized that porous PMMA 
implants with reproducibly tunable pore structure could be fabricated using a 
carboxymethylcellulose (CMC) hydrogel as an aqueous porogen.  When tested in a 
clean/contaminated rabbit mandibular defect, we hypothesized these implants would be 
able to maintain the defect space while promoting soft tissue coverage of the implant.   
3.1. Material and Methods 
3.1.1. Experimental design 
For the first part of this study, porous PMMA implants were synthesized and 
characterized using a CMC hydrogel as an aqueous phase to impart porosity on the 
implants.  The percent of CMC in the aqueous phase and the ratio of aqueous 
phase:polymer phase were varied in order to control the bulk and surface characteristics.  
Following characterization of the porous implants, two formulations, one with high bulk 
porosity and pore interconnectivity and one with lower porosity and less pore 
interconnectivity, were compared over 12 weeks in vivo to a solid PMMA implant within 
a modified rabbit mandibular defect. 
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3.1.2. Implant fabrication and characterization 
Solid and porous PMMA implants were fabricated using a clinical grade PMMA 
bone cement (SmartSet High Viscosity, DePuy Orthopaedics, Warsaw, IN) consisting of 
a powder of methylmethacrylate / methyl acrylate copolymer, benzoyl peroxide, and 
zirconium dioxide and a liquid phase with methylmethacrylate (MMA), N,N-dimethyl-p-
toluidine, and hydroquinone.  For the solid implants, the solid and powder phases were 
mixed according the manufacturer’s specifications for approximately 90 seconds and, 
once they reached a dough-like consistency, packed into custom-fabricated 10 mm 
diameter × 6 mm height cylindrical Teflon® (DuPont, Wilmington, DE) molds.  The solid 
implants were then allowed to harden at room temperature for 30 minutes before being 
removed from the molds and vacuum-dried overnight. 
For porous implants, 7 wt% and 9 wt% CMC hydrogels were prepared by 
dissolving the appropriate amount of United States Pharmacopeia grade low viscosity 
CMC (Spectrum Chemical Manufacturing Corp., Gardena, CA) in distilled water.  The 
powder component of the PMMA cement was then mixed with the CMC hydrogel such 
that the powder was uniformly suspended within the aqueous phase.  The liquid 
component of the PMMA cement was then added to the mixture of aqueous/powder 
phases.  Aqueous phase weight percentages of 30, 40, and 50 wt% were used to fabricate 
the implants, resulting in 6 experimental groups.  The aqueous and polymer phases were 
then stirred by hand for approximately 90 seconds and packed into Teflon® molds of the 
same size as the solid PMMA implants.  The porous implants within molds were then 
allowed to harden for 30 minutes before being removed from the molds, placed within 
individual cassettes, and the aqueous phase was then leached from the implants in 
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deionized, distilled water as previously described [92].  The porous PMMA implants 
were then vacuum dried overnight in a laboratory freeze dryer (Lyph-Lock 4.5, Labconco 
Corp., Kansas City, MO). 
Implant porosity and pore interconnectivity were analyzed using microcomputed 
tomography (microCT) as previously described [93].  Briefly, implants (n=3) from all 
experimental groups were scanned using a SkyScan 1172 microCT imaging system 
(SkyScan, Aartselaar, Belgium).  High resolution 1280 × 1024 pixel images were created 
by scanning at an 8 µm/pixel resolution with no filter at voltage and current settings of 40 
kV and 250 µA, respectively.  Serial tomograms were reconstructed, resliced, and 
analyzed using NRecon and CTAn software packages provided by SkyScan.  For 
porosity and pore interconnectivity analyses, the scanned object volumes were binarized 
using a global threshold of 60-255.  Porosity and interconnectivity were determined using 
a 9 mm diameter × 5 mm height cylindrical volume of interest to eliminate edge effects.  
Pore interconnectivity was determined by repeatedly applying a shrink wrap algorithm 
with minimum interconnection sizes ranging from 40-320 µm.  Interconnectivity is 
reported as the percentage of pore volume accessible from outside the volume of interest 
with pores considered accessible only if the interconnection to that pore allowed a sphere 
with diameter of the user defined minimum interconnection size to pass through.   
Scanning electron microscopy (SEM) was also used to examine the external 
surface of the implants.  Implant surfaces were sputter-coated with gold for 40 s at 100 
mA using a CrC-150 sputtering system (Torr International, New Windsor, NY) and 
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observed at an accelerating voltage of 10 kV using a FEI Quanta 400 field emission 
scanning electron microscope (FEI company, Hillsboro, OR).  
3.1.3. In vivo implant evaluation 
Solid PMMA implants and porous implants (9 wt% CMC within the aqueous 
phase and both 30 and 40 wt% total aqueous phase in the implant) were evaluated in vivo 
using a modification of a nonhealing rabbit mandibular defect model [94].  All surgical 
procedures followed protocols approved by the Institutional Animal Care and Use 
Committees at both Rice University and the University of Texas Health Science Center at 
Houston.  Eighteen healthy male adult New Zealand White rabbits (n = 6 per group), at 
least 6 months old and weighing 3.5-4 kg were purchased from Myrtle’s Rabbitry 
(Thompson Station, TN).  Prior to implantation, all implants were sterilized using 
ethylene oxide.  
Briefly, each animal was given preoperative intramuscular doses of 
buprenorphine hydrochloride (0.1 mg/kg body weight) for postoperative analgesia and 
0.5 mL Durapen® (150,000 U/mL penicillin G benzathine and 150,000 U/mL penicillin G 
procaine) for perioperative antibiotic coverage. Prior to induction, ketamine 
hydrochloride (40 mg/kg body weight) and xylazine hydrochloride (7.5 mg/kg body 
weight) were given, after which rabbits were placed in a supine position, intubated and 
placed under general anesthesia using an isoflurane/O2 mixture (2.5-3% isoflurance for 
induction, 2% for maintenance) with constant cardiac and respiratory monitoring.  The 
animals were then surgically prepped and draped, after which a 7 cm midline incision 
through the skin and superficial fascia was made beginning 0.5 cm posterior to the 
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mentum.  Using blunt dissection and electrocauterization, the left masseter was exposed 
and the soft tissue along the inferior border of the body of the left hemimandible was 
mobilized such that the periosteum covering the body of the mandible could be incised 
and elevated, exposing a 4 cm × 1.5 cm area on the lateral surface of the mandible. A 10 
mm titanium trephine (Ace Surgical Supply, Inc., Brockton, MA) attached to a Stryker 
TPS® surgical handpiece (Stryker, Kalamazoo, MI) operating at 15,000 rpm with copious 
normal saline irrigation was used to create a bicortical defect through the exposed body 
of the left mandible. A 701 bur in combination with the surgical drilling unit was used to 
cut a 2-3 mm window through the alveolar ridge in the middle of the defect to provide 
access for removal of the crowns of the associated teeth and provide intraoral exposure of 
the defect. The defect site was thoroughly washed with normal saline, after which an 
implant was placed within the defect.  The order of implant placement was randomized; 
and none of the surgical personnel, who were the same throughout the study, were aware 
of which implant was being used.  Prior to closure, a titanium supporting plate (1.5 mm 
6-hole heavy gauge titanium; Synthes, West Chester, PA) was secured in place to prevent 
iatrogenic fracture during the course of the study.  The incision was then closed in 3 
layers (muscle, fascia, and skin) using degradable sutures (Vicryl polyglactin sutures, 
Ethicon, Somerville, NJ).  Following wound closure, anesthesia was reversed, and the 
animals were extubated. 
Postoperatively, the animals were given access to food and water ad libitum.  
Food was limited to a soft recovery diet (Critical Care for Herbivores, Oxbow Pet 
Products, Murdock, NE) and shredded or mashed fruits and vegetables to reduce stress on 
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the mandible. All animals survived the 12-week post-operative period without 
complications. 
3.1.4. Gross characterization 
After 12 postoperative weeks, each rabbit was euthanized via intravenous 
injection of 1 mL Beuthanasia-D® (390 mg/mL pentobarbital sodium and 50 mg/mL 
phenytoin sodium).  The left hemimandibles were then carefully dissected from the 
cranium with care taken to preserve the soft tissue surrounding the implant and within the 
oral cavity.  The oral mucosa and dentition covering the alveolus of each specimen was 
examined to detect any areas of implant or bone exposure.  Specimens were individually 
placed in 10% neutral buffered formalin and stored on a shaker table at 4 ˚C for 72h.   
3.1.5. Histology 
After fixation, samples were dehydrated and stored in 70% of ethanol and then 
embedded in MMA.  Following polymerization of the MMA, 3 coronally oriented 10 µM 
thick sections through the center of each implant were cut using a modified diamond saw 
technique [95] and subsequently stained using methylene blue/basic fuchsin. 
Each of the stained sections was analyzed using light microscopy (Zeiss Axio 
Imager Z1 and AxioCam MRc 5, Carl Zeiss AG, Oberkochen, Germany) by two blinded 
observers (SY and FKK).  A quantitative scoring system (Table 3.1) was used to score 
the tissue response at the implant interface and within the pores of the porous implants. 
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3.1.6. Statistical analyses 
Implant porosity data were analyzed using single factor analyses of variance 
(ANOVA) with post hoc pairwise comparisons made using Tukey’s HSD.  Oral mucosal 
wound healing, as observed grossly and confirmed by microscopy, was analyzed using a 
Fisher-Freeman-Halton test.  Histological scoring was analyzed using nonparametric 
statistics.  The tissue response at the implant interface was analyzed using a Kruskal–
Wallis one-way analysis of variance with subsequent pairwise analyses made using the 
Dwass-Steel-Critchlow-Fligner test.  A Mann-Whitney U test was used to analyze the 
tissue response within the pores of the two porous implant types.  The a priori level of 
significance for all analyses was chosen as α = 0.05.  All analyses were performed using 
R version 2.10.0 (R Foundation for Statistical Computing, Vienna, Austria). 
3.2. Results 
3.2.1. Implant fabrication and characterization 
Porous PMMA/CMC implants were reproducibly fabricated as described in the 
Materials and Methods section.  MicroCT analyses showed that porosity increased as 
expected with increasing incorporation of the aqueous phase (Figure 3.1).  Significant 
differences in implant porosity were observed between all groups as the aqueous phase 
incorporation increased.  Varying the amount of CMC within the aqueous phase did not 
significantly alter the implant porosity. 
Pore interconnectivity also increased with increasing aqueous phase incorporation 
(Figure 3.2).  Interconnectivity appeared to be affected by the percentage of CMC in the 
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aqueous phase; the more negative slope observed for implants with 9% CMC within the 
aqueous phase indicates that more of the interconnections in these implants were smaller 
than for those implants fabricated with 7% CMC in the aqueous phase.   
SEM images and microCT reconstructions also showed differences in the porosity 
and surfaces of the fabricated implants (Figure 3.3).  The porosity increases with 
increasing aqueous phase incorporation quantitatively detected with microCT are seen in 
cross sections and surface images of the implants.  Furthermore, the pore size appears 
more consistent within implants fabricated using 9% CMC in the aqueous phase, likely 
resulting in the relative abundance of smaller pore interconnections within these implants 
when compared to those fabricated using 7% CMC. 
3.2.2. In vivo implant evaluation 
Based on the implant characterization, solid PMMA implants, 9% CMC 30 wt% 
(16.9 ± 4.1% porosity, 39.7 ± 9.4% interconnectivity at a 40 µm minimum connection 
size) and 9% CMC 40 wt% (44.6 ± 2.1% porosity, 81.2 ± 1.0% interconnectivity at a 40 
µm minimum connection size) implants were chosen for implantation in the in vivo phase 
of the study.  All animals survived the surgery and post-operative period without 
complications.  No changes in eating habits or activity were noted by the investigators, 
husbandry staff, or veterinary staff. 
3.2.3. Gross characterization 
At the time of animal euthanasia and implant/hemimandible harvest, no signs of 
mobility or infection were noted in any of the animals or visible tissues following 
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harvest.  Wound healing (closure) of the oral mucosa over the alveolar ridge at the site of 
the intraoral communication was assessed grossly (Figure 3.4) and correlated to 
histological results (Figure 3.6) to confirm the gross observations.  Wound healing was 
considered incomplete when any exposed bone or implant could be grossly observed and 
histology also indicated a failure of soft tissue coverage over the implant or within the 
defect.  The increase in oral mucosal wound healing observed in defects filled with both 
low and high porosity implants (83% of defects healed in each group) versus non-porous 
PMMA implants (50% healed) was not statistically significant (p > 0.08). 
3.2.4. Histology 
Histology and histological scoring were performed to assess the ability of the 
implants to maintain space within the surgically created osseous void and to view and 
quantify the soft tissue response around and within the implants.  At low magnifications 
allowing coronal views of the entire implant and defect in cross section, all implants 
successfully maintained the defect space within the hemimandible.  This space 
maintenance was confirmed by the lack of tissue collapse or contracture into the space 
occupied by the implants with the exception of tissue invading the pores of the porous 
implants (Figure 3.6).   
At higher magnification, the tissue response at the implant-tissue interface and 
within the implant pores could be observed (Figure 3.7).  At the implant-tissue interface, 
both the low porosity and solid implants were in many cases surrounded by a thin, well-
organized fibrous capsule.  The low porosity implants were also in direct contact in many 
areas with any newly formed bone observed at the implant interface.  The high porosity 
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implants were primarily surrounded by an abundance of inflammatory plasma cells at the 
implant interface, and a similar inflammatory cell population was observed within the 
pores of the highly porous implants.  When a quantitative scoring system was applied, the 
interfacial tissue response for the highly porous implants was statistically significantly 
different from the response observed around both the solid and low porosity implants 
(Figure 3.8, p < 0.05).  Similarly, the difference in tissue response within the pores of the 
low and high porosity implants was statistically significant (Figure 3.8, p < 0.05). 
3.3. Discussion 
Temporary space maintainers have historically been used clinically to prevent soft 
tissue collapse into bony defects and provide a template for delayed bone healing or 
grafting [75, 96].  Recently, however, space maintenance has been used infrequently, 
particularly in the staged repair of traumatic injuries, as immediate free tissue transfer has 
eliminated the need for space maintenance and staged repair.  Additionally, problems 
with existing biomaterials such as problems with healing of surrounding tissues, implant 
extrusion, or bacterial colonization have further limited the use of space maintainers, 
particularly in applications where soft tissue healing or infection may be a concern [97, 
98]. Unfortunately, due to limitations in current tissue engineering technology, injuries 
involving lacking or devitalized soft tissues or the possibility of infection are precisely 
the type a staged repair using temporary space maintenance might allow a regenerative 
medicine approach to be undertaken.   
The present study aimed to evaluate methods to reproducibly fabricate and 
characterize porous PMMA implants using a CMC porogen and to then develop an 
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animal model to test selected formulations in a non-healing bone defect that 
approximated a more toxic wound environment than most traditional animal models.  In 
the first part of the study, porous PMMA implants were fabricated in a one step process 
by incorporating a CMC hydrogel that could be leached away rapidly in vitro or in vivo.  
Varying both the amount of CMC within the aqueous phase and the relative amount of 
aqueous phase to polymer phase allowed for well-controlled porosity and pore 
interconnectivity.  As expected, higher percentages of porogen resulted in greater implant 
porosity, while increasing the viscosity of the aqueous phase porogen by incorporating of 
greater amounts of CMC within the hydrogel led to a more consistent pore size and 
higher pore interconnectivity when the minimum interconnection size was decreased. 
In the second part of the study, two formulations of porous PMMA implants and 
solid PMMA implants were implanted into non-healing rabbit mandibular defects that 
had been contaminated through an open communication with the oral cavity.  Porous 
PMMA formulations were selected such that both a highly porous, highly interconnected 
implant (9% CMC 40 wt%) and an implant of lower porosity and lower interconnectivity 
could be compared (9% CMC 30 wt%).  Healing of the communication into the oral 
cavity was assessed as well as the tissue response both around and within the implants.  
All formulations successfully maintained space within the defect.  Soft tissue was only 
observed within the defect when it was penetrating the pore network in the two 
formulations of porous implant.  The oral mucosal defects created to allow 
communication into the bone defect healed in more cases (5/6 healed for both low and 
high porosity implants) when the bony defects were filled with porous implants than 
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when filled with solid implants (3/6 healed), although the differences between groups 
was not statistically significant.   
Although the gross mucosal defect closure over the high and low porosity 
implants was equivalent, microscopically, the tissue response around and within the pores 
of the low porosity implants was more favorable.  At the implant – tissue interface, a 
small, well formed capsule or direct tissue – implant contact was typically observed 
around the low porosity implants.  Immature fibrous tissue with few inflammatory 
elements was generally seen within the filled pores of the low porosity implants.  
Contrastingly, the tissue surrounding and within the pores of the highly porous implants 
was almost exclusively inflammatory, consisting mostly of plasma cells.  Thus the low 
porosity and solid implants elicited a more favorable soft tissue response than the highly 
porous implants, while the porous implants may have provided a template for improved 
wound healing in comparison to the solid implants. 
The current study has a number of strengths.  First, although porous PMMA has 
been well studied [87, 89, 99-102], including porous PMMA fabricated using an aqueous 
phase consisting of a CMC hydrogel as a porogen [88, 103], the present study is one of 
the first systematic studies of fabrication methods to quantitatively examine the effect of 
both the ratio of aqueous phase to polymer phase but also the effect of the aqueous phase 
viscosity as done by varying the amount of CMC within the aqueous phase.  Increasing 
the viscosity of the aqueous phase by using a 9 wt% CMC hydrogel, as opposed to a 7 
wt% CMC gel as has been previously used [104], resulted in a more consistent pore 
architecture with smaller, more consistently sized pore interconnections.  Because of this, 
both porous implant formulations chosen for the in vivo study were fabricated with 9 wt% 
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CMC hydrogels.  An additional benefit of the chosen materials is that both PMMA and 
CMC are FDA regulated for craniofacial applications, and the fabrication of the implants 
can be done in a standard operating room with only minor alterations in the manufacturer 
recommended preparation of PMMA. 
A strength of the in vivo portion of the study was the development of a more 
clinically relevant animal model that may better simulate the type of clinical situation in 
which the technology investigated may be used.  The animal model was based on a 
previously developed rabbit mandibular defect [94] that was modified to allow 
contamination of the wound through an opening into the oral cavity.  This conferred 
several advantages.  First, mucosal wound healing within the rabbit oral cavity is a well-
established method for evaluating wound healing [105-109], particularly when evaluating 
biomaterial-guided wound healing [110-115].  Second, in the clinical setting, the 
presence of intraoral communication is significantly correlated to decreased bone graft 
survival time [85], and thus an implant evaluation strategy that focuses on the closure of 
these communications is relevant for a situation where definitive repair will be performed 
using a standard or tissue engineered bone graft.  With relation to the presence of these 
intraoral communications, infection is a major concern when dealing with any 
implantable biomaterial [116], particularly PMMA [117, 118], and thus evaluating the 
tissue response to the implant in an environment where it will most likely be exposed to 
bacteria strengthens any conclusions drawn with respect to optimal material formulations.  
Finally, although the observed differences in oral mucosal wound healing does not allow 
one to draw any definitive conclusions about how the presence of porosity affected the 
oral mucosal wound healing, this study establishes the statistical parameters necessary to 
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determine the statistical power needed to achieve significance in future studies using this 
model. While a difference in healing clearly existed between both the high and low 
porosity implants and the solid PMMA implants, the difference was not significant.  
Somewhat surprisingly, the difference in tissue response to the porous implants based on 
histological scoring was significantly different and may be an important parameter not 
only for initial wound healing but also for subsequent bone regeneration [119-121]. 
This study is not, however, without weaknesses.  First, an ideal tissue engineering 
solution to the problem of complicated craniofacial bone defects would not involve 
multiple interventions and delayed reconstruction.  An ideal solution would use a 
degradable material [122] that could address the issues of soft tissue coverage, infection, 
and bone regeneration concurrently, thus eliminating the need for and risks associated 
with repeated operations.  At present, such a solution does not exist nor does there appear 
to be any such solution developed for use in the near future.  While the animal model 
developed is viewed by the authors as one of the strengths of this method of material 
evaluation, the complexity of the model may also be viewed as a weakness.  Not only is 
the tooth bearing segment of the mandible more complicated in structure than many 
craniofacial bones, it also is exposed to very different mechanical stresses than other 
bones [123].  Furthermore, the method of wound contamination was poorly controlled.  
Oral flora of the rabbits and the amount of flora that passed through the communication 
was likely variable between animals.  
Limited research is available investigating PMMA strictly for use as a space 
maintainer; however, PMMA has a long track record of use in craniofacial applications.  
In an early study using PMMA to repair canine mandibular defects, Worley reported that 
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repair failed in 7 of 11 dogs due to wound dehiscence over solid PMMA implants [124].  
Kangur et al. reported similar problems with mucosal dehiscence over solid PMMA used 
to fix canine mandibular fractures and attributed the presence of an acute inflammatory 
tissue response to the PMMA to this oral communication [125].  Despite these findings, a 
number of studies exist that report no complications with solid PMMA use in craniofacial 
applications [75, 98, 126, 127]. 
Porous PMMA, as previously mentioned has also been investigated in animal 
studies and limited clinical use.  In a long term study in guinea pigs comparing porous 
and solid PMMA implanted in the hypodermis, van Mullem et al. reported implant 
extrusion occurred in 4/36 solid implants and none of the porous implants [90].  Similar 
to the present study, the same study noted that foci of inflammatory cells were found 
more frequently around and within the porous PMMA implants (1:1 aqueous 
phase:polymer phase) than the solid implants.  Clinically, the porous PMMA seems to 
have been used successfully with little note of complications [128], and, while reports of 
long-term results are rarely found, it should be noted that the current study differs from 
those previously published as the intent is for the porous implants to only be used as 
temporary implants.   
 
Using the presented methods for fabrication and evaluation, the porous PMMA 
implants appeared to promote or allow wound healing of the oral mucosa better than the 
solid implants, although not significantly so.  Significant differences in the tissue 
response to the two formulations of porous implants were also observed.  A number of 
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possible explanations exist for these two findings.  The trend of improved wound healing 
with use of the porous implants may best be explained by increased tissue integration 
within the pores of the implants.  This may have limited implant micromovement and 
improved the rate at which new tissue formed across the implant to close the 
communication.  Similar improvements in wound healing and implant retention have 
been found when using porous polyethylene for the fixation of bone-anchored hearing 
aids [129, 130]. 
The inflammatory tissue response around and within the highly porous implants 
was likely caused by increased bacterial seeding of these implants.  The increased 
porosity and interconnectivity of these implants compared to those of the low porosity 
and lower interconnectivity group likely led to bacterial accumulation deeper within the 
implant in areas where the bacteria could not effectively be cleared.  Kiechel et al. 
compared infection control within porous and nonporous PMMA seeded with 
Staphylococcus aureus and implanted in the paravertebral fascia of rabbits and found 
increased infections occurred in animals implanted with porous PMMA implants [131].  
Sclafani et al. found that increased porosity increased the resistance to infection in 
implants inoculated 14 days after implantation but not if the implants were inoculated at 
the time of implantation [132].  Thus in applications and models where contamination or 
infection exists at the time of implant placement, an appropriate balance with respect to 
porosity is needed to allow tissue ingrowth and implant integration but not bacterial 
seeding deep within the implant.   If contamination is not present at the time of 
implantation, fibrovascular ingrowth has been shown to occur rapidly and thus a more 
porous implant may be acceptable [133].  Additionally, studies of induced membranes or 
 54 
 
capsules around PMMA implants suggest that the formation of well-formed capsule 
around the implants, as seen more frequently around the low porosity implants in this 
study, may facilitate greater success of later efforts aimed at definitive bone regeneration, 
provided the capsule is not destroyed during implant removal and any necessary 
debridement [119-121].  Finally, it is important to note that the method of fabrication of 
the porous PMMA implants may lead to particulate PMMA release [134], which could 
account for the inflammatory response elicited by the highly porous implants [135]. 
Based on the results of the present study, the low porosity space maintainers 
appear to be a promising alternative to solid PMMA for temporary implantation as part of 
a regenerative medicine approach to treating traumatic craniofacial injuries.  Future work 
in this area should focus on tissue regeneration within the maintained space as well as 
release of any bioactive factors from the space maintainer such as antibiotics or growth 
factors that may better ensure success of later stage tissue engineering efforts.  The 
characterized implants may provide a critical step in allowing the use of regenerative 
medicine approaches as an alternative to traditional approaches in treating contaminated 
or open traumatic defects.  The methods described for the fabrication of these implants 
may be applicable to a wide variety of different materials, and the animal model 
described may provide a more useful analogue to clinical situations where tissue 
engineering strategies may need to be used in possibly contaminated environments. 
3.4. Conclusions 
Methods were developed allowing porous PMMA space maintainers to be 
reproducibly fabricated using a CMC hydrogel as an aqueous phase porogen.  Porosity 
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and pore interconnectivity can be controlled by varying the ratio of the aqueous phase to 
polymer phase and the concentration of CMC within the hydrogel, respectively.  In vivo, 
porous space maintainers potentially improve oral mucosal healing over a 
clean/contaminated bone defect created in the rabbit mandible.  The tissue response to a 
porous implant of low porosity and pore interconnectivity was more favorable than the 
response to a more porous and interconnected implant.  This low porosity implant may be 
ideal for temporary space maintenance within craniofacial defects.  The described 
methods may be applicable in a variety of tissue engineering applications and may allow 
broader application of current tissue engineering approaches that may not be suitable for 
use in more harsh wound environments. 
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3.5. Tables and Figures 
Table 3.1.  Histologic scoring system for implants at the implant-tissue interface as 
wel as in the pores of porous implants. 
Hard tissue response at the implant-bone interface Score 
Direct bone-to-implant contact without soft interlayer 4 
Remodeling lacuna with osteoblasts and/or osteoclasts at surface 3 
Majority of implant is surrounded by fibrous tissue capsule  2 
Unorganized fibrous tissue (majority of tissue is not arranged as 
capsule)  
1 
Inflammation marked by an abundance of inflammatory cells and poorly 
organized tissue 
0 
Hard tissue response within the pores of the scaffold  
Tissue in pores is mostly bone  4 
 Tissue in pores consists of some bone within mature, dense fibrous 
tissue and/or a few inflammatory response elements 
3 
 Tissue in pores is mostly immature fibrous tissue (with or without 
bone) with blood vessels and young fibroblasts invading the space with 
few macrophages present  
2 
Tissue in pores consists mostly of inflammatory cells and connective 
tissue components in between (with or without bone) or the majority of 
the pores are empty or filled with fluid  
1 
Tissue in pores is dense and exclusively of inflammatory type (no bone 
present) 
0 
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Figure 3.1. Porosity values as calculated by microcomputed tomography (microCT). 
Samples were scanned and the resultant scans were reconstructed, reoriented, and 
binarized. Implant porosity was determined using a cylindrical (9 mm diameter ×  5 
mm height) volume of interest slightly smaller than the impalnt dimensions to 
eliminate edge effects.  Data are reported as means ±  standard deviation (n = 3).  
The asterisk indicates a significant difference (p < 0.05) as detected using analysis of 
variance and Tukey’s post hoc tests between the groups marked with the same wt % 
of carboxymethylcellulose (CMC) (7 or 9 wt%).  No significant differences were 
found as a result of changing the % CMC from 7 to 9 wt%. 
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Figure 3.2. Implant interconnectivity percntages as a function of the minimum 
interconnection size.  Samples were scanned and processed as reported in the 
Materials and Methods section, and a built in software package was used to 
determine the percentage of the implant porosity that was accessible from outside 
the volument of interest.  Data are reported as means ±  standard deviation (n = 3). 
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Figure 3.3. Representative images of implant cross sections and surfaces. 
Cylindrical implants (10 mm diameter ×  6 mm height) from each experimental 
group were scanned by microCT or scanning electron microscopy (SEM).  Virtual 
microCT cross sections of the implants were made by slicing through the center of 
the axially oriented implant.  For electron micrographs, the scale bars represent 500 
µm. 
 
 
Figure 3.4. Representative gross views of harvested tissue covering the alveolus and 
the implant. (A) Failure of wound healing over a solid polymethylmethacrylate 
(PMMA) implant is shown.  The exposed implant is denoted by white arrows. (B,C) 
Well-healed soft tissue covering the intraoral exposure is seen where dentition is 
missing over low-porosity (B) and high-porosity (C) implants. 
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Figure 3.5. Oral mucosal coverage over implant by type. 
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Figure 3.6. Representative light micrographs (25X magnification) of coronally 
sectioned tissue samples throught the center of the (A) solid PMMA, (B) low-
porosity, and (C) high-porosity space maintainers.  The intraoral exposure of the 
solid implant (A) is shown with black arrows.  Blue arrows denote the titanium plate 
used to stabilize the mandible.  Tissue ingrowth is seen within both porous implants; 
for all implants, the original defect space appears well maintained with minimal 
tissue collapse or contracture.  In (B) and (C), soft tissue discontinuities at the left 
(buccal) side of the implant capsule are due to embedding and processing artifacts.  
Scale bars represent 1 mm. 
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Figure 3.7. Representative light micrographs (200×  magnification) of the lingual 
surface of coronally sectioned tissue samples through the center of the implanted (A) 
solid PMMA, (B) low-porosity, and (C) high-porosity space maintainers. 
Regenerated bone is seen near the surface of all implants.  A well-formed capsule is 
seen in (A), while only a thin layer of loosely organized fibrous tissue is seen at the 
surface of the low-porosity space maintainer (B). An abundance of plasma cells is 
seen at the surface and penetrating the surface porosity (inset) of the highly porous 
space maintainer (C). Scale bars represent 100 µm for the larger images; the inset 
scale bar represents 25 µm. 
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Figure 3.8. Score distributions for the graded (A) implant interface for all 
formulations tested in vivo and (B) tissue response within the pores for the two 
porous implant formualtions.  Scoring criteriea are defined in Table 3.1.  Significant 
differences (p < 0.05) between groups, denoted by asterisk, were determined using 
pairwise Dwass-Steel-Critchlow-Fligner tests for implant interface scoring (A) and a 
Mann-Whitney U-test for the tissue response within pores (B).
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Chapter 4 
In situ Formation of Porous Space 
Maintainers in a Composite Tissue 
Defect‡ 
Craniofacial defects present a complex set of injuries to repair due to the diversity 
of tissue form, function and type.  Consequently, craniofacial trauma and tumor 
resections frequently result in composite defects, with greater than 90% of significant 
mandibular reconstructions involving an additional soft tissue defect [136].  Several 
studies have shown that the immediate reconstruction of craniofacial defects results in 
improved outcomes measured both aesthetically and functionally [71, 137-140].  
However, the complication rates are greater for immediate reconstructions than for 
                                                
 
‡ This chapter was published as Spicer PP, Kretlow JD, Henslee AM, Shi M, Young S, 
Demian N, Jansen JA, Wong ME, Mikos AG, Kasper FK.  “In situ Formation of Porous 
Space Maintainers in a Composite Tissue Defect.” J Biomed Mater Res A. 100, 827-833 
(2012). 
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secondary reconstructions [141].  These complications typically involve the failure of a 
bone graft or the lack of viable soft tissue to support bone regeneration [141, 142].   
Space maintenance alleviates many of these complications by allowing an 
alloplastic material to conserve the bony space, thereby preventing wound contracture 
and delaying bone regeneration within the defect until a suitable wound bed has been 
created.  However, the implantation of bone grafts or synthetic graft materials commonly 
results in failure due to infection or wound dehiscence [126, 142-144].  Previous research 
has shown that porous materials for space maintenance or contouring lead to greater soft 
tissue integration and therefore decreased wound dehiscence relative to non-porous 
materials [50, 51, 132].  For example, in a study by Sclafani et al., the use of porous 
polyethylene implants led to decreased extrusion in a rat subcutaneous model [132].  
Additionally, the skin healed more frequently after intentional exposure in the porous 
implants compared to solid silicone either by secondary intention or skin grafting [132].  
Kretlow et al. investigated the tissue response to the implantation of porous PMMA space 
maintainers in a rabbit composite craniofacial tissue defect [50].  In this study, porous 
PMMA implants were fabricated by mixing PMMA bone cement with 
carboxymethylcellulose (CMC) gels, which created a porous structure through phase 
separation, as PMMA and CMC are hydrophobic and hydrophilic, respectively.  
Implantation of the porous PMMA constructs resulted in soft tissue healing with a 
reduced inflammatory response in the case of low porosity (16.9 ± 4.1%) implants as 
compared to those of high porosity (44.6 ± 2.1%). Additionally, in a study by Shi et al., 
PMMA/CMC constructs were evaluated mechanically compressively and found to have 
adequate properties to maintain the bony space with compressive moduli and 2.0% offset 
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strength of 262-586 MPa and 8-20 MPa, respectively.15  However, while formulating a 
relationship between soft tissue healing and inflammatory response and the porosity of a 
space maintainer, the study by Kretlow et al. utilized prefabricated implants created in the 
laboratory with shape-specific molds.  While prefabrication provides a controlled manner 
by which to evaluate eventual material parameters for scientific study, in situ 
polymerizable implants are important for clinical use as craniofacial defects non-uniform 
in shape and size.  However for in situ polymerization any generated heat or unreacted 
monomer, as well as any variability due to intraoperative mixing, molding, and 
polymerization, can adversely affect the implant performance. 
The present study investigates the biocompatibility of low porosity PMMA 
implants formed in situ as space maintainers in a rabbit composite craniofacial tissue 
defect. We hypothesize that low porosity space maintainers formed in situ will enhance 
soft tissue healing as compared to solid space maintainers formed in situ.  We also 
hypothesize that low porosity space maintainers will not increase the inflammatory 
response of the hard and soft tissue surrounding the implants over solid space 
maintainers. 
4.1. Materials and methods 
4.1.1. Materials 
 Clinical grade bone cement (SmartSet High Viscosity Bone Cement, 
Depuy Orthopaedics, Warsaw, IN) was used as received.  U.S. Pharmacopeia grade CMC 
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(Spectrum Chemical Manufacturing Group, Gardena, CA) was sterilized by exposure to 
UV light for 30 min. 
4.1.2. Materials Preparation 
 Solid and porous PMMA implants were made as previously described [50, 
145].  Briefly, CMC gels were made by dissolving sterilized CMC powder into sterile 
distilled water at 9 wt%.  PMMA implants were prepared using the ratio (40 g of the 
powder phase to 18.88 g of the monomer phase of bone cement) set forth in the 
manufacturer’s instructions and for the porous implants the CMC gel accounted for 30 
wt% of the total implant.  The porous implants had a porosity of 16.9 ± 4.1% and an 
interconnectivity of 39.7 ± 9.4%, 17.8 ± 1.2% and 13.1 ± 3.0% with a 40, 80 and 160 µm 
minimum interconnection size, respectively, as reported previously [50]. 
4.1.3. Surgical Procedure 
 22 adult male New Zealand White rabbits (Myrtle’s Rabbitry, Thompsons 
Station, TN) aged greater than 6 months for skeletal maturity were used in this study.  All 
manipulations followed protocols approved by the Institutional Animal Care and Use 
Committees of Rice University and the University of Texas Health Science Center at 
Houston and NIH guidelines for the care and use of laboratory animals (NIH Publication 
#85-23 Rev. 1985) have been observed.  The surgical procedure was completed as 
described previously [50].   
Briefly, anesthesia was induced with injection of a mixture of ketamine 
hydrochloride (40 mg/kg body weight) and xylazine hydrochloride (7.5 mg/kg body 
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weight).  The rabbits were then intubated and maintained on 2% isoflurane in oxygen.  
Each animal was given a preoperative dose of buprenorphine hydrochloride (0.1 mg/kg 
body weight) for perioperative pain control and 0.5 mL Durapen® (150,000U/mL of 
penicillin G benzathine and penicillin G procaine each) for perioperative antimicrobial 
coverage.  The animals were sterilely prepped and a midline incision, 1 cm posterior to 
the mentum, was used to expose the inferior border of the mandible.  The masseter was 
lifted from the buccal surface of the body of the mandible.  Using a 10 mm trephine 
(ACE Surgical, Brockton, MA) and a surgical drill (Stryker, Kalamazoo, MI), a 10 mm 
bicortical defect was created.  Additionally, using a 701 cutting bur, a 2-3 mm notch was 
created in the superior border of the defect and the overlying crown removed to create 
intraoral communication and a mucosal defect as shown in Figure 4.1.   
Solid implants (n=10) were prepared by mixing the liquid phase of the bone 
cement into the powder phase.  Porous implants (n=10) were made by first mixing the 
powder phase (containing polymeric microparticles, benzoyl peroxide and barium 
sulfate) of the bone cement into the CMC gel, then mixing in the liquid phase (containing 
methyl methacrylate monomer and N,N-dimethyl-p-toluidine).  All implants were mixed 
by hand until doughy and then shaped by hand to approximately fit the bone defect.  The 
implants were placed into the bone defect approximately 5 min after initiation of 
polymerization (addition of liquid phase) and molded to fit once inside the defect as 
shown in Figure 4.1.   
A 6-hole 1.5 mm titanium plate (Synthes, West Chester, PA) was attached with 
two screws on each side of the defect to prevent iatrogenic fracture of the mandible.  
Finally, the wound, except the mucosal defect, which was left open to allow for 
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continued oral communication, was closed in layers.  Animals were given a postoperative 
intramuscular dose of ketoprofen for inflammation control.  Each rabbit was extubated 
and closely monitored postoperatively.  The animals were fed ad libitum with a diet of 
soft chow (Critical Care for Herbivores; Oxbow Pet Products, Murdock, NE) to reduce 
stress on the mandible. 
4.1.4. Gross Observation 
 After 12 weeks, animals were euthanized with 1 mL of Beuthanasia-D® 
(390 mg/mL pentobarbital sodium and 50 mg/mL phenytoin sodium) and the 
hemimandible was extracted.  The oral mucosa was observed grossly for complete 
coverage of the implant and bone.  Each sample was assigned a healed or non-healed 
status based on this coverage, where exposure of bone or the implant was deemed non-
healed and complete coverage was considered healed. 
4.1.5. Histology 
 Each hemimandible was placed in 10% neutral buffered formalin for 72 
hours.  After fixation, each specimen was dehydrated using an ethanol gradient (70%-
100%).  The dehydrated samples were embedded in methylmethacrylate and three 10 µm 
sections were taken coronally through the center of the implant to include the mucosal 
defect using a microtome with an inner circular diamond blade (Leica Microsystems, 
Nussloch, Germany).   The sections were stained with methylene blue and basic fuchsin 
to assess the soft tissue and hard tissue responses to the implant.  The stained sections 
were scored by three reviewers (P.P.S., A.M.H. and F.K.K.) using a quantitative tissue-
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implant scoring system for the tissue-implant interface and within the pores for porous 
samples as shown in Table 4.1 and as previously described [92].  Each sample received 
one score from a consensus of the reviewers based on the average of the three sections 
from the sample.   
4.1.6. Statistical Analysis 
 Healing status based on gross observations was analyzed with Fisher’s 
Exact Test, while histology scores, a nonparametric data set, were analyzed with the 
Mann Whitney-U Test.  An a priori level of significance was set at α = 0.05. 
4.2. Results 
4.2.1. Surgical Procedure 
 All rabbits underwent surgical manipulation and recovery well.  Two 
rabbits were replaced within the study due to complications, resulting in 22 total rabbits, 
with 10 rabbits included in each group for analysis.  Both complications were unrelated 
to the surgical manipulation or implantation and involved a foot problem and an 
abdominal infection. 
4.2.2. Gross Observation 
Representative gross images of healed and non-healed specimens from each group 
are shown in Figure 4.2.  As shown in Figure 4.3, 6 out of the 10 rabbits that received 
solid implants and 3 out of the 10 that received porous implants were considered non-
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healed based on the criteria described above. These results do not show significantly 
greater healing in the porous group (p = 0.185).   
4.2.3. Histology 
 Representative histologic images from each group showing similar tissue 
responses for both solid and porous implants are shown in Figure 4.4.  Histologic scoring, 
shown in Figure 4.5, revealed no significant difference between the solid and porous 
groups for the tissue-implant interface, although, as can be seen in Figure 4.4, the porous 
group did have several instances of direct interaction with the bone surface, a feature not 
seen in any solid implants.  Additionally, the scores for the tissue inside the pores for the 
porous group are presented in Figure 4.5, reflecting the presence of primarily fibrous 
tissue. 
4.3. Discussion 
Early intervention has been shown to be advantageous in the reconstruction of 
craniofacial defects; however, the ultimate success of a bone regeneration technique 
applied early after bone excision or wound debridement may be limited, given the 
complexity of the tissue environment, need for critical care stabilization or availability of 
reconstructive surgeons at that time.  Consequently, temporary placement of a material to 
support soft tissue healing around the defect can prime the wound bed to support the 
success of a subsequent definitive repair. Yet, current materials fail to properly integrate 
with the surrounding tissue to sustain healthy soft tissue healing during implantation in 
such space maintenance approaches. 
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 In a previous study, our group found that, when fabricated ex vivo, porous 
PMMA constructs enhanced wound healing and elicited a favorable soft tissue response 
compared to solid constucts [50].  This approach, while a useful proof of principle, does 
not accurately reflect the intraoperative construct fabrication and implantation technique 
that would ideally be utilized to address complex craniofacial wounds.  This study 
hypothesized that porous implants created in the operating room and formed in situ 
would enhance soft tissue healing over a bone defect in a composite tissue model 
compared to non-porous implants.  Additionally, porous implants were hypothesized not 
to increase the inflammatory response of the surrounding tissue compared to non-porous 
implants, as evaluated by histology.   
 Porous implants showed a trend towards increased soft tissue healing of 
the composite defect, although differences were not statistically significant with the given 
sample size.  This trend is consistent with previous studies using the same materials in 
prefabricated implants [50].  This result validates the use of porous PMMA space 
maintainers as an alternative to solid PMMA. 
 Histologically, the porous implants performed similarly to the solid 
implants with scores that were not significantly different.  This finding indicates that the 
in situ formation of porous space maintainers does not increase the inflammatory 
response of the surrounding tissue as could be postulated based on the potential for 
inflammatory stimuli, such as thermal energy release during polymerization or exposure 
to unpolymerized monomer. 
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 The composite tissue defect used in this study separates the healing of a 
soft tissue defect over an implant from the inflammatory response of the tissue to the 
implant, which allows for study of the gross soft tissue healing over such implants.  
Additionally, this study perpetuates the enhancement of soft tissue healing over porous 
space maintainers in a clinically relevant scenario using clinically available materials, 
validating the process and procedure for fabricating porous space maintainers in situ.  
However, while separating the effects of solid and porous implants formed in situ, the 
presence of materials is less controlled.  In the study by Kretlow et al., the CMC gel 
porogen was leached from the prefabricated implants prior to implantation, whereas this 
phase was included in the implants in the present study [50].  While the effect on soft 
tissue to the implant could be altered by the presence of CMC, previous in vitro studies 
have shown that the dissolution of CMC out of the implant occurs very rapidly, thus 
minimizing the duration of immediate tissue contact.  Moreover, while this model 
includes a composite defect more similar to that of craniofacial trauma or resection, the 
possibility of dehiscence is limited to the mucosal surfaces, as the implant is surrounded 
by bone on all other sides.  Skin dehiscence is an important complication of craniofacial 
reconstruction, and further studies would be necessary to elucidate any differences 
between the soft tissue healing in a composite defect with a skin defect.   
Previous studies have investigated the in situ polymerization of PMMA in contact 
with bone.  Many of the studies have focused on the temperature rise and the residual 
monomer release from the implants, both of which have been shown to contribute to 
increased inflammatory responses in the tissue immediately adjacent to the PMMA 
implanted [146-150].  Several studies have shown decreased setting temperature of 
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porous PMMA versus solid PMMA, as there is reduced monomer per unit volume as well 
as a non-reacting phase acting as a heat sink [104, 145]. Similar to this study, where the 
solid and porous groups performed similarly histologically, a 14 week study by 
Nathanson et al. and a 12 week study by Kretlow et al. showed no difference in 
histological assessment of solid or porous implants at the end time point [50, 100]. 
Contrary to these studies, van Mullem et al. observed porous implants with 50 wt% of 
CMC gel as the porogen were surrounded by well-vascularized fibrous tissue, while solid 
implants had a thick fibrous capsule in a long term study of 8 and 24 months, indicating 
the possibility for further remodeling of the surrounding tissue in the porous implant 
group, which could differentiate the histological scores [90].   
The hypothesis that porous implants enhance tissue remodeling around the 
implant is supported by studies investigating the role of surface structure on tissue 
interfaces.  These studies have shown a response dependent on surface roughness, where 
increased surface roughness leads to greater remodeling of the surrounding tissue [151, 
152]. In addition, these studies indicate the possibility for greater bone remodeling for 
rough surfaces over smooth surfaces, as increased bone deposition is seen when cultured 
with osteoblast like cells and increased osteoclastic activity when cultured with 
macrophages. 
 In addition to surface characteristics, PMMA particulates play an 
important role in the inflammatory response, as they have been shown to increase 
macrophage activation and release of tumor necrosis factor-alpha, a cytokine that 
enhances bone resorption when produced chronically [153-156].  In a study by Beck and 
Boger, PMMA particulate release was observed to be greater for porous PMMA than for 
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solid PMMA [134].  While these particulates may play a role in the remodeling process 
of the tissue surrounding the porous implants, the histological results from the present 
study indicate no difference, suggesting the effect of surface characteristics balances that 
of particulates.   
 In addition to effects described above regarding the advantages of porous 
structures for soft and hard tissue integration, interconnected porous structures increase 
the surface area available for drug delivery.  In space maintenance, drug delivery can be 
used to prime the wound bed by treating any infection present [145, 157]. Alternatively, 
growth factors could be used to enhance the regeneration of soft tissue or vascularity 
around the implant. 
 While this study validates the effectiveness of porous space maintainers in 
a more clinically relevant model and formation process, further studies could be 
warranted to elucidate the effects observed.  Firstly, an increase in animal numbers could 
be utilized to determine the significance of the mucosal healing or histological 
differences.  As stated above, moving from prefabricated implants to those formed 
intraoperatively, several parameters are changed: in situ polymerization, exposure to 
unpolymerized monomer, and presence of the porogen, CMC.  To adequately understand 
the effect of each of the parameters, further study would be necessary, such as 
investigation of a prefabricated implant from which the porogen had not been leached 
prior to implantation.  Additionally, wound dehiscence, while more common on the 
mucosal surface of mandibular implants, can occur on the skin surface.  The intact 
inferior border of the mandible does not allow for testing of this possibility, while a 
continuity defect of the mandible would provide such an analysis.  Nevertheless, the 
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present study supports the use of porous space maintainers for the treatment of composite 
tissue defects in the craniofacial region.   
4.3.1. Conclusion 
This study analyzed the effects of porous PMMA space maintainers formed in situ 
on the mucosal healing and long term tissue response in a rabbit composite mandibular 
defect model against similarly formed solid implants.  The porous implants showed a 
trend of enhanced soft tissue healing and coverage of the implant over solid groups. 
Additionally, the increased surface area and presence of porogen did not elicit an 
extended inflammatory response over the solid implants.   
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4.4. Tables and Figures 
Table 4.1. Histologic scoring system for implants at the implant-tissue interface as 
well as in the pores of the porous implants. 
Hard tissue response at the implant-bone interface Score 
Direct bone-to-implant contact without soft interlayer 4 
Remodeling lacuna with osteoblasts and/or osteoclasts at surface 3 
Majority of implant is surrounded by fibrous tissue capsule  2 
Unorganized fibrous tissue (majority of tissue is not arranged as 
capsule)  
1 
Inflammation marked by an abundance of inflammatory cells and poorly 
organized tissue 
0 
Hard tissue response within the pores of the scaffold  
Tissue in pores is mostly bone  4 
 Tissue in pores consists of some bone within mature, dense fibrous 
tissue and/or a few inflammatory response elements 
3 
 Tissue in pores is mostly immature fibrous tissue (with or without 
bone) with blood vessels and young fibroblasts invading the space with 
few macrophages present  
2 
Tissue in pores consists mostly of inflammatory cells and connective 
tissue components in between (with or without bone) or the majority of 
the pores are empty or filled with fluid  
1 
Tissue in pores is dense and exclusively of inflammatory type (no bone 
present) 
0 
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Figure 4.1. Schematic (A) and photograph (B) of defect in rabbit mandible (scale 
bars indicate 10 mm and 5 mm, respectively).  Photograph (C) of rabbit mandibular 
defect filled with a porous implant (scale bar indicates 5 mm).  
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Figure 4.2. Photographs of the oral mucosa over the composite defect for (A) a well-
healed porous implant and (B) a poorly healed, exposed solid implant after 12 weeks 
of implantation.  The black arrow indicates implant exposure. 
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Figure 4.3. Number of implants with healed and non-healed oral mucosa for solid 
and porous implants after 12 weeks of implantation (n = 10 for each group). 
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Figure 4.4. Representative images (1000 µm scale bar) from (A) the solid implant 
group and (B) the porous implant group with higher magnifications, highlighted in 
yellow, (200 µm scale bar) of each (C) and (D), respectively. Histologic scores were 
made using magnifications shown in images (A-D). Additional higher magnification 
images (C) and (D), highlighted in yellow, are shown in (E) and (F), respectively (50 
µm scale bar). The solid implant shown was scored as a 1 according to Table 4.1, as 
an unorganized fibrous capsule was present around the majority of the implant (A 
and C). The porous implant shown was scored as a 2 due to the presence of an 
organized fibrous capsule, based on the magnifications shown in (B and D). Black 
arrows show the titanium plate. Red arrow indicates dehiscence. 
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Figure 4.5. Histologic scores of the inflammatory response at the (A) tissue-implant 
interface of solid and porous implants and (B) the tissue in the pores of the porous 
implants.  There was not a significant difference between the solid and porous 
groups as determined by the Mann-Whitney U test. 
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Chapter 5 
Antibiotic-releasing Porous 
Polymethylmethacrylate/Gelatin/Anti
biotic Constructs for Craniofacial 
Tissue Engineering‡,* 
Traumatic injuries in the craniofacial area are one of the most debilitating forms 
of injury due to the important aesthetic and functional role of the craniofacial complex 
[12]. Using current technologies, traumatic craniofacial bone injuries accompanied by 
local infection, significant vascular injury, and large-scale tissue devitalization (e.g., 
those encountered on the battlefield) involve a staged repair [158]. Tissue engineering 
approaches to regenerating the devitalized tissues is usually delayed until soft tissue 
                                                
 
‡ This chapter was published as Shi M, Kretlow JD, Spicer PP, Tabata Y, Demian N, 
Wong ME, Kasper FK, Mikos AG. “Antibiotic-releasing Porous 
Polymethylmethacrylate/Gelatin/Antibiotic Constructs for Craniofacial Tissue 
Engineering.” J Control Release. 152, 196-205 (2010). 
* The doctoral candidate performed portions of this work including fabrication of 
constructs and in vitro antibiotic release. 
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coverage and a sterile wound environment are achieved [72]. One of the major challenges 
faced by reconstructive surgeons is contracture and scarring of the overlying soft tissue 
envelope before definitive reconstruction, which compromises the restoration of 
functional characteristics of the affected region and makes the aesthetic restoration 
particularly challenging. Over the course of a staged reconstruction, the placement of a 
temporary space-maintaining implant may eliminate many of the aforementioned 
complications [50, 75, 159].  
Towards the goal of treating traumatic craniofacial injuries with significant 
bone/tissue loss and active/latent infection, our laboratory is developing a two-stage 
regenerative medicine approach that initially uses an alloplastic implant (i.e., a space 
maintainer) to not only maintain the void space but also to prime the wound site (e.g., 
promote tissue healing/coverage and address local infections) for later, definitive 
reconstruction [50, 145]. The deliberate maintenance of the bony space prevents 
distortion of surgical landmarks, wound contracture into the space, and fibrosis of the 
tissue bed [50, 75]. Successful space maintenance creates a soft tissue envelope with 
preserved volume and well-healed surrounding tissues, ideal for the placement of a tissue 
engineered construct designed for bone regeneration during the subsequent reconstruction 
stage [75]. To fulfill these functions, a porous space maintainer is favorable because 
fibrovascular and other soft tissues can potentially grow into the surface pores to promote 
wound/tissue healing [50, 86, 103, 160-163]. Tissue ingrowth into the pores also creates a 
stable interface to anchor the implant to the host tissues, possibly preventing the wound 
dehiscence encountered when using a solid implant [50]. Additionally, a space maintainer 
capable of local antibiotic delivery can potentially eliminate infection-associated 
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complications during the space maintenance phase and later reconstruction. Infections 
following traumatic injuries (including combat wound infections and osteomyelitis, a 
bone infection usually associated with severe fractures exposed to environmental 
bacteria) are a common occurrence [72, 159, 164-166]. Active and latent posttraumatic 
and postsurgical infections may potentially hinder wound healing and tissue regeneration, 
underscoring the importance of effective, early eradication/prevention of infection 
through the use of antibiotics. Given that most supporting materials lack the capacity to 
release drugs in a precisely controlled manner, incorporating a drug delivery system into 
the space maintainer (which is capable of controlled antibiotic release during the space 
maintenance phase) becomes an important strategy [145].  
Previously we have demonstrated that a porous polymethylmethacrylate (PMMA) 
construct with porosity imparted by incorporating a carboxymethylcellulose (CMC) 
hydrogel phase successfully maintained the bony space within a nonhealing rabbit 
mandibular defect model and provided a template for improved wound healing when 
compared to solid PMMA implants [50]. To modify this system enabling local drug 
delivery, drug-loaded poly(lactic-co-glycolic acid) (PLGA) microspheres were also 
incorporated into the PMMA/CMC constructs, creating porous constructs capable of 
extended antibiotic delivery [145]. 
Simplifying these porous PMMA constructs by incorporating a porogen and 
particulate drug carrier, we further developed a gelatin microparticle (GMP)-
incorporating PMMA construct (i.e., a PMMA/gelatin/antibiotic construct) in which the 
GMPs serve as both drug carrier and porogen (Figure 5.1).  
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Gelatin is derived from collagen, a natural polymer that is the major constituent of 
skin, bone and connective tissue. Used in pharmaceuticals, wound dressings and 
adhesives, gelatin has a number of desirable biomaterial properties (e.g., 
biodegradability, biocompatibility and biosafety) [167-170]. As a protein, gelatin has a 
high content of amino acids such as glycine, proline, and hydroxyproline that potentially 
accelerate soft tissue healing, making gelatin particularly attractive as a major component 
of a space maintainer for promoting tissue healing and coverage. With respect to drug 
delivery, the highly hydrophilic gelatin absorbs drug solution upon contact to form a 
hydrogel. The loose gel matrix is able to immobilize drug molecules and subsequently 
control drug release by a diffusion or degradation-controlled mechanism [168]. 
In PMMA/gelatin/antibiotic constructs, the GMPs are loaded by absorbing the 
drug solution while swelling to form a particulate hydrogel. This hydrogel is then 
dispersed within the PMMA polymer phase, creating porosity during the curing of 
PMMA (Figure 5.1). In practice, the assembly of PMMA bone cement, GMPs, and 
antibiotic drug can be completed within minutes using a simple mixing procedure. Such 
an approach provides great flexibility with respect to the material composition during the 
course of fabrication: the type and amount of antibiotic can be decided at the time of 
fabrication based on a specific clinical need, and the physical properties of constructs 
(e.g., porosity and mechanical strength) can be tailored to meet the requirements of space 
maintenance and drug release kinetics. The system is a simple combination of materials 
with United States Food and Drug Administration (FDA) history. PMMA bone cement is 
FDA-approved for adhering prosthesis to bone, kyphoplasty and repairing cranial defects 
[171, 172]. Gelatin-based/containing products have been approved by FDA for 
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commercial use [173, 174]. Given the ease of practical handling and FDA-regulatory 
status of each component, the PMMA/gelatin/antibiotic construct engineered for clinical 
applications has the potential to transition readily from experimental research into clinical 
use.    
The aim of the present in vitro study was to elucidate the influence of material 
composition on PMMA/gelatin/antibiotic construct physicochemical properties and 
provide predictive insight into the expected space maintenance and drug delivery 
capability of these space maintainers over time in vivo. Specifically, colistin, a polymyxin 
antibiotic, was chosen to address infections with Acinetobacter species [175, 176], the 
most common pathogen associated with combat-related traumatic injuries [165, 166, 177, 
178]. It was hypothesized that the overall porosity (which impacts tissue ingrowth as well 
as drug release from the space maintainer) would be tailored by the percent of gelatin 
incorporated and the gelatin swelling, as controlled by varying the weight ratio of drug 
solution versus gelatin. To test these hypotheses, five formulations of 
PMMA/gelatin/antibiotic constructs with swelling ratio (3:1, 4:1, or 5:1 drug solution : 
gelatin by weight), gelatin incorporation (15 or 20 wt% in the polymer phase), or drug 
loading (15 or 20 wt% in GMPs) were investigated for drug release kinetics over 2 
weeks. The construct morphology, porosity, compressive mechanical property, and 
degradation were also examined over a period of 12 weeks.   
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5.1. Materials and Methods 
5.1.1. Materials 
Gelatin (isoelectric point, IEP = 9) was obtained from Nitta Gelatin Corporation 
(Osaka, Japan). Colistin sulfate salt was purchased from Sigma-Aldrich (St. Louis, MO). 
Clinical PMMA bone cement (SmartSet®, High Viscosity) from DePuy Orthopaedics Inc. 
(Warsaw, IN) was used. The bone cement formulation is supplied as a two-component 
system, consisting of separate liquid and powder components. The liquid component 
consists mainly of MMA monomer with hydroquinone as a stabilizer. The powder 
component contains a PMMA based polymer with the initiator benzoyl peroxide and the 
radiopaque agent zirconium dioxide. All other reagents were purchased from Sigma-
Aldrich (St. Louis, MO) and used as received.    
 
5.1.2. Preparation of gelatin microparticles 
Chemically crosslinked GMPs were fabricated via a water-in-oil-emulsion 
process followed by glutaraldehyde crosslinking in aqueous solution [179]. Briefly, 
gelatin (5 g) was dissolved in double-distilled water at a concentration of 10 w/v% and 
added dropwise to 250 ml olive oil (containing 0.5 v/v% Span 80 as stabilizer) to create a 
water-in-oil emulsion under stirring at 500 rpm. The solution was chilled by ice water 
and stirred for 30 min. The solution was then added to 100 ml chilled acetone and stirred 
for another 1 h. GMPs were then collected by washing with chilled acetone and vacuum 
filtration. The GMPs were allowed to air dry and then dispersed into 500 ml double 
distilled water containing 0.1 v/v% Tween 80 as stabilizer and 10 mM glutaraldehyde for 
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chemical crosslinking. The reaction was continued for 20 h and then terminated by the 
addition of glycine (25 mM) to block residual aldehyde groups. The microparticles were 
washed by chilled double-distilled water and then acetone and collected by filtration. The 
air-dried microparticles were then quickly frozen with liquid nitrogen and lyophilized for 
24 h. The lyophilized GMPs were sieved through a mesh with 250 µm pores to remove 
undesired aggregations.  
The morphology of dehydrated GMPs was characterized by scanning electron 
microscopy (SEM). The dry microparticles were sputter-coated with gold for 40 s at 100 
mA using a CrC-150 sputtering system (Torr International, New Windsor, NY) and 
observed under a FEI Quanta 400 field emission scanning electron microscope (FEI 
Company, Hillsboro, OR) at an accelerating voltage of 10 kV.  
To study the swelling behavior of GMPs in varying amount of phosphate buffered 
saline (PBS) solution, dry microparticles were swollen in PBS buffer (pH 7.4) at weight 
ratios of 3:1, 4:1, 5:1, 7:1 or excess (infinite). The swollen microparticles were observed 
under a light microscope (Nikon microscope, Eclipse E600, Japan) immediately. The 
diameter of the swollen microparicles in each image was measured using Image-Pro Plus 
5.1 software (Media Cybernetics Inc., Bethesda, MD). Each measurement took the 
average diameter of over 100 particles. The mean diameter of swollen microparticles was 
expressed as mean ± standard deviation for n=3 separate swelling experiments.  
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5.1.3. Preparation of gelatin-incorporating PMMA constructs 
Antibiotic-releasing porous PMMA/gelatin/antibiotic constructs were fabricated 
by the sequential assembly of GMPs, antibiotic drug, and a clinical grade PMMA bone 
cement (Figure 5.1). The incorporation of GMPs (15 wt% or 20 wt% of dry GMPs 
relative to the polymer phase of gelatin+PMMA+MMA), the swelling ratio of drug 
solution versus GMPs (3:1, 4:1, or 5:1 by weight), and the drug loading in the GMPs (15 
wt% or 20 wt%) were varied to tailor the bulk porosity and drug content of the 
constructs. The weight of powder components (gelatin, drug and PMMA) and volume of 
liquid components (PBS solution, MMA) were predetermined based on the composition. 
The components were assembled according to the following procedure: the antibiotic 
drug was first dissolved in PBS solution. This solution was then added dropwise to the 
dry GMPs which absorbed the solution to form swollen microparticles. These drug-
loaded GMPs were then immediately dispersed (or incubated at 37ºC for 1 h or 24 h 
before dispersing) in the PMMA powder by manually stirring the mixture. The monomer 
liquid was then added into the mixture and the two phases were mixed carefully to 
facilitate uniform distribution of the monomer while minimizing air entrapment. After 
reaching a dough-like consistency (approximately 90 s), the mixture was inserted into 
custom fabricated Teflon molds (sized as described below depending on the type of 
testing to be performed) and allowed to harden at ambient temperature (21°C) for 30 min. 
After removal from the molds, the cured constructs were used directly for in vitro drug 
release characterization or were lyophilized prior to drug release. The constructs were 
lyophilized prior to the characterization of porosity, compressive strength, and internal 
morphology by SEM.  
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The compressive mechanical properties of cylindrical constructs (6 mm in 
diameter, 12 mm in height, n=6-8) were measured in accordance with ISO5833 [180] 
using a mechanical testing machine (MTS, 858 Mini Bionix, Eden Prairie, MN) [145]. 
The offset compressive yield strength was determined as the stress at which the stress–
strain curve intersected with a line drawn parallel to the slope defining the modulus, 
beginning at 2.0% strain (based on ISO5833).  
Cylinders 10 mm in diameter and 6 mm in height, as designed for a previously 
developed rabbit mandibular defect model [50, 94], were used for the in vitro drug 
release and degradation study.  
 
5.1.4. In vitro drug release  
An in vitro drug release study was carried out in triplicate at 37°C in PBS buffer 
(pH 7.4) containing bacterial collagenase 1A — an enzyme that recognizes and digests 
part of the gelatin amino acid sequence [181]. A concentration of 400 ng/ml collagenase 
1A was utilized in this study to model the tissue collagenase concentration in the synovial 
fluid mimicking that found following surgical trauma or in the presence of osteoarthritis 
[182-184]. Each construct was incubated in 5 ml PBS-collagenase buffer under mild 
shaking. At predetermined time intervals, the release medium from each sample was 
completely removed and replaced with fresh PBS-collagenase buffer. The release 
medium was filtered with a 0.2 µm filter. The colistin concentration in the release 
medium was determined using a high-performance liquid chromatography (HPLC) 
system consisting of a Waters 2695 separation module and a 2996 photodiode array 
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detector (Waters®, Milford, MA) [145]. The separation was performed using an XTerra® 
RP 18 column (250 cm × 4.6 µm, Waters®) at a column temperature of 45°C and flow 
rate of 0.5 ml/min in a mobile phase consisting of acetonitrile (HPLC grade with 0.1 
vol% trifluoroacetic acid) and water (HPLC grade with 0.1 vol% trifluoroacetic acid). 
Peaks were eluted with a linear gradient of 5–65% acetonitrile in water over 20 min. 
Absorbance was monitored at λ = 214 nm. The two main components colistin A and 
colistin B were eluted at approximately 16.2 min and 16.9 min, respectively. Standard 
solutions with colistin in PBS buffer (pH 7.4) were tested in the range of 5–1000 µg/ml. 
Calibration curves were obtained using the combined peak area of colistin A and colistin 
B versus the colistin concentration.   
 The daily release of colistin was calculated from the absolute amount of colistin 
released between three or four consecutive days divided by the corresponding release 
time as well as the construct volume, and was expressed as µg colistin/ml construct/day 
[145]. The cumulative release (%) was expressed as the percent of total colistin released 
over time. 
5.1.5. Degradation of PMMA/gelatin/antibiotic constructs 
PMMA/gelatin/antibiotic constructs were degraded over a period of 12 weeks. 
Each construct was incubated in 5 ml PBS-collagenase buffer under mild shaking. At 
predetermined time intervals, the release medium from each sample was completely 
removed and replaced with fresh PBS-collagenase buffer. The degraded constructs were 
washed with double-distilled water and lyophilized for testing to determine the change of 
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porosity with degradation. The bulk porosity of each construct before and after 
degradation was determined using a microcomputed tomography imaging system. 
5.1.6. Microcomputed tomography (microCT) 
A SkyScan 1172 microCT imaging system (Aartselaar, Belgium) was used to 
perform nondestructive imaging and quantify the 3D microarchitectural morphology of 
original and degraded constructs [145]. The samples (n=3) were imaged with an X-ray 
tube voltage of 40 kV and current of 250 mA without a filter. Volumetric reconstruction 
and analysis were conducted using the software NRecon and CTAn provided by SkyScan 
[145].  
5.1.7. Statistical analysis 
To compare in vitro colistin release at a single time point, porosity, and 
compressive modulus, single-factor analyses of variance (ANOVA) with a 95% 
confidence interval (p<0.05) were performed. In the case of statistically significant 
differences, Tukey’s post hoc test was conducted. Data are presented as means ± standard 
deviation.  
 
5.2. Results 
5.2.1. Gelatin microparticles 
Dehydrated microparticles had a dense polymer structure after fabrication (Figure 
5.2A), which, upon contact with PBS solution, swelled immediately forming hydrogel 
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microparticles (Figure 5.2B). The mean diameter of swollen microparticles (20.5±1.6-
26.8±2.5 µm) is greater than that of dehydrated particles (15.2±0.4 µm) (p<0.05). The 
mean microparticle diameter increased with increasing weight ratios of PBS solution 
versus gelatin (p<0.05), suggesting an increase in the total volume of swollen GMPs with 
greater amounts of PBS solution present for swelling. When a swelling equilibrium was 
likely reached at 5:1 or higher weight ratio of PBS solution versus gelatin, the mean 
diameter of swollen gelatin particles remained relatively constant (Figure 5.3).  
5.2.2. Microparticle-incorporating PMMA/gelatin/antibiotic constructs  
The GMPs with swelling ratio of 3:1, 4:1 and 5:1, which covered a wide range of 
particle size, were used for incorporation into PMMA cement. Curing of the mixture 
occurred when the initiator in the powder phase started polymerization of the reactive 
MMA monomer, thus trapping the gelatin hydrogel microparticles within the 
polymerizing matrix and yielding various drug loadings and porosities depending on the 
material composition (Table 3.1 and Figure 5.4).  
Cross sections of gelatin-incorporating PMMA constructs are shown in the SEM 
images (Figure 5.4A). All constructs were porous with the GMPs homogenously 
distributed within the PMMA polymer phase. MicroCT analysis yielded 2D cross 
sections (Figure 5.4B), which showed a uniform pore distribution. By visual inspection, 
the structure became looser and the pores were more extensively interconnected with 
increasing porosity. MicroCT was also used to nondestructively quantify the porosity 
(Figure 5.4B inset data) and interconnectivity (Table 5.1). The bulk porosity of constructs 
was tailored by the amount of gelatin incorporated and the amount of drug solution added 
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for gelatin swelling (Table 5.1and Figure 5.4). Greater drug solution addition (higher 
weight ratio of drug solution versus gelatin) led to significantly higher porosity (e.g., the 
porosity increased from 9.3±1.4% to 27.0±1.5% when the swelling ratio of drug solution 
versus gelatin increased from 3:1 to 5:1 by weight, p<0.05). Increasing gelatin 
incorporation (20 wt% versus 15 wt%) also resulted in significantly greater porosity 
when the weight ratio of drug solution versus gelatin was fixed (p<0.05). Varying drug 
loading in the microparticle phase did not alter the porosity (p>0.05). The pore 
interconnectivity (determined by microCT with a 40 µm minimum connection size) 
correlated closely with the porosity (Table 5.1). The constructs containing higher 
amounts of aqueous phase (G15D15S5:1 and G20D15S4:1) and thus significantly higher 
porosities than the other three formulations, featured extensively interconnected pore 
structures (49.0±6.7% and 51.4±1.8%, respectively), suggesting that approximately half 
pores in the each construct were connected to their outside environment through openings 
of at least 40 µm. 
As shown in Table 5.1, the weight percent of drug in the construct was affected 
by both the gelatin incorporation in the construct and the drug loading in the GMPs. 
Generally, higher gelatin incorporation in the construct or higher drug loading in the 
microparticles resulted in a greater weight percent of drug incorporated in the construct. 
With the same weight percent of gelatin incorporation and microparticle drug loading, the 
construct drug content per unit volume depended on the porosity (which correlated to the 
density of constructs). Constructs with lower porosity had higher amounts of drug per 
unit volume (mg drug/ml construct). The five formulations investigated in this study 
featured a drug content 2.6-3.6 wt%, or 18.2-28.3 mg/ml construct (Table 5.1).  
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The compressive moduli and offset yield strengths (2.0% offset) were determined 
based on ISO5833 (Table 5.1). The compressive moduli of porous 
PMMA/gelatin/antibiotic constructs varied between 180±30 and 450±30 MPa depending 
on the bulk porosity of constructs, with the higher porosity constructs having lower 
compressive moduli. The compressive moduli of PMMA/gelatin/antibiotic constructs 
were 6-15 fold lower than that of solid PMMA (2670±220 MPa). The offset yield 
strengths of PMMA/gelatin/antibiotic constructs had similar porosity dependence and 
were lower than that of solid PMMA (p<0.05). 
5.2.3. In vitro colistin release 
Colistin release from the PMMA/gelatin/antibiotic constructs was studied in vitro 
immediately after fabrication. As shown in Figure 5.5 and Figure 5.6, where the colistin 
release was described as average drug release rate per day (µg colistin/ml construct/day) 
as well as % cumulative drug release, all five formulations of PMMA/gelatin/antibiotic 
construct achieved continuous colistin release over 10 or 14 days with the drug release 
rate higher than 10 µg/ml construct/day. The drug release duration and drug release rate 
were dependent on both the construct composition (Figure 5.5 and Figure 5.6) and the 
fabrication procedure (Figure 5.7 and Figure 5.8).  
When the porosity was tailored by gelatin swelling ratio (with the drug loading in 
the GMPs fixed at 15 wt%), the constructs with lower porosity had reduced initial burst 
(both % and µg/ml/day) and relatively longer release durations (Figure 5.5). For example, 
the construct G15D15S3:1 (porosity 9.3±1.4%) released colistin over 14 days. The 
constructs G15D15S4:1 (porosity 15.6±1.8%) and G15D15S5:1 (porosity 27.0±1.5%), 
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which featured significantly higher porosities, achieved relatively shorter release 
durations of 10 days. Notably, the drug release rate of the construct G15D15S3:1 
remained the highest after day 1 (Figure 5.5) (p<0.05), although its % cumulative release 
was significantly lower relative to the other two formulations after 14 days release 
(p<0.05).   
 
When comparing the drug release from two constructs with different drug 
loadings but the same porosity (i.e., G15D15S4:1 and G15D20S4:1), a constantly greater 
rate of drug was released by the construct with the higher drug loading until day 3 
(p<0.05). The release duration, however, was not altered by the drug loading (Figure 5.6). 
If both the porosity and the drug loading of one construct were significantly greater than 
those of another, the porosity played a more important role in modulating drug release 
(Figure 5.6). For example, the construct G20D15S4:1 featured greater porosity 
(29.4±0.9%) and higher drug loading (23.8 mg/ml) than G15D15S4:1 (porosity 
15.6±1.8%, and drug loading 20.6 mg/ml). The drug release rate of G20D15S4:1 was 
significantly greater on the first day, but much lower after day 1 (i.e., the construct with 
higher porosity featured greater initial burst) (Figure 5.6) except on day 10 (p<0.05).  
To elucidate whether incubating the drug-loaded GMPs at 37ºC for various 
periods prior to mixing with the PMMA cement will strengthen the association between 
the gelatin and drug, therefore impacting the release kinetics of constructs, the colistin 
release of G15D15S4:1 (which was fabricated by immediately mixing the drug-loaded 
gelatin with the PMMA cement) was compared with those of constructs fabricated from 
incubated (1 h or 24 h) drug-GMPs (Figure 5.7). Short term incubation (e.g., 1 h) of drug-
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GMPs prior to construct fabrication did not significantly alter drug release kinetics. Both 
the drug release rate and the % cumulative release were similar (p>0.05). Incubating the 
drug-GMPs at 37ºC for 24h, however, reduced the first day initial burst (both % 
cumulative release and µg/ml/day) (p<0.05). In addition, the G15D15S4:1_24h 
incubation offered the highest drug release rate from day 7-10 (Figure 5.7) (p<0.05).  
Interestingly, lyophilizing the gelatin-incorporating construct prior to the drug 
release study had an impact on the drug release kinetics (Figure 5.8). This was reflected 
by the reduced initial burst on the first day and enhanced drug release (i.e., greater drug 
release rate created from day 2 to day 14) of the lyophilized construct relative to the non-
lyophilized construct (p<0.05). The release duration was extended from 10 days to 14 
days by the lyophilization process (Figure 5.8).  
The release kinetics of colistin from PMMA/gelatin/antibiotic constructs were 
analyzed using the Ritger-Peppas equation given by the following equation [163, 185, 
186]: 
Equation 5.1. Ritger-Peppas equation. 
 
where 
 
Mt
M∞
 is the fraction of drug release at time t, k is the apparent release rate 
constant that incorporates the structural and geometric characteristics of the drug delivery 
system, and n is diffusional exponent which assumes the transport mechanism of the 
drug. Table 5.2 lists the n and k values of the tested formulations, which were obtained by 
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fitting the initial 60% of the release data in the logarithmic form of the equation. All the n 
values were close or equal to 0.45 with the coefficient of determination approaching to 1.  
5.2.4. Degradation behavior of PMMA/gelatin/antibiotic constructs  
To elucidate the porosity change of constructs due to gelatin degradation, 
constructs (cylinders 6 mm in height and 10 mm in diameter) designed for implantation 
within a recently developed rabbit mandibular defect model [50] were degraded in vitro 
over 12 weeks. The porosity was characterized by microCT and described as a function 
of time (Figure 5.9). The constructs G15D15S4:1, G15D15S3:1 and G15D20S4:1 which 
had relative low initial porosity (9.3±1.4-16.8±0.6%) did not undergo significant changes 
in porosity over 12 weeks (p>0.05); however, constructs with higher initial porosity 
(G15D15S5:1 with 27.0±1.5% porosity and G20D15S4:1 with 29.4±0.9%) exhibited an 
increased porosity over time. After 12 weeks, the porosity was significantly greater than 
the initial porosity before degradation (p<0.05).  
5.3. Discussion 
Space maintenance, as the initial stage of a two-stage regenerative medicine 
approach toward reconstructing large bony defects, preserves the bony volume and 
primes the wound site for the subsequent reconstructive or regenerative stage. While the 
porous structure of the space maintainer facilitates tissue healing and material retention 
by allowing tissue ingrowth into the pores, incorporating a drug delivery system into the 
space maintainer provides controlled antibiotic delivery to address local infections, 
potentially eliminating infection-associated complications during space maintenance. The 
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purpose of the current study is to design a porous PMMA-based construct with 
particulate gelatin incorporated for the dual purpose of space maintenance and drug 
release. The gelatin-incorporating PMMA construct, where the GMPs not only imparted 
porosity but also controlled the drug release of the construct, is a simple system that 
meets the aforementioned requirements. The fast assembly of drug and material makes 
the approach particularly practical in the operating room (Figure 5.1), offering a great 
deal of flexibility in the material composition of constructs. The current study focuses on 
the relationship between material composition and construct properties (porosity, drug 
release kinetics and degradation), providing direction in tailoring the material 
composition to meet specific clinical needs.    
In these gelatin-incorporating constructs, chemically crosslinked gelatin was used 
in order to prolong the drug release duration. Our previous experiences demonstrated that 
PMMA constructs incorporating uncrosslinked gelatin, which undergoes rapid 
dissolution in PBS solution at 37ºC, rapidly released colistin (data not shown). In 
contrast, chemically crosslinked gelatin produces a smaller mesh size and degrades 
through polymer chain cleavage over a defined period (4-6 weeks for complete 
degradation in collagenase-containing PBS buffer, data not shown), providing a three–
dimensional gel network for drug diffusion. From a practical standpoint, crosslinked 
GMPs were more stable during construct fabrication and remained as independent 
particles as they were dispersed in the curing PMMA phase, ensuring a uniform drug 
distribution within the polymeric matrix.  
Crosslinked gelatin absorbed drug solution upon contact to form a hydrogel 
(Figure 5.2). Colistin was therefore loaded within the swollen GMPs at high weight 
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percentages (15 wt% or 20 wt%) by simple partitioning from a concentrated drug 
solution. The fast drug loading makes GMPs more practical than a majority of polymeric 
carriers where drugs have to be pre-loaded during carrier fabrication [145]. In such cases, 
the type and payload of drugs in the carrier are more difficult to modify for specific 
applications.  
Due to the immiscibility between the gelatin hydrogel phase and PMMA polymer 
phase, a porous structure was successfully created in the curing material where the 
porosity (initial porosities of 9.3±1.4-29.4±0.9% and degraded porosities of 7.6±1.8-
38.4±1.4%) was dependent on the amount of hydrogel phase incorporated (Figure 5.3 and 
Figure 5.4). The porosity characteristics of space maintainers potentially impact not only 
soft tissue penetrating the pore network [50, 162] but also the availability of open paths 
for drug release [145]. Previously we reported that both low-porosity PMMA/CMC 
constructs (16.9% porosity) and high-porosity constructs (44.6% porosity) were able to 
improve oral mucosal healing as compared to solid PMMA in a rabbit mandibular defect, 
while the low-porosity construct elicited a more favorable soft tissue response than the 
high-porosity construct [50]. In contrast, drug delivery may benefit from a more 
extensively connected pore network to achieve the complete release of entrapped drug 
[145]. Having the ability to control the porosity of gelatin-incorporating PMMA 
constructs over a wide range will allow a balance to be achieved between construct 
porosity and subsequent drug release to meet a specific need of space maintenance.  
In the PMMA/gelatin/antibiotic construct, the incorporation of GMPs created a 
pore network consisting of interconnected pores among the PMMA polymer phase and a 
loose network of GMPs entrapped in the PMMA phase. The extensive availability of 
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open paths allows the drug loaded in GMPs to elute to the outer environment. This was 
reflected by the high cumulative release of colistin (77.8±0.6-96.5±0.7%) by 
PMMA/gelatin/antibiotic constructs over 10 or 14 days. The greater cumulative releases 
of colistin from the high-porosity constructs (G15D15S4:1, G15D15S5:1, G20D15S4:1 
and G15D20S4:1) as compared to the low-porosity construct G15D15S3:1 (which 
featured the most limited porosity among the five formulations) also suggested that more 
open paths facilitated complete drug release from the construct.  The % drug release of 
PMMA/gelatin/antibiotic constructs was significantly enhanced relative to those reported 
for existing antibiotic-releasing PMMA constructs in which antibiotic drugs are directly 
entrapped into the non-degradable cement, leading to an ineffective slow release [187-
191]. With respect to the stability of released colistin, HPLC has been demonstrated to be 
a valid technique for evaluating the stability of colistin [192-194]. The high cumulative 
release determined by HPLC suggested that the majority of released colistin remained 
intact and stable.  
In these gelatin-incorporating PMMA constructs, the material composition 
affected the colistin release kinetics. For example, the drug release duration could be 
extended by reducing the overall porosity of constructs (e.g., G15D15S3:1 with 9.3±1.4% 
porosity achieved 14 days release) (Figure 5.5); the drug release rate created by the 
released colistin was enhanced by loading greater amounts of drug in the GMPs (Figure 
5.6). Mathematical analysis of the release data using the Ritger-Peppas equation helped to 
elucidate the drug transport mechanism from the PMMA/gelatin/antibiotic constructs 
[163, 185, 186]. According to this equation, all n values for the PMMA/gelatin/antibiotic 
constructs were close or equal to 0.45 (Table 5.2), indicating that the release of colistin is 
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governed by a Fickian diffusion mechanism [185]. For a defined polymer-drug device 
with a Fickian-controlled mechanism, the drug release can be manipulated by varying the 
initial concentration of drug within the matrix (which creates various penetrant 
concentration gradient of drug from the inside to the outside), and the geometry and 
composition of the pore network of the matrix. Our findings that the porosity and drug 
loading of PMMA/gelatin/antibiotic constructs affect the drug release kinetics thus agree 
with the Fickian diffusion mechanism.  
Interestingly, incubating the colistin-loaded GMPs for 24 h prior to construct 
fabrication potentially allowed for stronger association between the gelatin and drug 
(probably via hydrogen bonding or electrostatic attractions [168, 169]). Therefore, the 
rate of colistin release was decreased as evidenced by the reduced initial burst and higher 
drug release rate at the later stage of drug release (Figure 5.7). Lyophilizing the construct 
before drug release could also result in reduced initial burst and extended the release 
duration (Figure 5.8), which could be attributed to the stronger association of polymer-
drug or gelatin-PMMA achieved by the lyophilization process. These findings suggest 
alternative fabrication protocols could be explored to improve the drug release kinetics; 
however, utilizing such fabrication processes may result in increased drug loading or 
more preferable release at the expense of the ease of fabrication. 
Local antibiotic delivery is ideal as a means of controlling local infection while 
eliminating systemic exposure to potentially toxic drug concentrations. Sufficient drug 
concentration created in the local environment promises higher efficacy relative to 
systemic administration. For example, local 5-day colistin release from PMMA beads 
significantly reduced the incidence of Acinetobacter baumannii–associated chronic 
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osteomyelitis caused in mice [178]. For these gelatin-incorporating PMMA constructs, 
the concentrations of daily released drug, which was calculated by dividing the amount of 
released drug by the construct volume, remained constantly higher than 10 µg/ml over 
the release duration. This suggests that an immediate drug level higher than 10 µg/ml 
may be created in vivo depending on the drug transport away from the construct. The 
drug level 10 µg/ml is well above the minimum inhibitory concentration (MIC) of 
colistin against Acinetobacter baumannii (0.5 µg/ml) [195], holding great potential for 
clearing local infections. Considering the cytotoxicity that the drug release may induce, 
the constructs are anticipated to be well tolerated in vivo since the drug loading per 
construct (8-13 mg) is far below the recommended one-time dosage of systemically 
administrated colistin (50-100 mg every 8 hours for a 60 kg adult) [175]. With the 
controlled release feature, the system will supply the drug over a prolonged period of 
time and create a favorable drug concentration. The systemic toxicity might be 
minimized further. Not only is the release rate favorable, but the 10 or 14-day release 
duration of PMMA/gelatin/antibiotic constructs meets the criteria of antibiotic coverage 
for treating an active infection (i.e., 5-10 day coverage required). In its current form, the 
system, however, is not suitable for long term antibiotic therapy.  
As a space maintainer, the porosity change over time may consequently impact 
mechanical performance in an in vivo environment since mechanical strength is simply 
proportional to bulk porosity [145]. Providing that the degradation of gelatin 
microparticles is enzymatically accelerated with the presence of collagenase, the 
PMMA/gelatin/antibiotic construct was incubated in collagenase-containing PBS buffer 
to elucidate the impact of gelatin degradation on the construct porosity. A 12-week 
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degradation time was designated which was the designed postoperative evaluation period 
for a rabbit mandibular defect model [50] and similarly would most likely remain in place 
for human applications. As seen in Figure 5.9, the bulk porosity of G15D15S3:1, 
G15D15S4:1 and G15D20S3:1 remained unchanged with respect to bulk porosity over 
12 weeks, suggesting limited gelatin degradation over time which was likely due to the 
relatively low porosity of the construct. Although the constructs with relatively higher 
porosities had slightly increased porosities after 12 weeks, the porosity was far below 
50% and believed useful for application in the craniofacial complex. PMMA constructs 
with 50% porosity have been demonstrated to be mechanically sufficient in correcting 
craniofacial contour deformities and repairing defects in clinical applications and animal 
models [50, 86, 160]. 
The PMMA/gelatin/antibiotic approach has a number of strengths. First, it is a 
simple system involving few components with the capacity to easily modulate the 
physical properties of the fabricated constructs. Although various polymer systems 
entrapping gelatin have been described for the purpose of drug delivery [92], the present 
study is the first example using gelatin as both drug carrier and porogen. It is also the first 
systematic study of fabrication methods to quantitatively examine the effect of material 
composition on both release kinetics and porosity characteristics. Second, the practicality 
of this approach is applicable to a wide range of drug classes where drug loading can be 
completed via the fast assembly of drug, gelatin and PMMA. Drugs that may otherwise 
be damaged during the exothermic PMMA curing process may potentially be 
incorporated into such a system, as previous studies have shown the curing temperature 
of PMMA is reduced in the presence of an aqueous phase [145]. Besides the inclusion of 
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thermally sensitive drugs, alternative drug delivery mechanisms can be explored in this 
system. In addition to small molecules such as antibiotics delivered by a diffusion-
controlled release mechanism, large proteins associate with gelatin by electrostatic 
attractions and release through gelatin degradation [92, 168, 169, 179, 196-198]. For 
example, vascular endothelial growth factor [179], which is able to promote wound 
healing and vascular ingrowth, could be incorporated and delivered in a controlled 
manner for the function of priming the wound site during space maintenance. 
Additionally, the particulate gelatin hydrogel plus the easy drug loading protocol may 
potentially allow the simultaneous loading and delivery of multiple types of bioactive 
molecules. Further studies should focus on broadening the versatility of this system and 
evaluating efficacy in vivo.   
5.4. Conclusions 
An antibiotic-releasing porous PMMA/gelatin/antibiotic construct was developed 
as a temporary implant for space maintenance/infection control during the initial step of a 
two-stage regenerative medicine approach to posttraumatic wound healing. The construct 
was fabricated through the sequential assembly of GMPs, antibiotic drugs, and PMMA 
bone cement where the GMPs served as both drug carrier and porogen. The porosity of 
constructs was tailored by both the amount of gelatin incorporated and the amount of 
drug solution added for gelatin swelling. The constructs achieved continuous release of 
colistin over 10 or 14 days, potentially creating a concentration of daily released drug 
well above the MICs of colistin against susceptible species. The porosity and in vitro 
colistin drug release kinetics of the PMMA/gelatin/antibiotic constructs were tuned by 
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varying the material composition, offering optimal opportunities to further refine the 
construct to match a specific clinical application in the two-stage regenerative medicine 
approach.  
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5.5. Tables and Figures 
Table 5.1. Physical properties of PMMA/gelatin/antibiotic constructs. 
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Table 5.2. Diffusion parameters of various PMMA/gelatin/antibiotic constructs 
determined based on Ritger-Peppas equation (n=3).  
Construct 
Cumulative 
release 
(%) 
n k (1/hn) 
Coefficient of 
determination 
(r2) 
G15D15S3:1 79.6±0.6% 0.44±0.01 0.18±0.01 0.9982-0.9984 
G15D15S4:1 90.9±0.9% 0.45±0.01 0.25±0.00 0.9963-0.9973 
G15D15S5:1 90.8±2.4% 0.45±0.02 0.30±0.00 0.9993-0.9999 
G20D15S4:1 85.9±1.3% 0.45±0.01 0.27±0.01 0.9960-0.9971 
G15D20S4:1 98.5±0.7% 0.45±0.00 0.25±0.00 0.9971-0.9973 
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Figure 5.1. Fabrication of PMMA/gelatin/antibiotic constructs by the sequential 
assembly of GMPs, antibiotic drug, and PMMA bone cement: 1). antibiotic drug is 
dissolved in a predetermined volume of PBS buffer solution; 2). GMPs are swollen 
in the drug solution; 3). swollen GMPs are mixed with the two components of 
PMMA bone cement, first the PMMA powder and then the liquid MMA monomer. 
Fabrication can be completed within minutes.   
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Figure 5.2. Morphology of GMPs: A) SEM image of dehydrated GMPs showing 
spherical shape and dense polymer structure; B) optical microscopy image of 
swollen microparticles in PBS solution showing spherical shape of hydrogel GMPs.  
 
Figure 5.3. Swelling of GMPs in PBS solution by various swelling ratios (solution : 
gelatin by wt : wt): the mean diameter (mean ± SD based on n=3 separate swelling 
experiments) of swollen GMPs increased with greater amount of PBS solution 
added for swelling (p<0.05).  
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Figure 5.4. Morphology of PMMA/gelatin/antibiotic constructs characterized by A) 
SEM (scale bars represent 200 µm) and B) microCT (scale bars represent 2 mm, the 
porosity is indicated at upper left): a porous structure was created by the 
incorporation of gelatin microparticles; the bulk porosity is controlled by both the 
percent of gelatin incorporated and the weight ratio of drug solution versus gelatin 
for swelling. 
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Figure 5.5. In vitro colistin release from the PMMA/gelatin/antibiotic constructs 
G15D15S3:1, G15D15S4:1and G15D15S5:1 where the higher weight ratio of drug 
solution versus gelatin resulted in greater porosity of constructs: the daily release 
rates indicated a continuous colistin release over 10 or 14 days with the drug release 
rate higher than 10 µg/ml; the longest release duration (14 days) was achieved by 
the construct featuring the lowest porosity (G15D15S3:1); the construct 
G15D15S3:1 created the lowest release rate on day 1 but the highest release rate on 
the following days of release (p<0.05); the cumulative release of colistin 
demonstrated that the lower porosity resulted in reduced % initial burst (on day 1) 
(p<0.05). Error bars represent standard deviation for n=3. 
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Figure 5.6. Comparison of colistin release from two constructs with the same 
porosities but different drug loadings (G15D15S4:1 and G15D20S4:1) and different 
porosities (G15D15S4:1 and G20D15S4:1). Comparing the different drug loading, 
the construct with higher drug loading had a higher drug release rate over the 10 
day release duration (p<0.05); the cumulative drug release was similar.  
Comparison of colistin release from G15D15S4:1 and G20D15S4:1 where the higher 
weight percent of gelatin resulted in greater porosity and drug loading: the 20 wt% 
gelatin-incorporating construct created a higher release rate on day 1 but a lower 
release rate after day 1 (p<0.05); the cumulative drug release was similar. Error 
bars represent standard deviation for n=3.       
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Figure 5.7. Comparison of colistin release from G15D15S4:1, G15D15S4:1_1h 
incubation, and G15D15S4:1_24h incubation where the drug-loaded GMPs were 
immediately mixed with the PMMA cement or incubated for 1 h or 24 h at 37ºC 
prior to mixing with the PMMA cement for the fabrication of constructs: incubating 
drug-GMPs prior to construct fabrication did not alter the release duration; 
incubating drug-GMPs for 24h prior to the construct fabrication reduced the initial 
burst on day 1 and increased the drug release rate from day 7-10 (p<0.05); the 
cumulative drug release was similar. Error bars represent standard deviation for 
n=3. 
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Figure 5.8. Comparison of colistin release from G15D15S4:1 and Lyophilized where 
the latter underwent 24 h lyophilization before the release study: the lyophilized 
constructs presented reduced initial burst, higher release amount after day 1 and 
longer release duration (p<0.05); the cumulative drug release was similar. Error 
bars represent standard deviation for n=3. 
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Figure 5.9. Bulk porosity changes of gelatin-incorporating PMMA constructs over a 
12-week degradation period as determined by microCT: higher gelatin 
incorporation (20 wt%) or higher swelling ratio (5:1) resulted in greater porosity 
initially and throughout the degradation process (p<0.05); the porosity increased 
significantly after 12 week degradation (p<0.05); the three formulations that 
featured relatively lower porosity (G15D15S3:1, G15D15S4:1and G15D20S4:1) 
presented no change on the porosity over degradation (p>0.05). Error bars 
represent standard deviation for n=3. 
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Chapter 6 
Evaluation of Antibiotic-releasing 
Porous 
Polymethylmethacrylate/Gelatin 
Constructs 
Non-porous space maintainers have been previously shown to enhance 
craniofacial reconstruction by maintaining the bony structure and soft tissue envelope for 
later bone regeneration [199].  However, in many cases of bone loss, such as trauma or 
resection of a tumor that has invaded the mucosae, implantation of a foreign body could 
precipitate an infection.  Some clinical products, such as polymethylmethacrylate 
(PMMA)-based bone cements, have incorporated antibiotics for local control of infection 
[190, 200-203].  In general, the release of these antibiotics is rapid and the majority of the 
loaded antibiotic remains in the cement, making them ineffective at long-term infection 
control [190].   
Previous work from our laboratory has utilized particulate delivery systems, such 
as gelatin and poly(DL-lactic-co-glycolic acid) (PLGA) microparticles, to control the 
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release of antibiotics from porous PMMA-based constructs [145, 157].  A 
carboxymethylcellulose or gelatin gel was used as a porogen for these studies and 
increased weight percent of gel increased the porosity [50, 145].  Additionally, these 
studies illustrated that the antibiotic release, whether from PLGA or gelatin 
microparticles, could be controlled through fabrication parameters such as swelling, 
weight percent of gel or drug loading [145, 157].  In these studies, colistin, a polypeptide 
antibiotic, was incorporated into the gelatin or PLGA microparticles.  Colistin was 
selected due to decreased resistance of Acinetobacter baumannii to the antibiotic [204].  
A. baumannii is a common multi-drug resistant bacterial strain that has been observed to 
have increased incidence of infection in traumatic combat wounds [205-208].  
Additionally, colistin is infrequently used systemically due to nephrotoxicity [209], 
which may be mitigated by local delivery because of decreased systemic concentrations. 
This study investigated porous PMMA/PLGA/gelatin/colistin constructs for 
antibiotic release.  It asked the following questions: 1) What are the effects of 
formulation parameters on the structure of the construct, including the setting 
temperature, porosity, and topography and 2) What are the effects of construct structure 
on the antibiotic release kinetics and activity? 
6.1. Materials and Methods 
6.1.1. Materials 
Poly(DL-lactic-co-glycolic acid) (PLGA) was obtained from Lakeshore 
Biomaterials (Birmingham, AL) and had a copolymer ratio of 50:50, a weight average 
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molecular weight of  61.1 kDa, and a number average molecular weight of 37.3 kDa as 
measured by gel permeation chromatography [145].  Colistin sulfate salt was purchased 
from Sigma-Aldrich (St. Louis, MO).  Poly(vinyl alcohol) (PVA) was 88% hydrolyzed 
with a nominal molecular weight of 22 kDA and was purchased from Acros Organics 
(Geel, Belgium).  Surgiflo Hemostatic Matrix® was obtained from Ethicon (Somerville, 
NJ) and used as a source of gelatin. Bone cement was obtained from Depuy Orthopaedics 
(Smartset HV, Warsaw, IN).  
6.1.2. Microparticle Fabrication 
PLGA microparticles containing colistin were fabricated as previously described 
[145].  Briefly, a water-in-oil-in-water double emulsion solvent extraction technique was 
used.  Colistin was dissolved in a solution of 0.4 wt% PVA at a concentration of 325 
mg/mL as the internal phase.  PLGA was dissolved in methylene chloride at a 
concentration of 50 mg/mL, added to the internal phase in a ratio of 20:1 oil:internal 
phase, and homogenized.  This emulsion was added to a rapidly stirring outer phase of 
0.4 wt% PVA with 0.5 M NaCl in a ratio of 10:1 outer phase:oil.  After solvent 
extraction, the particles were washed, dried, and stored at -20°C.  Blank microparticles 
were fabricated with an internal phase of 0.4 wt% of PVA alone.  The entrapment 
efficiency of the microparticles was assumed to be 16.1 ± 2.5% based on previous 
determinations using the above fabrication method [145].  
6.1.3. Space Maintainer Fabrication 
Various groups of space maintainers were fabricated with the components shown 
in Table 1.  For the setting temperature and porosity determinations, constructs with no 
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incorporated drug were used with weight percents of gelatin similar to previous studies 
which showed favorable results in vivo [50], namely 30 and 40 wt%.  Similarly, two 
different gelatin matrix swelling ratios were chosen, low (LS, 1:1.9 water:gelatin weight 
ratio) and high (HS, 1:1.1 water:gelatin weight ratio) swelling, to determine the effect of 
matrix swelling ratio on the setting temperature and porosity.  For the antibiotic-loaded 
constructs, antibiotic was loaded by swelling the gelatin matrix with an antibiotic solution 
with a concentration of 150 mg/mL or by incorporating antibiotic-loaded PLGA 
microparticles described above.  Antibiotic-loaded gelatin swollen with the low swelling 
ratio (1:1.9) was added to constructs in 30 and 40 wt% to elucidate the effect of the 
amount of gelatin on the drug release kinetics.  For these groups, the drug loading per 
amount of gelatin remained constant, altering the drug loading per scaffold; however, 
previous studies indicated that changing the drug loading per weight of gelatin did not 
affect cumulative release, but rather the amount of gelatin included affected the release 
kinetics [157].  Constructs with colistin-loaded gelatin in a high swelling ratio were not 
completed as previous experiments indicated high swelling ratios of gelatin resulted 
greater burst release compared to lower gelatin swelling ratios [157]. Finally, PLGA 
microparticles were used in the LS30, LS40, HS30 and HS40 groups with the same 
PLGA:PMMA ratio for all groups.  Bone cement was used for all samples in a ratio of 
2.11:1 of powder phase to monomer phase as supplied by the manufacturer.   
To fabricate the various groups a simple mixing procedure was followed as 
previously described [145].  For Bone Cement control samples, the powder and monomer 
phases were mixed without the addition of a gel phase.  The gelatin matrix was swollen 
in a 1:1.1, and 1:1.9 ratio of solution weight to gelatin weight for the high (HS), and low 
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(LS) swelling ratios, respectively.  To fabricate the constructs, the powder phase of the 
bone cement was mixed into the gelatin hydrogel until completely incorporated.  The 
monomer phase of the bone cement was added and mixed, and the mixture was pressed 
into poly(tetrafluoroethylene) (PTFE) molds (10 mm in diameter and 6 mm thick) and 
allowed to cure for 30 min.  This procedure was followed for all methods except for 
thermal profiling where a larger mold according to ISO 5833 was used as described 
below in section 2.4 Setting Characterization.  
For groups with colistin-loaded gelatin matrix, 300 mg of colistin were dissolved 
in the ddH2O used to swell the gelatin matrix at a concentration of 150 mg/mL.  The 
swollen gelatin matrix was used to fabricate porous constructs as described above in 30 
and 40 wt% of the total construct mass. For groups with colistin-loaded PLGA 
microparticles, PLGA microparticles were added to the powder phase of the bone cement 
before fabrication.  For the 30 and 40 wt% gelatin matrix constructs, 11 and 9.6 wt% 
PLGA microparticles were used.  The drug content for each construct as shown in Table 
1 was calculated based on the entrapment efficiency and PLGA wt% for the PLGA-
loaded constructs and the swelling solution concentration and gelatin matrix wt% for the 
gelatin-loaded constructs. 
6.1.4. Setting Characterization 
The setting time and temperature were determined for the Bone Cement, LS30, 
LS40, HS30 and HS40 groups using ISO 5833.  Briefly, the powder phase and powder 
phase/gelatin hydrogel mixture, for the non-porous and porous constructs respectively, 
were mixed with the monomer phase.  This mixture was placed into a cylindrical PTFE 
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mold, 60 mm in diameter and 6 mm in height, with a thermocouple probe in the middle 
of the specimen disc penetrating the surface.  The temperature was recorded over time (n 
= 1). 
6.1.5. Porosity Characterization 
Porous constructs from the LS30, LS40, HS30 and HS40 groups were 
characterized in terms of bulk porosity by microCT. A SkyScan 1172 microCT imaging 
system (Aartselaar, Belgium) was used to perform nondestructive imaging and quantify 
the 3D microarchitectural morphology of the constructs. The specimens (n=3) were 
imaged with an X- ray tube voltage of 40 kV and current of 250 µA without a filter. 
Volumetric reconstruction and analysis were conducted using the software NRecon and 
CTAn provided by SkyScan. 
The surfaces of specimens were characterized by scanning electron microscopy 
(SEM).  The surface was sputter-coated with gold for 40 s at 100 mA using a CrC-150 
sputtering system (Torr International, New Windsor, NY) and visualized under a FEI 
Quanta 400 field emission scanning electron microscope (FEI company, Hillsboro, OR) 
at an accelerating voltage of 10 kV.   
Finally, gelatin was leached from within the constructs by submersion into 5 mL 
of phosphate buffered saline (PBS, pH = 7.4) at 37°C with mild agitation.  The PBS was 
exchanged at 1 and 3 days and at 1, 2, 4, 8, 9, 10, 11 and 12 weeks.  MicroCT tomograms 
were taken according to the method described above at 1 and 3 days and at 1, 2, 4, 8, and 
12 weeks.   
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6.1.6. Colistin Release 
The release of each group containing colistin was determined by high 
performance liquid chromatography (HPLC) as previously reported [145, 157].  Each of 
three space maintainers for each group was placed in 5 mL PBS (pH = 7.4) at 37°C under 
mild agitation. For groups where the antibiotic was loaded into the gelatin matrix (names 
ending with Gel), the supernatant from each sample was completely removed and 
replaced with fresh PBS at 2 and 6 hrs and at 1, 2, 3, 7, 10 and 14 days.  For groups 
where the antibiotic was loaded into PLGA microparticles (names ending in PLGA), the 
supernatant from each sample was completely removed and replaced with fresh PBS at  
1, 2, 4, 7, 11, 14, 18, 21, 25, 28, 32, 35, 39, 42, 46, 49, 53, 56, 60, and 63 days. The 
timepoints were selected based on previous studies using similar particulate carriers with 
the addition of a greater number of timepoints for the PLGA-loaded constructs to ensure 
complete release of the drug [145, 157].  The supernatant was filtered with a 0.2 µm filter 
and the colistin concentration was determined using HPLC.  The HPLC system 
comprised a Waters 2695 separation module and a 2996 photodiode array detector 
(Waters®, Milford, MA) with an XTerra® RP 18 column (250mm × 4.6mm, Waters®) at 
45 °C.  The elution was performed with a flow rate of 0.5 mL/min in a mobile phase 
consisting of acetonitrile (HPLC grade with 0.1 vol% trifluoroacetic acid) and water 
(HPLC grade with 0.1 vol% trifluoroacetic acid). Peaks were eluted with a linear gradient 
of 5–65% acetonitrile in water over 20 min. Absorbance was monitored at λ = 214 nm 
with the two components of colistin, colistin A and colistin B, eluted at approximately 
16.2 min and 16.9 min, respectively. Standard solutions with colistin in PBS (pH 7.4) 
were tested in the range of 5–1000 µg/mL. Calibration curves were obtained using the 
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combined peak area of colistin A and colistin B versus the colistin concentration.  The 
cumulative release (%) was expressed as the percent of total colistin released over time.  
6.1.7. Bacterial Culture and Susceptibility 
Acinetobacter baumannii (Isolate # 170) was obtained from Brook Army Medical 
Center as a cultured specimen from a deep wound of a soldier returning from Operation 
Iraqi Freedom.  Antibiotics released from the LS30Gel and LS30PLGA groups on day 1 
were tested by sterile filtering the supernatant and using the solution as a stock solution in 
the microdilution minimum inhibitory concentration (MIC) protocol according to ISO 
20776.  These solutions were selected as day 1 resulted in a sufficiently high stock 
solution concentration to complete the standard experiment for drug released from the 
gelatin matrix and from PLGA microparticles.  This experiment compared the drug 
released from gelatin matrix and that released from PLGA microparticles with fresh 
colistin not loaded into a construct.  Briefly, the stock solution was serially diluted with 
sterile Mueller Hinton broth to 50 µL aliquots with concentrations from 0 mg/L to 32 
mg/L.  A. baumannii cultured in Mueller Hinton broth was diluted to 1 × 106 CFU/mL 
and 50 µL of the inoculum was added to each well.  The experiment was performed in 
triplicate and the concentration of colistin without growth at 18 hr of culture at 37°C was 
denoted the MIC.   
6.1.8. Statistical Analysis 
The porosity at each timepoint, the colistin released at each timepoint and the 
MICs were compared using ANOVA with post-hoc analysis by Tukey’s honestly 
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significant difference.  An a priori level of significance was set a α=0.05.  All analyses 
were performed using MATLAB (Version R2011B, Natick, MA). 
6.2. Results and Discussion 
This study evaluated porous constructs fabricated from clinically available 
materials and the effect of their formulation on setting temperature, porosity, and 
topography of the construct.  It also evaluated the effect of the structure on antibiotic 
release kinetics and activity.   
6.2.1. Setting Characterization 
The temperature profiles of the porous constructs are shown in Figure 1 compared 
to the profile of non-porous bone cement (Bone Cement).  The exothermic reaction of 
MMA polymerization produced a rise in temperature in all groups, with the greatest 
increase in temperature with the Bone Cement group.  The maximum temperatures 
reached were 40, 38, 43, 36, and 89°C for the LS30, LS40, HS30, HS40, and Bone 
Cement groups, respectively.  During the curing of these constructs, the maximum 
temperature of porous constructs was diminished as compared to the Bone Cement group.  
The decreased maximum setting temperature of porous constructs compared to Bone 
Cement is consistent with previous studies where carboxymethylcellulose hydrogels were 
used as the porogen [145].  The setting temperature decrease in the porous constructs is 
due to the decreased amount of MMA per unit volume and the hydrogel acting as a heat 
sink during the exothermic polymerization.  
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6.2.2. Porosity 
Figure 2 illustrates the increase in porosity over time for the porous constructs, 
which is consistent with previous studies showing the dissolution of the gelatin matrix 
from the pores of the construct [157].  HS40 had a significantly greater porosity than all 
other formulations for all timepoints, and LS40 had significantly less porosity than all 
other formulations after 1 week.  Also, the LS40 and HS30 groups were significantly 
different at day 3.  Representative microCT cross-sections are shown in Figure 3A-D 
illustrating the homogeneous distribution of pores.  The increased porosity with an 
increase in aqueous porogen incorporation for the high swelling groups is consistent with 
a previous study also utilizing gelatin as the porogen [157].  The increase in porosity with 
increased porogen content seen in the high swelling group is expected; however, the 
decrease in porosity with greater porogen content in the low swelling group is 
unexpected.  The change in concentration of gelatin in the porogen matrix may alter the 
interaction between the hydrophilic (gelatin hydrogel) and hydrophobic (PMMA) phases 
of the mixture, changing the stability of the pores before curing. Furthermore, Figures 
3A-D show the homogeneity of the pore structure created with these materials.   
Representative SEM images are shown in Figure 3E-H of the LS30, LS40, HS30, 
and HS40 groups.  All four groups had roughness from pores exposed to the surface, an 
important feature for both tissue interaction and drug release.   
6.2.3. Colistin Release 
 Colistin was released for up to 8 weeks from the constructs in vitro.  
Figures 4 and 5 show the release of colistin from the gelatin matrix and PLGA within the 
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PMMA-based constructs, respectively.  Additionally, the release from the PLGA 
microparticles alone, not in a construct, is shown in Figure 5.  Comparing the release 
from colistin-loaded gelatin matrix, the LS40Gel group released significantly more 
antibiotic than the LS30Gel group at 1 and 6 hours, but there was no difference in the 
cumulative release.  The effect of porogen weight percent on release rate was shown 
previously in a study utilizing gelatin microparticles as the porogen [157], where 
increasing the amount of gelatin microparticles increased the release rate of colistin from 
the construct.  However, in the previous study, increased weight percent of gelatin 
microparticles also increased porosity [157].  In this study, increased weight percent of 
gelatin matrix in the LS groups led to decreased porosity.  Thus the weight percent of 
gelatin matrix may serve as an important factor for release of drug beyond the formation 
of porosity. 
The swelling ratio significantly affected the release of colistin from the PLGA-
loaded constructs (Figure 5), where increased matrix swelling in the PLGA-loaded 
constructs decreased the burst release of colistin.  This was true for both 30 and 40 wt% 
constructs, which as shown in Figure 2, had differing effects on porosity.  Thus, it is the 
matrix swelling ratio and not the porosity that affected the burst release of the PLGA-
loaded constructs.  In the previous study with gelatin microparticles, increased swelling 
of gelatin microparticles led to increased burst release; however, the porosity also 
increased with increased swelling [157].  Additionally, the colistin was loaded into the 
gelatin phase of the construct and not into PLGA microparticles.   
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6.2.4. Bacterial Susceptibility 
 The susceptibility of A. baumannii to colistin, colistin released from 
LS30Gel and colistin released from LS30PLGA was measured as the MIC according to 
ISO 20776 using the microdilution method.  Colistin alone had an MIC of 5.33 ± 2.31 
µg/mL, colistin released from the gelatin matrix (LS30Gel) had an MIC of 0.25 ± 0.00 
µg/mL, and colistin released from PLGA microparticles (LS30PLGA) had an MIC of 
0.17 ± 0.07 µg/mL.  The MIC of colistin alone was statistically greater than the MIC of 
colistin released from either the gelatin matrix or PLGA.  This result may be due to other 
molecules present in the supernatant of the released samples.  The colistin control was 
dissolved in water per the standard, ISO 20776. However, the colistin released from 
samples was in the supernatant from the release study, which likely had degradation 
products and leachables from the constructs such as MMA, lactic and glycolic acid and 
the gelatin matrix.  The supernatant could therefore have an effect on the antimicrobial 
efficacy of the test samples. 
While this study evaluated several formulations with varying compositions, the 
consistency of each formulation’s composition varies in more than one parameter as 
indicated in Table 1.  This feature is evident in the drug content column, which shows 
various amounts of drug per mass of construct.  These differences are caused by the other 
factors such as the loading of drug per mass of microparticle or the loading of drug per 
mass of dry gelatin matrix.  These parameters were kept constant and thus when more 
gelatin matrix was incorporated into a construct a similar increase in drug content could 
be seen.  While this allows for comparison between groups based on cumulative release, 
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similar studies where the drug content is maintained and the loading of drug per unit 
(PLGA or gelatin matrix) is altered could be similarly completed.   
6.3. Conclusions 
 This study illustrated that the physicochemical properties of colistin-loaded 
porous space maintainers could be controlled through fabrication parameters.  
Specifically, the inclusion of the gelatin porogen decreased the setting temperature of the 
constructs and the weight percent of the gelatin included had variable effects on porosity 
for different swelling ratios.  Also, the release of colistin from these constructs could be 
controlled through fabrication parameters, such as swelling and porogen weight percent 
as well as the delivery vehicle, such as the gelatin matrix or PLGA microparticles.  The 
release kinetics in this study were shown to depend more on fabrication parameters than 
the physicochemical properties of the construct, which could have impact on future 
studies as physicochemical properties and release kinetics may be tuned separately.  
Antibiotic release constructs can be fabricated to release various amounts of drug over an 
extended period of time by varying the fabrication parameters. 
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6.4. Tables and Figures 
Table 6.1. The composition of PMMA/PLGA/gelatin/colistin constructs examined. 
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Figure 6.1. Temperature profiles of the LS30, LS40, HS30 and HS40 groups during 
curing compared to Bone Cement (n=1).   
 
Figure 6.2. Change in porosity over time illustrating the dissolution of the gelatin 
matrix as measured with microcomputed tomography for the LS30, LS40, HS30 
and HS40 groups (n = 3).  HS40 is significantly different from all other groups for 
all timepoints, LS40 and HS30 were significantly different at day 3, and LS40 was 
significantly different from all other groups after 1 week (p < 0.05). 
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Figure 6.3. Scanning electron micrographs (A-D) and microcomputed tomography 
cross-sections (E-H) of the LS30 (A, E), LS40 (B, F), HS30 (C, G), and HS40 (D, H) 
groups.  Scale bars indicate 500 µm and 2 mm for the SEM and microCT cross-
sections, respectively. 
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Figure 6.4. Cumulative release of colistin from constructs (n = 3) where colistin was 
loaded into the gelatin matrix at 30 and 40 wt%.  There were significant differences 
between the LS40Gel and LS30Gel groups at 1 and 6 hours (p < 0.05). 
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Figure 6.5. Cumulative release of colistin from constructs (n =3) where colistin was 
loaded into PLGA microparticles.  There was a significant difference between the 
LS30PLGA and HS40PLGA groups at day 1.  Additionally, there were significant 
differences between HS30PLGA and HS40PLGA groups and LS30PLGA and 
LS40PLGA groups from day 2 to day 39.  Also, there was a significant difference 
between the HS30PLGA and the LS30PLGA and LS40PLGA groups, and a 
significant difference between LS40PLGA and HS40PLGA at day 42 (p < 0.05). 
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Chapter 7 
Evaluation of Antibiotic-releasing 
Porous Polymethylmethacrylate Space 
Maintainers in an Infected Composite 
Tissue Defect Model 
Non-porous space maintainers have been previously shown to enhance restoration 
of the craniofacial complex by maintaining the bony structure during craniofacial 
reconstruciton [199].  Current materials fail typically as a result of infection or by wound 
dehiscence.  There has been some modifications of materials to release antibiotics to help 
mitigate infection [190, 200-203], but the release of antibiotics from these materials is on 
a very short timescale (< 3 days) and the majority of the encapsulated drug remains in the 
implant, reducing their efficacy [190].   
Previous work from our laboratory has investigated gelatin and poly(DL-lactic-
co-glycolic acid) (PLGA) microparticles to affect the controlled release of antibiotics 
from constructs [145, 157].  Additionally, these constructs are porous by the inclusion of 
a carboxymethylcellulose or gelatin hydrogel [50, 52, 145, 157].  This porosity enhanced 
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the tissue integration and allowed for greater cumulative release of antibiotic [50, 52, 
145, 157].  In these studies, colistin, a polypeptide antibiotic, was selected for inclusion 
into these particulate delivery systems due to decreased resistance of Acinetobacter 
baumannii to the antibiotic [204].  A. baumannii  has been observed to have increased 
incidence of infection in traumatic combat wounds [205-208].   
This study investigated porous PMMA/PLGA/gelatin/colistin constructs serving 
as antibiotic-releasing space maintainers and evaluated their efficacy in vivo in a rabbit 
infected composite tissue defect model.  It asked the following question: What are the 
effects of antibiotic-releasing space maintainer fabrication parameters on wound healing, 
infection clearance, kidney function, and tissue response to the construct? 
7.1. Material and Methods 
7.1.1. Materials 
Surgiflo Hemostatic Matrix (Somerville, NJ) was used as a source of gelatin. 
Bone cement was obtained from Depuy Orthopaedics (Smartset HV, Warsaw, IN). 
Colistin sulfate salt was purchased from Sigma-Aldrich (St. Louis, MO).  Poly(vinyl 
alcohol) (PVA) was 88% hydrolyzed with a nominal molecular weight of 22 kDA and 
was purchased from Acros Organics (Geel, Belgium).  Poly(DL-lactic-co-glycolic acid) 
(PLGA) was obtained from Lakeshore Biomaterials (Birmingham, AL) and had a 
copolymer ratio of 50:50, a weight average molecular weight of  61.1 kDa, and a number 
average molecular weight of 37.3 kDa as measured by gel permeation chromatography 
[145].   
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7.1.2. Microparticle Fabrication 
PLGA microparticles containing colistin were fabricated as previously described 
[145].  Briefly, a water-in-oil-in-water double emulsion solvent extraction technique was 
used, where colistin was dissolved in a solution of 0.4 wt% PVA at a concentration of 
325 mg/mL as the internal phase.  The oil phase comprised PLGA in methylene chloride 
at a concentration of 50 mg/mL.  This oil phased was added to the internal phase in a 
ratio of 20:1 oil:internal phase, and homogenized.  The external phase consisted of 0.4 
wt% PVA with 0.5 M NaCl.  The emulsion created by the homogenization was added to 
the external phase in a ratio of 10:1 external phase:oil.  After 4 hours, allowing for 
solvent extraction, the particles were washed, dried, and stored at -20°C.  Additionally, 
blank microparticles were fabricated with an internal phase of 0.4 wt% of PVA alone.  
The entrapment of colistin-loaded microparticles was determined as previously described 
[145].   
7.1.3. Space Maintainer Fabrication 
The gelatin matrix was swollen in a 1:1.9 ratio of solution weight to gelatin 
weight.  The swollen gelatin matrix was used in 30 wt% of the total space maintainer 
mass.  Bone cement was used for all samples in a ratio of 2.11:1 of powder phase to 
monomer phase as supplied by the manufacturer.  To fabricate the space maintainers, the 
powder phase of the bone cement was first dispersed into the gelatin matrix.  The 
monomer phase of the bone cement was added and mixed, and the space maintainer was 
molded and allowed to cure. 
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For colistin release, space maintainers were fabricated with the antibiotic-loaded 
in PLGA microparticles or in the gelatin matrix.  For groups with colistin loaded into the 
gelatin matrix, the gelatin matrix was swollen with ddH2O with a colistin concentration 
of 150 mg/mL.  For groups with colistin loaded into the PLGA microparticles, PLGA 
microparticles in 11 wt% of the total mass were added to the powder phase of the bone 
cement.  For the PLGA High group this 11% consisted entirely of colistin-loaded 
microparticles, while for the PLGA Low group approximately half was replaced with 
blank PLGA microparticles.  Table 7.1 summarizes the groups used for all analyses 
including the drug content based on the entrapment efficiency for the PLGA groups and 
the concentration for the Gelatin group.  Each sample was sterilely aliquoted in sterile 
containers for intraoperative fabrication and cured in situ.   
7.1.4. Bacterial Culture  
Acinetobacter baumannii (Isolate # 170) was obtained from Brook Army Medical 
Center as a cultured specimen from a deep wound of a soldier returning from Operation 
Iraqi Freedom.  For the in vivo inoculum, A. baumannii was cultured in tryptic soy broth 
(BD, Franklin Lakes, NJ).  Colony forming unit (CFU) concentration for inoculation was 
determined by absorption the morning of each surgery, diluted by sterile tryptic soy broth 
to 2 × 107 CFU/mL, and stored on ice until inoculation.  Control defects were inoculated 
with the sterile tryptic soy broth.   
7.1.5. Surgical Procedure 
All procedures followed protocols approved by the Rice University and 
University of Texas Health Science Center at Houston Institutional Animal Care and Use 
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Committees.  Four groups were selected for evaluation in an infected composite tissue 
defect model with 10 implants per group.  A. baumannii was inoculated into defects filled 
with three different formulations: Gelatin, and two PLGA groups, PLGA High and an 
approximately half dose of colistin, called PLGA Low, where approximately half of the 
microparticles loaded were blank.  The fourth group, Uninfected, served as a control, 
which was uninfected and had the same formulation as the PLGA High.  The surgical 
procedure was completed as previously described [50-52].  Briefly, a midline incision 
extending posteriorly from the mentum was used to expose the inferior border of the right 
hemimandible.  The soft tissue and periosteum were lifted from the body of the mandible 
and a 10 mm diameter bicortical defect was made in the body of the mandible with a 
dental trephine (Ace Surgical, Brockton, MA) powered by a micromotor handpiece 
(NSK, Kanuma, Japan) with copious irrigation.  A crosscut bur (Stryker, Kalamazoo, MI) 
was used to cut a 2-3 mm notch in the superior aspect of the defect.  The overlying crown 
was removed, creating an oral mucosal defect with intraoral communication.  The defect 
was inoculated with 100 µL of the bacterial suspension, amounting to 2 × 107 CFU/mL of 
bacteria, or sterile broth by pipette on the defect walls.  The implant was fabricated by 
first mixing the powder phase into the swollen gelatin until evenly mixed.  The monomer 
phase was added and mixed until doughy, then shaped by hand and packed into the 
defect.  The time from inoculation to packing was maintained at 7 min.  A titanium plate 
was placed over the defect to prevent iatrogenic fracture.  The defect was closed in layers 
with 4-0 Vicryl suture (Ethicon, Somerville, NJ) in running and subcuticular stitch 
patterns for the muscle and fascia, and skin, respectively.  Each rabbit received a fentanyl 
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patch and carprofen subcutaneously for pain management and inflammation, 
respectively, for 48 hours postoperatively.   
7.1.6. Kidney Function 
The kidney function of the rabbits was analyzed at 0, 1 and 5 weeks by measuring 
plasma creatinine and blood urea nitrogen from blood drawn from the ear vein.  The 
plasma concentrations were measured using an IDEXX Vet Test 8008 (IDEXX 
Laboratories, Westbrook, ME).   
7.1.7. Sample Culture 
At 12 weeks postoperatively, the rabbits were euthanized by barbiturate overdose.  
A blood sample was taken sterilely from cardiac puncture with 3.8% sodium citrate.  The 
anterior edge of the defect was exposed by sterile dissection.  Sterile cotton swabs were 
used to collect samples from saliva, the anterior edge of the defect, and any abscesses in 
the craniofacial region.  The swabs were cultured at 37°C on tryptic soy agar (BD, 
Franklin Lakes, NJ) and tryptic soy agar with 5% sheep blood (BD, Franklin Lakes, NJ) 
for blood samples.  Individual colonies were tested for oxidase activity by oxidase 
reagent (PML Microbiologicals, Wilsonville, OR).  The same colonies were smeared on 
glass slides and stained with Gram’s stain.  All gram negative oxidase negative colonies 
were further identified by the API 20 NE kit (bioMerieux, Marcy l’Etoile, France).  
7.1.8. Gross Observation 
At the time of euthanasia, the right hemimandible was explanted.  The mucosa 
over the defect was classified as healed or non-healed and the other oral mucosa was 
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classified as dehisced or non-dehisced.  The mandibles were then placed in 10% neutral 
buffered formalin for fixation for 72 hours.  After 72 hours, the mandibles were 
transferred to 70% ethanol. 
7.1.9. Histology 
The mandibles were dehydrated by serial solutions of ethanol (70-100%) and 
embedded in methylmethacrylate.  After complete polymerization, 10 µm sections were 
cut coronally using an inner circle diamond microtome (Leica, Wetzlar, Germany) and 
stained with methylene blue and basic fuchsin.  Three blinded reviewers scored each 
specimen according to the scoring system shown in Table 7.2 to assess the tissue 
response around the implant and within the pores of the implant [92].  Images were 
obtained using an AxioImager Z.2 microscope (Zeiss, Oberkochen, Germany). 
7.1.10. Statistical Analysis 
The creatinine, and the blood urea nitrogen values were compared using ANOVA 
with post-hoc analysis by Tukey’s honestly significant difference.  The classifications of 
oral mucosae were compared using the Fisher-Freeman-Halton test with post-hoc 
analysis by Fisher’s exact test. The histological scores of the space maintainers were 
compared using the Kruskal-Wallis test with post-hoc analysis by the Mann-Whitney U 
test.  An a priori level of significance was set a α=0.05.  All analyses were performed 
using MATLAB (Version R2011B, Natick, MA). 
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7.2. Results 
7.2.1. Microparticle Fabrication 
The entrapment of colistin into the PLGA microparticles was 6.1 ± 0.9 wt%.  This 
value was used to determine the drug content of PLGA-loaded implants shown in Table 
7.1. 
7.2.2. Animal Care 
Surgery was performed on 45 rabbits with 5 prematurely euthanized animals.  All 
prematurely euthanized animals had complications unrelated to the treatment but rather 
due to general problems including unresolved postoperative diarrhea, neurological 
deficits due to spinal fracture, and unresolved foot wounds.  The remaining 40 animals 
were healthy and were euthanized at 12 weeks postoperatively. 
7.2.3. Kidney Function 
All mean values for creatinine and BUN were within normal range (creatinine: 
0.8-1.8 mg/dL; BUN: 10-24 mg/dL) and there were no significant differences between 
groups at each time point (Figure 7.1). Creatinine and BUN remained below the threshold 
that would indicate acute tubular necrosis due to the use of nephrotoxic levels of colistin. 
7.2.4. Gross Observation 
In addition to healed (Figure 7.2A) and non-healed (Figure 7.2B) mucosal defects, 
some rabbits exhibited a separate medial mucosal dehiscence as seen in Figure 7.2C.  
Figure 7.3A shows the number of healed mucosae in each group and Figure 7.3B shows 
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the number of dehisced mucosae in each group.  There was a significantly greater number 
of healed mucosae in the PLGA High group compared to the Gelatin; however, there 
were no significant differences between groups for the dehiscences. 
7.2.5. Sample Culture 
All saliva swabs and 3 defect swabs grew bacteria; however, none of these 
bacteria were proven to be A. baumannii.  Colonies grown from saliva swabs were 
excluded based on gram stain, oxidase presence, or with the API 20NE kit.  No blood 
swabs grew bacteria.  Two defects had abscesses; however, only one grew bacteria, 
which were gram positive. 
7.2.6. Histology 
Histological assessment of the space maintainers in the mandible confirmed the 
presence of non-healed (Figure 7.4A) and healed (Figure 7.4B) oral mucosae in various 
samples.  PLGA had significantly higher histological score than the Uninfected group at 
the tissue implant interface.  As seen in Figure 7.5A, this is shown by all PLGA High 
samples receiving a score of 2, representative of a highly organized fibrous capsule.  The 
Uninfected group had scores of 0, 1, and 2, indicating an abundance of inflammatory 
cells (Figure 7.4D), a poorly organized fibrous capsule and highly organized fibrous 
capsule, respectively.  Although there were instances of direct bone implant contact 
(Figure 7.4C) this did not comprise the majority of the interface and thus could not 
receive a score of 3 or 4.  No other significant differences were found for the tissue 
implant interface.  None of the histological scores for the pore tissue were significantly 
different including scores of 0, 1, 2, and 3, representing exclusively inflammatory cells, a 
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majority of inflammatory cells, immature fibrous tissue, and fibrous tissue and bone, 
respectively, as indicated in Table 7.2. 
7.3. Discussion 
In the infected composite tissue defect, implants from the PLGA High group 
showed increased soft tissue healing over the Gelatin group.  While this is an indirect 
measurement of infection clearing, previous studies have shown decreased healing in the 
presence of infection [210, 211].  Previous studies in non-porous PMMA based materials 
showed similar results in that the duration of release impacted reduction in bacterial load 
[190, 202, 212].  This may be due to some bacteria entering a sessile state as biofilm, 
thereby increasing the effective concentration necessary for clearance of the infection.  
These bacteria may then proliferate and colonize the wound after the short duration of 
antibiotic delivery, whereas they remain sessile with continued delivery of antibiotics in 
the extended release groups [213].   
For the first time using this model, a dehiscence separate from the intentional 
mucosal defect was observed.  As seen in Figure 7.2C, these dehiscences were located on 
the lingual aspect of the mucosa overlying the implant.  Due to the presence of these 
dehiscences in the Uninfected group, the differences in formulation between these 
samples and previous studies is the use of gelatin matrix as the porogen and the delivery 
of antibiotics.  Previous studies have shown that antibiotics, while targeted at bacteria, 
have detrimental effects on viability and function of host cells [214, 215]. This effect 
could lead to breakdown of the soft tissue, fenestration, and dehiscence.   
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In addition to efficacy in infection clearance, safety was measured through the 
analysis of kidney function by plasma concentration of BUN and creatinine.  The early 
discovery of nephrotoxicity with colistin has led to increased research into local delivery 
of the drug for increased local concentration with decreased systemic exposure [209, 216-
218]. This study showed that with high local delivery to the wound site, the negative 
systemic effects of colistin administration were avoided.  Local delivery strategies may 
allow for increased application of powerful antibiotics that were previously underused 
clinically due to severe systemic adverse effects. 
Clearance of the infection was also evaluated by cultures of the saliva, blood, and 
defect at 12 weeks.  While a few of the defects and all of the saliva swabs grew bacteria, 
none were identified to be A. baumannii.  In the normal rabbit, saliva swabs would 
culture many different bacteria due to mucosal colonization.  In addition, these bacteria 
could inoculate and colonize the porosity of the implant through the mucosal defect.  This 
is corroborated by the few defect swabs that did culture bacteria, but were not identified 
as A. baumannii.  This finding is consistent with previous studies where increased 
inflammation in highly porous space maintainers was attributed to colonization of the 
implant by oral flora [50].  Additionally, a recent study showed that 37% of traumatic 
injuries resulted in polymicrobial infections [219].  Thus, while the delivery of a single 
antibiotic is likely inadequate alone to treat such polymicrobial wound infections, the 
animal model used in this study presents a complex environment very similar to the 
targeted problem area. 
Although there were significant differences in gross wound healing, the 
histological response was similar for the tissue-implant interface and the tissue within the 
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pores.  As seen in Figure 7.5A, many of the samples received scores of 2 for a mature 
fibrous capsule; however, for several of these samples, there was a layer of inflammatory 
cells between the fibrous capsule and the implant as shown in Figure 7.4D.  This has been 
previously demonstrated to be due to continued release of proinflammatory molecules 
being released from the implant resulting in the invasion by inflammatory cells [220]. 
Inflammatory molecules from bacterial colonization or the degradation products of 
PLGA or gelatin may be released from the implant at late time points, resulting in the 
recruitment of inflammatory cells.  Finally, there are several instances of direct bone-
implant contact either at the interface or in the pores of the implant as shown in Figure 
7.4C, illustrating that after 12 weeks, there is some growth of bone around and in the 
implant. 
Considering the results, there are a few areas from this study that could receive 
further investigation.  While this study elucidated the role of colistin release from the 
space maintainer against A. baumannii in this defect, the expansion of this study to 
include various antibiotics, bacterial strains and combinations thereof is important to 
address the clinical nature of many traumatic facial injuries.  Additionally, further study 
into the mechanisms and relationships of the tissue regeneration with respect to infection 
clearance and delivery of the antibiotic is important.  Finally, as traditional pharmacology 
focuses on the distribution of drug delivered systemically, adequate investigation into 
dose and duration on local concentrations of antibiotic and clearance of infection is 
warranted.     
 149 
 
7.4. Conclusion 
The loading parameters for the implants affected the gross soft tissue healing in 
an infected composite tissue defect model over a period of 12 weeks.  Also, local delivery 
did not result in systemic effects, specifically nephrotoxicity.  The results from this study 
indicate that the local delivery of antibiotic released from PLGA may increase soft tissue 
healing around an infected defect.  Finally, the polymicrobial nature of this animal model 
allows for complex study, simulating the clinical problem seen in infected wounds.  
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Tables and Figures 
Table 7.1. The composition of PMMA/PLGA/gelatin/colistin implants evaluated. 
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Table 7.2. Histological scoring system for the implant tissue interface and the tissue 
in the pores of the implant [92]. 
Hard tissue response at the implant-bone interface Score 
Direct bone-to-implant contact without soft interlayer 4 
Remodeling lacuna with osteoblasts and/or osteoclasts at surface 3 
Majority of implant is surrounded by fibrous tissue capsule  2 
Unorganized fibrous tissue (majority of tissue is not arranged as 
capsule)  
1 
Inflammation marked by an abundance of inflammatory cells and poorly 
organized tissue 
0 
Hard tissue response within the pores of the scaffold  
Tissue in pores is mostly bone  4 
 Tissue in pores consists of some bone within mature, dense fibrous 
tissue and/or a few inflammatory response elements 
3 
 Tissue in pores is mostly immature fibrous tissue (with or without 
bone) with blood vessels and young fibroblasts invading the space with 
few macrophages present  
2 
Tissue in pores consists mostly of inflammatory cells and connective 
tissue components in between (with or without bone) or the majority of 
the pores are empty or filled with fluid  
1 
Tissue in pores is dense and exclusively of inflammatory type (no bone 
present) 
0 
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Figure 7.1. Plasma concentrations of (A) BUN and (B) creatinine taken 
preoperatively (week 0) and 1 and 5 weeks postoperatively as measures of kidney 
function.  Data are presented as means ± the standard deviation for n = 10. Normal 
ranges: BUN: 10-24 mg/dL and creatinine: 0.8-1.8 mg/dL. There were no significant 
differences between groups for BUN or creatinine plasma concentrations.   
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Figure 7.2. Gross photographs of oral mucosae 12 weeks postoperatively.  Images 
show (A) well-healed, (B) non-healed, and (C) medially dehisced mucosae.  Black 
arrows in (B) and (C) indicate exposed implant through non-healed and dehisced 
mucosae, respectively. 
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Figure 7.3. (A) Number of healed versus non-healed mucosal defects as well as (B) 
dehisced and non-dehisced mucosae for each group.  * indicates a significant 
difference between the LS30PLGA and the LS30Gel groups (p < 0.05). 
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Figure 7.4. Representative histological images of (A-B) low and (C-F) high 
magnification stained with methylene blue and basic fuchsin.  The low 
magnification images show a non-healed (A) and healed (B) mucosal defect with the 
titanium plate indicated with a (p).  The exposure of the implant in (A) is indicated 
with a black arrow.  The healed mucosa over the implant in (B) is indicated with a 
black arrow.  Bone (b) can be seen in direct contact with the implant (i) in (C) at the 
tissue implant interface.  (D) shows an abundance of inflammatory cells (ic) inside a 
thick fibrous capsule (c) at the tissue implant interface.  Scale bars indicate 1 mm 
and 100 µm for the low (A and B) and high (C and D) magnifications, respectively. 
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Figure 7.5. Distribution of histological scores of the (A) tissue-implant interface and 
the (B) tissue within the pores of the implants using the scoring system described in 
Table 2.  * indicates a significant difference between the Uninfected and the 
LS30PLGA groups for the tissue-implant interface score (p < 0.05). 
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Chapter 8 
Biodegradable Composite Scaffolds 
Incorporating an Intramedullary Rod 
and Delivering Bone Morphogenetic 
Protein-2 for Stabilization and Bone 
Regeneration in Segmental Long Bone 
Defects‡ 
Despite the inherent healing capacity of bone tissue, segmental defects remain a 
significant clinical challenge and often result in non-union [221].  Current standard of 
care relies on the use of stabilization with plates or rods and bone regeneration through 
the use of bone grafts or flaps.  However, this strategy has inherent disadvantages with 
                                                
 
‡ This chapter was published as Henslee AM*, Spicer PP*, Yoon DM, Nair MB, 
Meretoja VV, Witherel KE, Jansen JA, Mikos AG, Kasper FK. “Biodegradable 
Composite Scaffold Incorporating an Intramedullary Rod and Delivering Bone 
Morphogenetic Protein-2 for Stabilization and Bone Regeneration in Segmental Long 
Bone Defects.” Acta Biomater. 7, 3627-3637 (2011). * indicates co-first authors. 
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donor site morbidity and subsequent removal of stabilization hardware or lifetime 
placement [222].  While many other bone regeneration strategies have been investigated, 
many do not consider stabilization of segmental long bone defects in combination with 
regeneration and thus still require fixation.  However, there are strategies in tissue 
engineering aiming to address these two issues simultaneously, and commonly include 
the use of a strong scaffold material with or without cells and/or growth factors to 
promote osteogenesis [223-226].   
In these strategies, the solid scaffold serves as the stabilization of the defect until 
the regenerated bone can sufficiently support the load.  Loading of long bones varies by 
location but can be as much as 45 MPa with simple movements [227]. To support such 
loads mechanically strong materials must be used such as ceramics and polymers [224-
226, 228-231].  Among those investigated, poly(propylene fumarate) (PPF) is a 
biodegradable linear polyester with many unsaturated double bonds capable of 
crosslinking and has been shown to be biocompatible[48, 232-234] and osteoconductive 
[225, 232-235].  Design issues such as scaffold porosity, shape, and architecture can all 
play a significant role in the tissue response, such that porosity is necessary for bone-
scaffold integration and has significant effects on osteoconductivity [236-238].  Studies 
have previously shown that while solid PPF has mechanical characteristics similar to 
those of bone, porous PPF, commonly used in tissue engineering strategies, decreases the 
mechanical strength of the scaffold with increasing porosity [224, 228].  Strategies to 
address stabilization and bone regeneration have typically employed a solid and porous 
composite structure or a solid structure with degradable porogens to become porous [51, 
239].  In a study by Kempen et al., a solid PPF intramedullary rod embedded with 
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poly(DL-lactic-co-glycolic acid) (PLGA) microparticles for growth factor delivery was 
used [239].  Intramedullary rods are used clinically to stabilize segmental defects and 
allow for bone growth and eventual union over the surface while maintaining mechanical 
support.  Traditional metal intramedullary rods are non-degradable and thus remain in the 
body for the patient’s lifetime but biodegradable systems allow for non-permanent 
fixation of these types of defects and could potentially mechanically stabilize segmental 
defects while allowing regeneration around them.  For this stabilization to be sufficient, 
the mechanical properties of the intramedullary rod would be required to sustain the loads 
of the bone and be fixed to each segment of bone to prevent defect collapse and increase 
torsional stability. 
In addition to scaffold design, delivery of drugs or bone healing promoting factors 
is commonly employed in tissue engineering strategies to accomplish several functions 
required for tissue regeneration [240-245].  A group of growth factors known as bone 
morphogenetic proteins (BMPs) have been studied extensively for applications related to 
bone regeneration.  They have been shown to increase bone formation and are 
osteoinductive when delivered in a controlled manner [243, 246, 247].  Controlled release 
of BMPs has been studied with various release mechanisms, such as microparticle 
delivery systems [92, 93, 179, 239, 244, 247-253].  Specifically PLGA microparticles 
have been studied with recombinant human bone morphogenetic protein-2 (rhBMP-2) 
entrapped and adsorbed onto the surface [253].  Protein adsorption presents an alternative 
delivery method, which maximizes control of the factors at the time of scaffold 
fabrication, as the rhBMP-2 or other factor is not entrapped and therefore fabricated with 
the microparticles.   
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In this study, a long intramedullary rod of solid PPF was used to meet these 
mechanical requirements in a rat segmental femoral defect with additional internal 
fixation.  Surrounding this rod, a porous PPF sleeve was used to increase bone integration 
and osteoconductivity and provide a structure for the delivery of rhBMP-2 adsorbed on 
PLGA microparticles.  The solid intramedullary rod was hypothesized to enhance the 
mechanical stability with further enhancement by bone integration into the porous sleeve 
when present.  Additionally, bone regeneration was hypothesized to be significantly 
affected by the delivery and dose of rhBMP-2. 
8.1. Materials and Methods 
8.1.1. PPF Synthesis and Scaffold Fabrication 
PPF was synthesized according to established methods [254, 255].  Molecular 
weight was confirmed via gel permeation chromatography (GPC) (Waters, Milford, MA) 
using polystyrene standards (Fluka, Switzerland).  For this study, PPF with a number 
average molecular weight of 2900 and a polydispersity index of 1.4 was used.   To make 
the solid PPF rods, a solution of PPF and N-vinyl pyrrolidone (N-VP, Sigma-Aldrich, St. 
Louis, MO) was combined in a 4:1 mass ratio and benzoyl peroxide (BP, Sigma-Aldrich, 
St. Louis, MO) was added in 2 wt% of the total PPF/N-VP solution.  The solution was 
poured into 1.6 mm diameter poly(tetrafluoroethylene) (PTFE) molds and allowed to 
crosslink for 24 hr at 60°C. The rods were removed, cut to 8.5 mm in length and 
sterilized by ethylene oxide gas.  For fabrication of porous scaffolds, the same PPF/N-
VP/BP solution was prepared as above and combined with 80% w/w NaCl (300-500 µm).  
 161 
 
The resultant slurry was packed around a 1.6 mm diameter glass rod concentrically 
placed in a 3.5 mm diameter x 25 mm cylindrical PTFE mold.  After packing the slurry to 
remove void spaces, the glass rod was removed and the resulting hollow cylinders were 
allowed to crosslink within the PTFE mold for 24 hr at 60°C.  Subsequently, the 
NaCl/polymer cylinders were removed and cut with a diamond saw into 5 mm long 
sections.  The salt porogen of the scaffolds was then leached in ddH2O for 1 week with 
daily water changes, freeze-dried, and sterilized with ethylene oxide gas. 
8.1.2. Scanning Electron Microscopy 
Scanning electron microscopy samples were prepared by placing longitudinally 
cut scaffolds on sample holders and sputter coating with approximately 20 nm of gold 
using a CrC-150 Sputter Coater (Torr International, New Windsor, NY). The top surfaces 
of scaffolds were viewed using a Quanta 400 Electron Microscope (FEI, Hillsboro, OR) 
operated at 30kV. 
8.1.3. PLGA Microparticle Fabrication and rhBMP-2 Adsorption 
 PLGA microparticles were fabricated by solvent extraction in a water in oil in 
water emulsion as previously described [256].  Briefly, 1 g of PLGA (52 mol% DL-
lactide:48 mol% glycolide, ~ 50,000 MW, Purac Biomaterials, Gorinchem, The 
Netherlands) was dissolved in 4 mL of methylene chloride.  500 µL of 0.1 wt% bovine 
serum albumin (BSA) in phosphate-buffered saline (PBS) was injected into the PLGA 
solution and vortexed for 60 s.  Six mL of 0.3 wt% aqueous poly(vinyl alcohol) (PVA) 
solution was added and vortexed for 60 s.  This solution was added to a stirring solution 
of 394 mL 0.3 wt% aqueous PVA solution and 400 mL of 0.2 vol% aqueous isopropanol 
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solution.  The extraction took place over 1 hr, when the microparticles were collected by 
centrifugation, rinsed with ddH2O three times, frozen and freeze-dried.  Microparticles 
were sterilized with ethylene oxide gas, stored at -20°C and handled thereafter with 
aseptic techniques. 
           To create PLGA microparticles with rhBMP-2 (PeproTech, Rocky Hill, NJ), 
PLGA microparticles were allowed warm to room temperature and a sterile rhBMP-2 
solution (0.65 mg rhBMP-2/mL PBS/BSA[0.1 wt%]) was adsorbed onto unloaded PLGA 
microparticles in a fluid:particle ratio of 0.8 mL/mg. This ratio provided complete 
wetting of the PLGA microparticles without fluid surplus. After 30 min adsorption time, 
microparticles were frozen at -20˚C and lyophilized. Thereafter, microparticles were 
transferred into a new vial. 
8.1.4. Composite Scaffold Preparation 
Four PPF based scaffold groups and one empty group were included in the in vivo 
study. The groups are described in Table 8.1 and include: Group E: empty defect; Group 
R: solid PPF intramedullary rod; Group RSB: solid PPF intramedullary rod and porous 
PPF sleeve filled with 30 µL of 24% w/v Pluronic F-127 with 16.67 mg of blank PLGA 
microparticles; Group RSLo: solid PPF intramedullary rod and porous PPF sleeve filled 
with 30 µL of 24% w/v Pluronic F-127 with 12.5 mg of blank PLGA microparticles and 
4.17 mg of rhBMP-2 adsorbed PLGA microparticles (corresponding to 2 µg of rhBMP-2 
per scaffold based off of previous studies [93, 239, 253, 257] and scaled to the volume of 
the defect); and Group RSHi: solid PPF intramedullary rod and porous PPF sleeve filled 
with 30 µL of 24% w/v Pluronic F-127 with 16.67 mg of loaded PLGA microparticles 
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(corresponding to 8 µg of rhBMP-2 per scaffold based off of previous studies [93, 239, 
257] and scaled to the volume of the defect).  To fabricate the scaffolds prior to the 
surgical procedure, the porous sleeves were prewetted with an ethanol gradient and 
loaded with the Pluronic F-127 and PLGA suspension described above with a vacuum 
loading process by pipetting 15 µL of the mixture into the center of the sleeve and 
applying 100 mbar of vacuum, which was held for 15 s.  This was repeated with an 
additional 15 µL of the Pluronic F-127 and PLGA suspension.  The resultant 30 µL 
solution penetrated the scaffold.  Each sleeve was incubated at 37°C for 10 min after the 
addition of the Pluronic F-127, to gel the solution within the pores.  Figure 8.1 shows the 
assembled composite scaffold. 
8.1.5. Surgical Procedure 
Scaffolds were placed in a critical sized segmental femoral defect in a rat as 
previously described [239, 258, 259].  Fifty-three Lewis rats between 325 and 350 grams 
were purchased from Harlan Laboratories (Indianapolis, IN).  All procedures complied 
with protocols approved by the Institutional Animal Care and Use Committee at Rice 
University. 
Briefly, anesthesia was induced using 4% isoflurane in oxygen then maintained 
on 2% isoflurane in oxygen at 0.5 L/min using a nosecone.  The rats were administered 
buprenorphine at 0.05 mg/kg intraperitoneally for perioperative analgesia and 
enrofloxacin at 10 mg/kg, subcutaneously for perioperative antimicrobial activity.  The 
right hind leg of the rat was clipped free of hair and 100 µL of 0.25% bupivicaine with 
1:200 of epinephrine were administered subcutaneously along the incision line.  The rat 
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was placed on a warming plate and the right leg was prepared sterilely.  A 2.5 cm 
incision was made on the lateral side of the right leg centered between the hip and knee.  
The femur was exposed by blunt dissection and a polyethylene plate (22x3x4 mm) was 
fixed to the anterolateral side of the femur with 4 threaded Kirschner wires (Zimmer, 
Warsaw, IN).  A 5 mm defect was created in the diaphysis of the femur using a cutting 
bur under irrigation of saline.  The defect was irrigated to remove any residual bone dust 
and bone marrow contents.  The two wires immediately adjacent to the defect were 
removed from the bone but remained in the plate.  The segments of bone were rotated to 
allow placement of the scaffold, where one side of the rod, with or without the porous 
sleeve, was placed in the intramedullary canal of the proximal end of the defect and the 
opposite end was placed in the intramedullary canal of the distal end while 
simultaneously rotating the segments of bone back into alignment.  This procedure 
allowed the placement of an 8.5 mm rod into the 5 mm defect.  Once in place, the two 
wires were screwed back into the bone and the wound closed in two layers, muscle and 
skin, with 5-0 Vicryl sutures (Ethicon, Somerville, NJ).  Each rat was given normal saline 
intraperitoneally at 10 mg/kg per hour of surgery and received a radiograph immediately 
post-operatively to ensure placement of the plate and alignment of the femur segments.  
Finally, each rat recovered in an elevated oxygen and warming environment until 
responsive and ambulating.  All rats received buprenorphine every 12 hr at 0.05 mg/kg 
for 48 hr postoperatively and at 0.025 mg/kg for the next 48 hr.   Additionally, each rat 
received radiographs every 3 weeks to assess bone formation throughout the study. 
All rats recovered immediately postoperatively and returned to ambulation.  Of 
the 53 rats operated on, 9 rats experienced loosening of the plate more than 3 days post-
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operatively.  These animals were euthanized at the discretion of the institutional 
veterinarian due to difficult ambulation.  The remaining 44 rats experienced no altered 
ambulation. 
8.1.6. Radiographic Analysis 
Radiographs were taken using an X-ray machine (Faxitron, Lincolnshire, IL), 
immediately after the surgery (Day 0) and periodically (3, 6, 9 and 12 weeks) after 
anesthetizing the animal with 2% isoflurane. The percentage of bone formation within the 
defect was evaluated blindly and independently by three observers (A.M.H., M.B.N., and 
V.V.M.).  Images were scored according to a modified system described previously[260] 
and shown in Figure 8.2. 
8.1.7. Microcomputed Tomography (Micro-CT) Analysis 
8.1.7.1. Porous PPF Sleeve:  
Three porous PPF sleeves were scanned using a SkyScan1172 micro-CT 
(SkyScan, Aartsellar, Belgium).  A voltage of 40 kV and current of 250 µA were set for 
the x-ray using a nominal resolution of 5.5 µm/pixel.  The scanned image slices were 
reconstructed with the NRecon program provided by Skyscan, which used a Feldkamp 
3D cone beam reconstruction algorithm [261].  The reconstructed images were oriented 
so that a cylindrical region of interest (ROI) could be created with the CT-Analyzer 
software provided by Skyscan.  A binary threshold of 60-255 was chosen when 
determining porosity and pore interconnectivity.  Scaffold porosity was determined by 
the following equation: 
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Equation 8.1. Porosity equation for microcomputed tomography. 
% Porosity = (1-V/Vtotal VOI) x 100% 
where V is the object volume composed of the polymer and Vtotal VOI is the total 
volume that was selected to encompass the whole scaffold.  Pore interconnectivity was 
quantified by the following equation, which is based on previous reports [93, 228]  
Equation 8.2. Interconnectivity equation for microcomputed tomography. 
% Pore Interconnectivity = (Vtotal VOI - Vpost)/(Vtotal VOI - V) x 100% 
where Vpost is the object volume that is present for the defined cube size.  Briefly, 
the pore interconnectivity percentage was determined by how much volume a pre-defined 
3D cube can migrate through the void spaces within a scaffold from the outside to the 
inside as a percentage of the total void volume of the scaffold. 
8.1.7.2. Rat Femurs:  
All rat femurs (n=8-10) were scanned using the SkyScan 1172 micro-CT imaging 
system prior to histology and mechanical testing.  A voltage of 80 kV and current of 125 
µA with a nominal resolution of 10 µm/pixel with a 0.5 mm aluminum filter were chosen 
based on previous reports [34, 48].  A binary threshold of 70-255 was chosen to 
accurately represent the bone as a grayscale image.  Three-dimensional images were 
created using the CT-Analyzer software for all samples and blindly reviewed by three 
individuals (A.M.H., M.B.N., and V.V.M.).  Percentage of guided bone growth within the 
defect area at 12 weeks was assessed using the same scoring system as previously 
described for radiographic analysis. 
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The percentage of bone formation was quantitatively determined by creating a 
volume of interest that incorporates the defect and all regenerated bone, with a height of 5 
mm, length of 8.1 mm and depth of 8 mm.  The ROI height was located equidistant from 
the two K-wires adjacent to the defect.  The data are reported as the percentage of bone 
volume found within the created ROI within the CT-Analyzer software. 
8.1.8. Biomechanical Testing 
Femurs from 5 rats from each group were excised after euthanasia at 12 weeks 
postsurgery.  Excess soft tissue was removed and the femurs were wrapped in PBS-
soaked gauze and stored at -20°C until testing.  Prior to mechanical testing, micro-CT 
scans were taken.  Briefly, samples were thawed at room temperature and the inner two 
K-wires were removed to prevent interference with the x-rays.  After micro-CT scans 
were taken, femur ends were potted in acrylic cement (Great Lakes Orthodontics, 
Tonowanda, NY) in custom made stainless steel holders up to the fixation plate while 
wrapped in PBS-soaked gauze to prevent dehydration.  After sufficient polymerization of 
the cement; gauze, the remaining outer two K-wires, and fixation plates were carefully 
removed and each sample was mounted in an MTS 858 Mini Bionix II testing system 
(MTS, Eden Prairie, MN) with the bones coaxially aligned to the system axis of rotation.  
Each femur was rotated at 6°/s until failure or for 20 s.   Maximum torque (N-mm) and 
torsional stiffness (N-mm/°) were recorded for each specimen, with the stiffness being 
measured as the slope of the linear portion of the torque–angular displacement curve 
[262, 263].  Mechanically unstable bones were not tested, and their values were 
considered to be zero in the statistical analysis. 
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8.1.9. Histological Processing 
After the rat femurs were excised, the femurs were placed in 10% neutral buffered 
formalin for at least three days (n=3-4).  After micro-CT scanning, the femurs were 
dehydrated in increasing concentrations of ethanol (70-100%) and then embedded in 
methylmethacrylate.  All samples were initially hemi-sectioned through the center of the 
defect and each section was cut in the longitudinal direction parallel to the polyethylene 
fixation plate using a microtome with an inner circular diamond blade (Leica 
Microsystems, Nussloch, Germany).  Sections were stained with methylene blue/basic 
fuchsin (n=3). 
8.1.10. Light Microscopy and Histological Scoring 
All sections were observed using an upright AxioImager.Z1and AxioCam MRc 5 
(Carl Zeiss AG, Oberkochen, Germany) and were reviewed by three blinded observers 
(A.M.H., M.B.N., and V.V.M.) using a quantitative scoring system (Table 8.2).  Samples 
were observed for tissue response at the implant surfaces (rod and sleeve), within the 
pores of the sleeve, as well as the presence of cartilage surrounding the implant (rod and 
sleeve). 
8.1.11. Statistical Analysis 
Mechanical testing values were analyzed using a one-way ANOVA and any 
significance was analyzed with a post-hoc unpaired t-test.  Radiographic and histologic 
scores were analyzed using nonparametric statistical tests.  For both radiograph and 
histology scores of hard tissues, the Kruskal-Wallis one-way analysis of variance was 
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used and post-hoc analysis with the Dwass-Steel-Critchlow-Fligner test.  For histology 
scores of cartilage tissues, the Fisher-Freeman-Halton analysis of variance was used and 
post-hoc analysis with Fisher’s exact test.  For all statistical methods, an a priori level of 
significance was set at α=0.05. 
8.2. Results 
8.2.1. Characterization of PPF Scaffolds  
Scanning electron micrographs as seen in Figure 8.1 revealed a porous network 
within the PPF sleeve, with pores ranging in size from 50 to 500 µm.  The pores were 
distributed evenly throughout the scaffold (both outer and inner surface) and were 
roughly cubical in shape.  Micro-CT analysis demonstrated a total porosity of 74.5 ± 
2.1%, where a larger minimum interconnection size (352 µm) from leached NaCl crystals 
resulted in 45.0 ± 3.1% interconnected porosity, whereas a smaller minimum 
interconnection size (44 µm) resulted in 93.2 ± 2.5% interconnected porosity. 
8.2.2. Radiographic Analysis at weeks 3, 6, 9, and 12 
Representative images of bone formation shown by radiography for each group at 
week 12 are shown in Figure 8.3.  The scores resulting from the level of bone formation 
from each radiograph are depicted in Figure 8.4.  Groups E, R, and RSLo showed an 
increasing trend in bone formation throughout the duration of the experiment.  However, 
only group E showed that bone formation was significantly higher at week 12 compared 
to that observed by weeks 3, 6, and 9 (p < 0.05).  While there was no significant bone 
formation between any of the groups at weeks 3 and 6, by week 9 differences were 
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observed.  The highest bone formation at week 9 was for groups R and RSLo compared 
to groups E, RSB, and RSHi (p < 0.05). The significant differences were similar to week 
12; however, group E was also significantly higher than RSB and RSHi (p < 0.05).  
8.2.3. Micro-CT Analysis  
The amount of bone formed within the defect was evaluated both qualitatively 
and quantitatively at 12 weeks with micro-CT.  Complete bone union was not observed in 
any sample as evaluated by observing three-dimensional images of the femurs as shown 
in Figure 8.5.  Bone formed along the outside edges of the defect area.  The majority of 
samples showed that the bone formation occurred along the polyethylene plate, which 
can be seen in the representative images.  The scores given to all the groups for bridging 
within the defect were not significantly different at 12 weeks as shown in Figure 8.6.     
Figure 8.7 shows the percentage of bone volume for intact femurs (C) and all 
experimental groups.  The percentage of bone volume for the intact femurs was 
significantly higher by approximately 2-fold compared to the experimental groups (p < 
0.05).  Additionally, the RSHi group had more bone formation at 12 weeks compared to 
the E and RSB groups (p < 0.05). 
8.2.4. Histological Analysis  
At the 12 week time point, a fibrous capsule or immature/mature bone was most 
commonly found surrounding the PPF rod and/or PPF porous sleeve for each group. 
 However, no bone union was observed.  When there was a presence of immature/mature 
bone around the scaffolds, it always surrounded the outer periphery of the PPF rod and/or 
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PPF porous sleeve for each group.  Immature cartilage was also observed in the samples, 
which was often near the presence of osteoids containing osteoblasts and osteoclasts. 
 Pores within the sleeve were mainly filled with fibrous tissue.  The RSLo and RSHi 
groups had some samples that contained bone within the outer pores of the porous sleeve 
versus the RSB group, which contained a layer of bone that did not penetrate the pores as 
shown in Figure 8.8.  For each group, at least one rod was broken by the end of the study 
at 12 weeks.  Whenever this occurred, one end of the rod within the intramedullary canal 
was always surrounded by bone. 
The tissue response was evaluated for all the groups (n=3-4) at the bone-rod 
interface, bone-sleeve interface, and within the pores of the sleeve at 12 weeks as shown 
in Figure 8.9A-C.  Figure 8.9A shows tissue response scores at the rod interface within 
the intramedullary canal (IM) and the defect area.  The RSLo and RSHi groups showed 
significantly lower scores compared to the R and RSB group within the intramedullary 
canal (p < 0.05).  However, within the defect area, no differences were observed.  
The scoring of the hard tissue response at the porous sleeve interface can be seen 
in Figure 8.9B.  Two different locations were evaluated at the porous sleeve interface: 
adjacent to the original defect and within the central defect area.  No significant 
differences were observed for either of the interface areas at week 12.  Tissue response 
scores within the pores of the PPF porous sleeve were given for the RSB, RSLo, and 
RSHi groups as shown in Figure 8.9C.  The results showed that no significant differences 
were observed between all the groups. 
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The presence of cartilage was also evaluated at the rod interface, within the 
intramedullary canal and defect area, as well as within the pores of the porous sleeve as 
shown in Figure 8.9 with a representative image shown in Figure 8.10.  The rod interface 
created significantly more immature cartilage tissue compared to the RSHi group within 
the intramedullary canal (p < 0.05).  The R group also showed more cartilage formation 
than the rest of the other groups along the rod interface within the defect area (p < 0.05). 
 Cartilage was not found for the RSB group at the rod-defect area.  The pores within the 
sleeve were also evaluated for cartilage tissue formation and no significant differences 
were found.  
8.2.5. Biomechanical Analysis  
Torsional mechanical testing was performed to assess the functional recovery of 
sample femurs.  All experimental groups exhibited significantly greater maximum torque 
(N-mm) and torsional stiffness (N-mm/°) when compared to empty defects (p < 0.01) as 
shown in Figure 8.11.  Additionally, the femurs of animals receiving low dose rhBMP-2 
exhibited significantly greater maximum torque than those with a rod alone (p < 0.05).  
For torsional stiffness, both groups receiving rhBMP-2 performed significantly better 
than the group with only the rod (p < 0.05).  Contralateral control femurs from each rat 
were also tested and exhibited significantly higher torque and stiffness for each sample (p 
< 0.05).    
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8.3. Discussion 
To address the mechanical as well as regenerative requirements of segmental 
defects, structural components of tissue engineering strategies must be considered.    
Clinically used intramedullary rods or internally fixed plates provide mechanical support, 
but require lifetime placement or subsequent surgical removal.  Considering the scaffold 
requirements for stabilization and tissue engineering two conflicting principles must be 
addressed, decreased porosity for strength and increased porosity for tissue ingrowth and 
remodeling.  A composite scaffold provides potential for these principles to be addressed. 
In this study, a composite scaffold design was hypothesized to increase 
mechanical stabilization through incorporation of a solid PPF intramedullary rod and 
bone tissue integration through a porous PPF sleeve in a critical size rat femoral defect.  
Additionally, increased bone regeneration was hypothesized in groups with increased 
levels of rhBMP-2.  The study results indicate that mechanical properties were enhanced 
by the presence of the scaffolds as shown in Figure 8.11 and the quantity of bone 
regeneration increased with rhBMP-2 delivery.  
 The scaffold clearly impacted the results through all analyses, including 
bone regeneration, mechanical stability and tissue response.  Presence of a scaffold 
increased mechanical stability in all groups and was further increased with rhBMP-2 as in 
the RSLo group.  The relationship between bone regeneration and mechanical strength 
has been previously reported in both ceramic and polymeric materials in calvaria [32, 
264, 265] and long bones [225, 262].  Consistent with the studies in long bones, increased 
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bone formation increased the mechanical stability of implants, even when bridging did 
not occur. 
Additionally, the radiographic scores showed that group R regenerated more bone 
than the RSB group at weeks 9 and 12.  In the group with only the rod, there was no 
direct apposition of the scaffold to the cut bone surface, which prevented direct growth of 
bone from the cut plane of bone.  In all groups with the porous sleeve, the scaffold was in 
immediate apposition to the cut surface of bone, filling the space of potential bone 
growth.  As indicated in Figure 8.8, there was not significant PPF degradation over the 12 
weeks, such that the potential space for bone growth was not created by degradation and 
bone regeneration was limited to the pores of the scaffold and the outer surface as seen in 
the radiograph (Figure 8.3) and micro-CT images (Figure 8.5).  This limited the majority 
of bone growth in groups with the porous sleeve to the surface, which has been 
previously described [237, 239, 266].  In a study by Woodard et al., growth into the 
scaffold was dependent upon the presence of micropores (2-8 µm) and limited to surface 
growth when only larger pores were present as is in this study [237]. Another study by 
Aronin et al. similarly found that smaller pore sizes (100 µm) had increased tissue 
infiltration compared to larger pore sizes (500 µm) in rat critical-sized cranial defects 
[267].  In addition to pore size, pore and scaffold architecture have also been shown to 
play a critical role in tissue response [236, 268-270]. For example, Kim et al. showed that 
scaffolds fabricated by stereolithography with a highly permeable and porous architecture 
induced upregulation of osteogenic signal expression with rat bone marrow stromal cells 
in vitro when compared to random porous architecture as in this study [270].  Another 
interesting study found that scaffold architectures that mimic the structure of native bone 
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have exhibited up to a 500% increase in bone volume when compared to defined 
architectures [271].   
Decreased bone formation as a result of the porous sleeve can also be attributed to 
isolation of cell sources.  The osteoprogenitor cells responsible for regenerating the bone 
in these acellular scaffolds would likely be cells from the periosteum or the bone marrow.  
As the porous sleeve separates these two populations with an open but tortuous route, the 
impact of both cell types on bone regeneration could be diminished. 
Scaffold design also had a significant impact on the cartilage tissue response.  
Within the defect area, group R showed significantly more cartilage formation than any 
other group.  Cartilage formation in bone defects has been previously reported by Sarkar 
et al. [272].  This immature cartilage formation could lead to bone regeneration through 
hypertrophy of the chondrocytes and ossification.  Additionally, other factors could 
contribute to the chondrogenesis present in the defect, such as low oxygen tension due to 
removal of vasculature present in the defect previously.   
Delivery of rhBMP-2 also affected the bone regeneration, mechanical stability 
and tissue response.  While radiography indicated group RSLo to have the greatest bone 
regeneration at 12 weeks, micro-CT indicated the most bone formation in group RSHi.  
As micro-CT is a quantifiable technique opposed to a viewer scored system, it is more 
reliable at accurately measuring bone formation although radiography may indicate 
density of bone growth in greater detail.  This hypothesis is supported by the mechanical 
data, which showed the group RSLo had increased mechanical stability of it over the R 
group.  Integration between the regenerated bone and the scaffold was not significant as 
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shown through the histological scores for the tissue present within the pores of the 
scaffold.  Therefore, the transmittance of load between the regenerated bone and the 
scaffold imparted in the group RSLo is attributed to the strength of bone surrounding the 
scaffold.  Previous studies have shown there can be a lack of correlation between the 
bone regeneration in a scaffold and the resultant mechanical properties at the interface as 
was seen with groups RSLo and RSHi [32, 264]. 
The tissue response showed decreased scores (more fibrous tissue and/or 
inflammatory cells present) adjacent to the rod in the intramedullary canal when there 
was rhBMP-2 present.  Recently, with the increased clinical use of rhBMP-2, case reports 
and studies have shown inflammatory processes likely caused by the release of rhBMP-2 
[273, 274].  While the mechanism has not been directly identified, the phenomenon has 
caused reconsideration of use of rhBMP-2 near swelling sensitive tissues such as airways.  
This same process could explain the increased inflammation present in the groups with 
rhBMP-2. 
  Finally, there was increased cartilage formation against the rod in the 
intramedullary canal when higher doses of rhBMP-2 were delivered compared to the rod 
alone.  Previous studies have shown that that mesenchymal stem cells can be induced 
down a chondrogenic lineage when in low oxygen tension environments and in the 
presence of rhBMP-2 [275].  This result also suggests higher concentration of rhBMP-2 
in the intramedullary canal in the RSHi group versus the RSLo group.  This observation 
is consistent with the decreased mechanical strength in the RSHi group versus RSLo 
group.  An increase in microparticle placement in the intramedullary canal could be due 
to scaffold loading parameters.  As is described above, rhBMP-2 was adsorbed onto a 
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subset of PLGA microparticles and these two groups of microparticles were used in ratios 
to create groups with 0, 2, and 8 µg of rhBMP-2 per defect.  This meant that for the RSHi 
group all microparticles had adsorbed proteins.  This adsorption could have increased 
electrostatic interactions between particles creating aggregates, that when loaded into the 
porous sleeve did not penetrate the scaffold due to size.  A lack of penetration of particles 
would increase the number of particles transferred to the rod as it slid into the sleeve 
during the surgical procedure.  As the cartilage formed could be well vascularized if 
given enough time this would be expected to undergo hypertrophy and ossification 
creating bone tissue, although that was not seen in the 12 weeks of this study.   
Several conclusions can be drawn from the model system described above 
regarding bone regeneration with rhBMP-2 with porous scaffolds in the defect, but to 
further understand the relationship between these two components more groups would be 
necessary.  Primarily, a group with the porous sleeve without the rod, while contrary to 
the objective of increased stability, could allow for more investigation into the role of 
bone marrow stromal cells in the regenerative process.  Additionally, including groups 
which deliver rhBMP-2 without the porous scaffold, could show the degree of effect of 
the porous scaffold has on bone regeneration.  Finally, a larger animal model would be 
necessary to further investigate the role of mechanical stability as this model describes a 
load-bearing bone, off-loaded by internal fixation.  While the majority of the defect load 
is supported by the polyethylene plate, the results indicate some degree of load transfer to 
the scaffold, indicated by the breaking of the rod in scaffolds where the rod was 
surrounded by new bone within the intramedullary canal.  Nevertheless, this study clearly 
indicates the increased stabilization effect of composite scaffolds utilizing both porous 
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and solid structures as shown by the increase in mechanical strength of group R over 
group E and group RSLo over group R.  Additionally, rhBMP-2 increased bone 
formation as hypothesized.   
8.4. Conclusion 
The presented study analyzed the effects of composite scaffold construction, 
which aimed to address the bone regeneration and stabilization concerns of non-union 
fractures.  While in no experimental groups was the segmental femoral defect in the rat 
bridged, many conclusions can be drawn concerning scaffold design from this model 
system.  These conclusions address issues regarding the source of stem cell populations 
in an acellular construct, factors associated with stabilization of non-unions, and 
environmental factors present in a defect driving cell differentiation.  Results showed 
increased bone formation in groups without the porous sleeve, suggesting the role of the 
sleeve as a physical barrier to both bone growth and to the migration of regenerative cells 
present in the bone marrow and periosteal regions.  Conversely, while the scaffold was 
shown to be hinder bone bridging, it did impart significant mechanical strength to the 
defect, a critical objective to non-union therapy.  Lastly, environmental factors, such as 
low oxygen tension or micromotion could contribute to the tissue formed and the control 
of these factors would be necessary to elucidate the causal effects of parameters tested.   
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8.5. Tables and Figures 
Table 8.1. Abbreviations for all the groups in the study.  
Group Description 
C Femur with no defect 
E Empty 
R Rod 
RS Rod + sleeve 
RSLo Rod + sleeve loaded with 2 µg BMP-2 
RSHi Rod + sleeve loaded with 8 µg BMP-2 
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Table 8.2. Quantitative histological analysis of the hard tissue response at the PPF 
rod and porous PPF sleeve interface within the intramedullary canal and adjacent 
to the initial defect margin, respectively.  Also, the hard tissue response for the PPF 
rod and porous PPF sleeve interfaces were evaluated in the defect.  For the porous 
PPF sleeve the hard tissue response within the pores was also investigated.  
Additionally, the presence of cartilage tissue formation was observed within the 
intramedullary canal for the PPF rod, around or within the PPF porous sleeve, and 
within the defect for both the PPF rod and porous PPF sleeve. 
Hard tissue response at PPF rod/porous sleeve interface   
Description Score 
Direct bone to implant contact without soft interlayer 4 
Remodeling lacuna with osteoblasts and/or osteoclasts at surface 3 
Majority of implant is surrounded by fibrous tissue capsule 2 
Unorganized fibrous tissue (majority of tissue is not arranged as a capsule) 1 
Inflammation marked by an abundance of inflammatory cells and poorly organized 
tissue 0 
  
Hard tissue response within the pores of the PPF sleeve  
Description Score 
Tissue in pores is mostly bone 4 
Tissue in pores consists of some bone within mature, dense fibrous tissue and/or few 
inflammatory response elements 3 
Tissue in pores is mostly immature fibrous tissue (with or without bone) with blood 
vessels and young fibroblasts invading the space with few macrophages present  2 
Tissue in pores consists mostly of inflammatory cells and connective tissue components 
in between (with or without bone) OR the majority of the pores are empty or filled with 
fluid 
1 
Tissue in pores is dense and exclusively of inflammatory type (no bone present) 0 
  
Presence of cartilage tissue formation at the PPF rod/porous sleeve interface  
Description Score 
Yes 1 
No 0 
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Figure 8.1. Structure of the PFF scaffold shown grossly in (A) where the rod is 
placed in the porous sleeve and microscopically through scanning electron 
microscopy shown in (B).  Scale bar in (B) represents 500 µm. 
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Figure 8.2. Schematic representation of the scoring system used for evaluation of 
radiographic and micro-CT images [260]. 
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Figure 8.3. Representative x-ray micrographs of the rat femoral segmental defect at 
12 weeks (refer to groups described in Table 8.1).  The distal side (knee) is located 
on the left and the proximal end (hip) of the femur is on the right of each 
radiograph.  The white arrow is pointing to the location of a K-wire.  The original 
defect (5 mm) is centered between the two inner K-wires.  Although bridging is close 
in several groups (R, RSLo), complete bone union was not observed in any groups at 
this time point. 
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Figure 8.4. Radiographic scores for bone formation within the defect at 3, 6, 9, and 
12 weeks.  Data are reported as means with standard deviations (n = 6-9). * 
indicates significant differences with other groups at the same timepoint (p < 0.05). # 
denotes that group E at week 12 is significantly different from weeks 3, 6, and 9 (p < 
0.05). 
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Figure 8.5. Representative micro-CT images for each group at 12 weeks.  The 
shaded area represents the defect space with a height of 5 mm with the polyethylene 
plate (not-visible) being located behind the bone images.  The arrow indicates the 
location of a removed K-wire.  Bone formation occurred along the periphery of the 
defect area for the groups that contained a PPF rod and/or sleeve. 
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Figure 8.6. Micro-CT scores for bone formation within the defect at 12 weeks.  Data 
are reported as means with standard deviations (n = 8-9). 
 
Figure 8.7. Percentage of bone volume formed at 12 weeks within the 5 mm femoral 
defect calculated by micro-CT for all groups.  Data are reported as the means with 
standard deviations (n = 8-9). * indicates statistical differences compared between 
the groups denoted (p < 0.05). 
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Figure 8.8. Representative histological images for each group at 12 weeks.  Bone 
formation readily occurred at the PPF rod interface or on the periphery of the PPF 
porous sleeve.  IM – intramedullary canal with bone marrow, R: PPF rod, B: newly 
formed bone, S: remaining porous scaffold, K: location of removed K-wire, arrows 
indicate the initial defect margin. Scale bars represent 500 µm. 
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Figure 8.9. Histological scores for the hard tissue response at week 12 (A) at the rod 
interface within the intramedullary canal and within the 5 mm defect area, (B) at 
the porous PPF sleeve interface along the initial defect margin and within the defect 
area and (C) within the pores of the porous PPF sleeve; as well as (D) for the 
presence of cartilage formation against the solid PPF rod within the intramedullary 
canal and within the defect area, and against the porous PPF sleeve.  Data are 
reported as means with standard deviations (n=3-4). * indicates statistical 
differences compared to other groups (p < 0.05). 
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Figure 8.10. Representative histological section of group R at 12 weeks.  Immature 
cartilage formation (C), noted by the dark purple matrix with blue cells, was found 
along the PPF rod surface (R).  Newly formed bone (B) was found along the 
cartilage.  Scale bar represents 100 µm. 
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Figure 8.11. Torsional stiffness (A) and maximum torque (B) for harvested 
specimens from each group at 12 weeks.  Data are reported as means with standard 
deviation (n=6).  # indicates significant differences between all experimental groups 
and empty defects (p < 0.01).  * indicates significant differences between groups 
marked (p < 0.05). 
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Chapter 9 
Summary 
 
The goals of this work were to evaluate aspects of the two stage strategy to 
craniofacial repair.  The first objective was to evaluate porous space maintenance.  In this 
first study, prefabricated implants were characterized for porosity and evaluated for soft 
tissue healing and tissue response in a composite tissue defect model of the rabbit 
mandible.  This study indicated that porous implants may have enhanced soft tissue 
regeneration over them and that low porosity implants reduced the amount of 
inflammation present around and in the implant at 12 weeks.  Study 2 evaluated the solid 
and low porosity implants in the same model using implants fabricated in situ.  This 
differences allowed for the evaluation of the curing of the construct on the soft tissue 
healing and tissue response.   
The second objective was to characterize and evaluate antibiotic-releasing 
scaffolds for their physicochemical characteristics, release kinetics, in vitro efficacy and 
in vivo efficacy.  Study 1 characterized porous space maintainers fabricated with PMMA-
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based bone cement and gelatin microparticles for their mechanical strength, porosity, 
interconnectivity and release kinetics.  The release of colistin from porous PMMA-based 
space maintainers could be tuned with fabrication and loading parameters.  Similarly, 
study 2 characterized the physical properties and release kinetics of porous space 
maintainers fabricated with PMMA-based bone cement and a gelatin matrix from a 
clinical product.  This study showed similar results in that fabrication parameters could 
control release kinetics and furthered the idea of rapid translation of these strategies 
considering the clinical products used.  Finally, study 3 evaluated these antibiotic 
releasing porous space maintainers in an infected composite tissue defect model of the 
rabbit mandible.  Extended release of antibiotics increased soft tissue healing over that of 
more burst release and that no inoculum was detected at the end of the 12 week study. 
Objective 3 investigated the regeneration of bone in large defects where 
stabilization of the defect ends may be necessary and vascularization of the implant 
preimplantation may be necessary.  Study 1 illustrated value of mechanically stabilizing 
structures in bone regeneration strategies to enhance biomechanical properties of the 
defect.   
The three objectives investigated in this work strengthen the strategy employed 
utilizing two stages of regeneration, isolating the regeneration of soft tissues around a 
bone defect from that of the bone itself.  Overall, this work provides evidence that while 
tissue engineering strategies with degradable scaffolds obviating the need for multiple 
surgeries is ideal, the principles of tissue engineering can be applied to clinical material 
in new strategies to enhance craniofacial reconstruction with more rapid clinical 
translation.
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